

**Objection Deadline: May 25, 2020 @ 12:00 p.m. (ET)**

**UNITED STATES BANKRUPTCY COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , <sup>1</sup>	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**SEVENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,  
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR  
ALLOWANCE OF COMPENSATION FOR SERVICES  
RENDERED AND FOR REIMBURSEMENT OF EXPENSES  
FOR THE PERIOD MARCH 1, 2020 THROUGH MARCH 31, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	March 1, 2020	March 31, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$1,365,644.60 (80% of \$1,707,055.75)	
Total expenses requested in this statement:	\$29,971.64	
Total fees and expenses requested in this statement:	\$1,395,616.24	
This is a(n): <u>  X  </u> Monthly Application    ___ Interim Application    ___ Final Application		

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

**ALIXPARTNERS, LLP**

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL  
FOR THE PERIOD MARCH 1, 2020 THROUGH MARCH 31, 2020**

<b>PROFESSIONAL</b>	<b>TITLE</b>	<b>RATE <sup>(1)</sup></b>	<b>HOURS</b>	<b>FEES</b>
Lisa Donahue	Managing Director	\$1,195	44.4	\$ 53,058.00
Richard Collura	Managing Director	\$1,090	90.5	98,645.00
Barry Folse	Managing Director	\$1,090	1.8	1,962.00
Jesse DelConte	Director	\$950	202.8	192,660.00
Jay K Lynn	Director	\$950	2.8	2,660.00
Kevin M McCafferty	Director	\$950	211.9	201,305.00
Mark F Rule	Director	\$910	124.9	113,659.00
Michael Hartley	Director	\$840	99.7	83,748.00
Gabe J Koch	Director	\$840	95.4	80,136.00
Ryan D Sublett	Senior Vice President	\$735	206.2	151,557.00
Isabel Arana de Uriate	Senior Vice President	\$690	174.6	120,474.00
Jon D Hecht	Senior Vice President	\$690	57.9	39,951.00
David Samikkannu	Senior Vice President	\$690	170.7	117,783.00
Sam J Canniff	Senior Vice President	\$645	114.0	73,530.00
Kristina Galbraith	Senior Vice President	\$645	10.6	6,837.00
Kyoko Shibuya	Senior Vice President	\$645	3.5	2,257.50
Fernando O Silva	Senior Vice President	\$645	88.8	57,276.00
Kaitlyn A Sundt	Senior Vice President	\$510	1.5	765.00
Laurie C Verry	Senior Vice President	\$510	0.2	102.00
Andrew D DePalma	Vice President	\$515	192.4	99,086.00
Hart Ku	Vice President	\$515	71.3	36,719.50
Sam K Lemack	Vice President	\$515	189.7	97,695.50
Nate A Simon	Vice President	\$515	150.5	77,507.50
Tammy Brewer	Vice President	\$450	28.8	12,960.00
Kiera M Davids	Vice President	\$415	18.1	7,511.50
Lia Marie Bonito	Associate	\$450	1.8	810.00
Roy Ellis Ochoa	Consultant	\$420	1.0	420.00
<b>Total Professional Hours and Fees</b>			<b>2,355.8</b>	<b>\$ 1,731,075.50</b>
Less 50% Travel Fees				(24,019.75)
<b>Subtotal</b>				<b>\$ 1,707,055.75</b>
Less 20% Holdback				(341,411.15)
<b>Invoice Total</b>				<b>\$ 1,365,644.60</b>

<sup>(1)</sup> Travel time rates are reduced by 50%

<b>Average Billing Rate</b>	<b>\$ 724.62</b>
-----------------------------	------------------

**ALIXPARTNERS, LLP**

**SUMMARY OF HOURS AND FEES BY MATTER CATEGORY  
FOR THE PERIOD MARCH 1, 2020 THROUGH MARCH 31, 2020**

<b>CODE</b>	<b>MATTER CATEGORY</b>	<b>HOURS</b>	<b>FEES</b>
101	Chapter 11 Process/Case Management	87.5	\$ 72,119.50
103	Cash Management	199.2	108,901.50
104	Communication with Interested Parties	259.0	146,169.50
105	U.S. Trustee / Court Reporting Requirements	59.3	38,009.50
106	Business Analysis & Operations	1,155.5	912,551.50
108	Executory Contracts	1.1	1,045.00
110	Special Projects	13.4	9,497.00
112	Retention and Engagement Administration	0.2	102.00
113	Fee Statements and Fee Applications	58.1	29,083.50
114	Court Hearings	7.3	6,951.50
115	Forensic Analysis	441.5	358,605.50
150	Travel Time <sup>(1)</sup>	73.7	24,019.75
		<b>2,355.8</b>	<b>\$ 1,707,055.75</b>
		<b>Average Billing Rate</b>	<b>\$ 724.62</b>

<sup>(1)</sup> Travel time rates are reduced by 50%

**ALIXPARTNERS, LLP**

**SUMMARY OF EXPENSES**  
**FOR THE PERIOD MARCH 1, 2020 THROUGH MARCH 31, 2020**

<b>EXPENSE CATEGORY</b>	<b>EXPENSE</b>
Airfare	\$ 7,288.45
Ground Transportation	5,160.08
Lodging	13,599.84
Meals	2,572.14
Other	1,351.13
<b>Total</b>	<b>\$ 29,971.64</b>

AlixPartners, LLP (“AlixPartners”), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Seventh Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period March 1, 2020 through March 31, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* (Docket No. 528) and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

**WHEREFORE**, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$1,707,055.75, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$29,971.64, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$1,365,644.60 (80% of \$1,707,055.75) and expenses in the amount of \$29,971.64, for a total amount of \$1,395,616.24.

Dated: May 11, 2020

ALIXPARTNERS, LLP  
909 Third Avenue, 28<sup>th</sup> Floor  
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue  
Managing Director

## **Exhibit A**

**Alix Partners, LLP**

### **Detailed Description of AlixPartners' Fees and Hours by Matter Category**

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/01/20	NAS	Correspondence re: current Mundipharma diligence status with counsel (Davis Polk).	0.20
03/02/20	JD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: outstanding diligence process.	0.20
03/02/20	MH	Update noticing information for vendors whose notices were sent to the Debtors address.	0.40
03/02/20	MH	Advise client on response to equipment lessor seeking to repossess leased equipment.	0.30
03/02/20	MH	Update the critical vendor tracking report and reconcile to all activity sources.	1.10
03/02/20	DS	Correspondence with S. Lemack (AlixPartners) re: Rhodes review of weekly sales report	0.20
03/02/20	DS	Provide S. Lemack (AlixPartners) with detailed workplan on the following items: outstanding requests, weekly sales, cash report, and customer programs report	1.40
03/02/20	DS	Provide data to S. Lemack (AlixPartners) re: monthly flash report	0.70
03/02/20	ADD	Conversation with A. DePalma and J. DelConte (both AlixPartners) re: outstanding diligence process.	0.20
03/03/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business planning progress and work plan going forward.	0.70
03/03/20	JD	Review the status of the latest diligence requests and responses, progress on document redactions, and timing to upload remaining documents.	0.70
03/03/20	JD	Review historical diligence requests from the unsecured creditors committee and the ad hoc committee since the bankruptcy filing.	1.70
03/04/20	JD	Draft an agenda for the meeting with PJT, AlixPartners,	0.70



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Davis Polk and management on Thursday re: case update.	
03/04/20	JD	Correspondence with C. McMillian (Davis Polk) and A. DePalma (AlixPartners) re: board material diligence requests.	0.60
03/04/20	JD	Correspondence with Associate General Counsel re: communications with various business development partners.	0.40
03/04/20	JD	Correspondence with J. Lowne (Purdue) re: autoinjector reporting requirements. Review order re: same.	0.30
03/04/20	DS	Correspondence with S. Lemack (AlixPartners) re: review process for weekly sales report	0.40
03/05/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: open diligence questions.	0.20
03/05/20	JD	Coordinate schedules and plan meetings for business plan presentation reviews with management and advisors.	0.70
03/05/20	JD	Review correspondence from C. McMillian (Davis Polk) and A. DePalma (AlixPartners) re: due diligence requests and proposed diligence materials.	0.40
03/05/20	JD	Review updated MA AG and UCC diligence questions and proposed responses.	0.50
03/05/20	RC	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	NAS	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	NAS	Review motion for extension of preliminary injunction and supporting declaration.	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/05/20	MH	Call with R. Collura, M. Hartley, and N. Simon (all AlixPartners) to discuss TXP Services data request process.	0.50
03/05/20	MH	Prepare for call with supply chain management on treatment of vendors with caps in trade agreements.	0.90
03/05/20	MH	Research legal invoices to Rhodes to prepare response to collection notices.	0.60
03/06/20	MH	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.70
03/06/20	FOS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	LJD	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	MFR	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	HK	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners team update call (partial attendance).	
03/06/20	IA	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	JDH	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	GJK	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	RC	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	JD	Update agenda for internal AlixPartners call.	0.60
03/06/20	JD	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	JD	Review correspondence from R. Aleali (Purdue) re: HR diligence files.	0.30
03/06/20	JD	Correspondence with A. DePalma (AlixPartners) re: data room structure	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/06/20	DS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, H. Ku, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	KM	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, R. Sublett, K. McCafferty, J. Hecht, H. Ku, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.70
03/06/20	RDS	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	ADD	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/09/20	JD	Review and comment on draft responses to various questions received from the Ad Hoc Committee.	0.70
03/09/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case progress check and ongoing work streams.	0.30
03/09/20	JD	Review data room files for files that can be initially produced for new committees.	0.50
03/09/20	NAS	Review and revise request tracker to be sent to TXP Services.	0.40
03/10/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: case progress.	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/10/20	JD	Review open diligence list and status of proposed responses.	0.40
03/10/20	JD	Correspondence with Davis Polk re: open UCC diligence questions.	0.80
03/10/20	JD	Correspondence with C. MacDonald (Purdue) re: open professional fee invoices.	0.30
03/10/20	JD	Review materials provided to Purdue legal to be responsive to UCC diligence questions.	0.70
03/11/20	JD	Develop Purdue travel plan and contingency work plans.	2.00
03/11/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case update.	0.30
03/11/20	JD	Meeting with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: open diligence questions and approval process.	0.50
03/11/20	JD	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/11/20	BF	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/12/20	BF	Catch up call with B. Folse and J. DelConte (both AlixPartners) re: go forward planning.	0.20
03/12/20	LJD	Participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, T. Graulich (both Davis Polk), J. Lowne, R. Aleali (both Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	0.50
03/12/20	JD	Review and provide ordinary course professional tracker. Provide comments re: same.	0.80
03/12/20	JD	Update Purdue travel planning and go forward team planning.	0.50
03/12/20	JD	Catch up call with B. Folse and J. DelConte (both	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		AlixPartners) re: go forward planning.	
03/12/20	JD	Participate in a call with J. O'Connell, J. Turner (both PJT), M. Huebner, T. Graulich (both Davis Polk), J. Lowne, R. Aleali (both Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	0.50
03/12/20	JD	Review executive team bios and job description details re: DOJ diligence questions.	0.80
03/12/20	JD	Analyze historical sales and promotion spending, historical Avrio operating profitability, historical Avrio cost allocations and new brokerage agreements.	2.10
03/12/20	JD	Review detailed Avrio innovation forecasts.	0.60
03/13/20	JD	Review ongoing workstreams and prepare agenda for weekly update call.	0.40
03/13/20	JD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	JD	Call with J. DelConte (AlixPartners) and Associate General Counsel re: case progress and ongoing work streams.	0.40
03/13/20	JD	Review materials previously provided to the UCC and AHC via email against materials posted to the dataroom.	0.70
03/13/20	JD	Review draft Ad Hoc Committee diligence responses and associated diligence materials.	0.80
03/13/20	RC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	NAS	Prepare for weekly AlixPartners engagement team	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		coordination call.	
03/13/20	NAS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	IA	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	GJK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call (partial attendance).	0.80
03/13/20	LJD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	BF	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	FOS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/13/20	MH	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	HK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	RDS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	KM	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	DS	Prepare for and attend conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/13/20	ADD	Prepare for AlixPartners Purdue engagement team update call.	0.30
03/13/20	ADD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, F. Silva, K. McCafferty, R. Sublett, D. Samikkannu, M. Hartley, and H. Ku (all AlixPartners) re:	0.80



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		weekly AlixPartners team update call.	
03/16/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: DOJ due diligence requests.	0.20
03/16/20	DS	Correspondence with S. Lemack (AlixPartners) re: diligence approval process	0.20
03/16/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: case work stream coordination and business plan progress.	0.40
03/16/20	JD	Call with J. Lowne (Purdue), R. Schnitzler (PJT), and J. DelConte (AlixPartners) re: business plan progress.	0.40
03/16/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) re: DOJ due diligence requests.	0.20
03/16/20	JD	Call with J. Turner (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/17/20	NAS	Review motions related to extension of preliminary injunction.	0.40
03/18/20	NAS	Attend (telephonically) 3/18 Purdue Pharma hearing and review docket filings related to extension of preliminary injunction.	3.10
03/18/20	JD	Prepare agenda for biweekly update call and talking points for discussion with management and advisors.	0.60
03/18/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: court update and outstanding diligence requests.	0.30
03/18/20	DS	Draft detailed workplan to I. Arana and S. Lemack (both AlixPartners) re: reporting items	1.20
03/19/20	DS	Follow up with Purdue analyst re: outstanding request items	0.30
03/19/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: case progress and open items.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/19/20	JD	Call with J. Turner (PJT), M. Atkinson (Province), and J. DelConte (AlixPartners) re: business status.	0.20
03/20/20	JD	Review ongoing workstreams and prepare agenda and talking points for weekly AlixPartners coordination and update call.	0.40
03/20/20	RC	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	JD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	NAS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	GJK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	HK	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	IA	Conference call with L. Donahue, B. Folse, R. Collura, A.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/20/20	SJC	DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	MH	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	FOS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	BF	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	LJD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	MFR	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	
03/20/20	DS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	KM	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	ADD	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/20/20	ADD	Prepare for weekly AlixPartners team update call.	0.50
03/20/20	RDS	Conference call with L. Donahue, B. Folse, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana de Uriarte, N. Simon, K. McCafferty, D. Samikkannu, M. Rule, M. Hartley, H. Ku, R. Sublett, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call	0.60
03/23/20	JD	Prepare team coordination plan for business planning workstream.	0.40
03/23/20	JD	Correspondence with Davis Polk and Wiggins & Dana re: diligence process.	0.40
03/23/20	JD	Call with R. Collura and J. DelConte (both AlixPartners) to discuss license agreements and related responses to the UCC's requests.	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
03/24/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Aleali (Purdue) to discuss third party information and MDL production	0.60
03/24/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Hoff (Wiggin and Dana) to discuss materials produced during the MDL.	0.30
03/24/20	JD	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	KM	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	RDS	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes updates.	0.30
03/24/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Hoff (Wiggin and Dana) to discuss materials produced during the MDL.	0.30
03/24/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners), C. McMillian (Davis Polk), and R. Aleali (Purdue) to discuss third party information and MDL production	0.60
03/25/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: diligence process.	0.20
03/25/20	JD	Call with C. Robertson (Davis Polk) and J. DelConte (AlixPartners) re: open items and information sharing.	0.20
03/26/20	JD	Call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, and J. DelConte (all AlixPartners) re: case progress update and planning call.	1.00
03/26/20	JD	Call with R. Aleali (Purdue) and J. DelConte (AlixPartners) re: diligence materials review.	0.30
03/26/20	JD	Call with C. Oluwole (Davis Polk), M. Florence (Skadden),	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		R. Aleali (Purdue), T. Melvin (PJT), J. DelConte, and A. DePalma (both AlixPartners) re: DOJ requests.	
03/26/20	ADD	Call with C. Oluwole (Davis Polk), M. Florence (Skadden), R. Aleali (Purdue), T. Melvin (PJT), J. DelConte, and A. DePalma (both AlixPartners) re: DOJ requests.	0.40
03/27/20	ADD	Prepare for weekly AlixPartners team update call.	0.50
03/27/20	JD	Correspondence with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) re: diligence productions.	0.50
03/27/20	JD	Review HRT funding motions and declarations and provide comments re: same.	0.80
03/27/20	JD	Finalize DOJ responses for Duff & Phelps and prepare for production.	0.70
03/27/20	JD	Review and provide comments on agenda for weekly call.	0.30
03/27/20	JD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/30/20	ADD	Update Purdue Interested Party list at request of Davis Polk.	3.30
<b>Total</b>			<b>87.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Chapter 11 Process/Case Management  
Client/Matter # 012589.00101

## Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	8.40	515.00	4,326.00
Nate A Simon	7.30	515.00	3,759.50
Hart Ku	1.70	515.00	875.50
Sam J Canniff	0.60	645.00	387.00
Fernando O Silva	2.10	645.00	1,354.50
David Samikkannu	6.50	690.00	4,485.00
Isabel Arana de Uriarte	2.10	690.00	1,449.00
Jon D Hecht	0.70	690.00	483.00
Ryan D Sublett	2.40	735.00	1,764.00
Gabe J Koch	2.10	840.00	1,764.00
Michael Hartley	5.90	840.00	4,956.00
Mark F Rule	1.30	910.00	1,183.00
Jesse DelConte	37.00	950.00	35,150.00
Kevin M McCafferty	2.40	950.00	2,280.00
Barry Folse	1.80	1,090.00	1,962.00
Richard Collura	2.60	1,090.00	2,834.00
Lisa Donahue	2.60	1,195.00	3,107.00
<b>Total Hours &amp; Fees</b>	<b>87.50</b>		<b>72,119.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/02/20	DS	Correspondence with J. DelConte (AlixPartners) re: professional fees budget	0.30
03/02/20	DS	Develop and send budget request list to Rhodes team	0.90
03/02/20	IA	Meeting with J. Tran (Purdue), D. Sammikkanu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40
03/02/20	SKL	Review, reconcile, and categorize all of the Paysource cash transactions for this week's cash report.	2.10
03/02/20	SKL	Provide cash report, flash report, and cash forecast to the DPW team for final sign-off and upload	0.50
03/02/20	SKL	Review and reconcile the latest EastWest cash transactions and categorize for this week's cash report.	1.80
03/02/20	SKL	Review and reconcile the latest Purdue investment activity for the weekly cash report.	2.40
03/02/20	SKL	Review the latest Purdue and Rhodes IAC activity and prepare list of updates for E. Nowakowski (Purdue) to comment on.	2.00
03/03/20	SKL	Review and reconcile the latest forecast-to-actuals variances for Purdue and update in the weekly cash report.	1.40
03/03/20	SKL	Review and reconcile the latest forecast-to-actuals variances for Rhodes and update in the weekly cash report.	1.30
03/03/20	SKL	Review the January cash actuals reports to pull the latest Purdue rebate payments and begin categorizing accordingly in the January Customer Programs report.	2.30
03/03/20	SKL	Review the January cash actuals reports to pull the latest Rhodes rebate payments and begin categorizing accordingly in the January Customer Programs report.	2.10



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/03/20	SKL	Begin reconciling the latest Purdue rebates from the cash actuals report against the Purdue rebates report provided by E. Nowakowski (Purdue).	1.90
03/04/20	SKL	Begin reconciling the latest Rhodes rebates from the cash actuals report against the Purdue rebates report provided by R. Haberlin (Purdue).	2.40
03/04/20	SKL	Prepare for and participate in Managed Care marketing meeting with B. Shank, M. Ronning (both Purdue), J. DelConte, and S. Lemack (both AlixPartners)	1.20
03/05/20	SKL	Begin reconciling the January Prompt Pay Discounts and update the January Customer Programs Report accordingly.	1.40
03/05/20	SKL	Prepare the updated weekly cash reporting deck and circulate internally for final sign-off.	2.30
03/05/20	SKL	Review and reconcile the latest IAC feedback provided from J. Lineage (TXP) and E. Nowakowski (Purdue) and update the weekly cash report accordingly.	1.30
03/05/20	SKL	Review the latest fee applications filed on the court docket and update the Retained Professional and Restructuring Professional trackers accordingly.	1.70
03/05/20	SKL	Review and reconcile the latest Private Insurance rebates and update the January Customer Programs Report accordingly.	1.00
03/05/20	IA	Review updated cash report for week ended 02.28	1.10
03/05/20	IA	Review updated funding request information received from Purdue rebates manager.	0.60
03/05/20	DS	Review and provide S. Lemack (AlixPartners) with detailed comments on cash report	1.60
03/06/20	IA	Review and provide comments to weekly cash report for week ended 02/28	1.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/06/20	SKL	Finalize remaining updates to the weekly cash report and circulate to J. Lowne (Purdue) for final sign-off.	2.20
03/06/20	SKL	Review the feedback and action items from the 03/04 Managed Care meeting and prepare updated Purdue timeline.	2.30
03/06/20	SKL	Conference call with L. Donahue, M. Hartley, R. Collura, A. DePalma, J. DelConte, G. Koch, I. Arana, M. Rule, H. Ku, R. Sublett, K. McCafferty, J. Hecht, S. Lemack, D. Samikkannu, and F. Silva (all AlixPartners) re: weekly AlixPartners team update call.	0.70
03/06/20	SKL	Finalize reconciliation of the Purdue and Rhodes rebate schedules.	1.70
03/06/20	JD	Review and provide comments on the weekly cash forecast to actual reporting.	0.50
03/09/20	SKL	Finalize updates to the Chapter 11 timeline for the Managed Care follow-up discussion.	1.30
03/09/20	SKL	Review the latest EastWest Cash transactions provided by J. Liceage (TXP) and categorize accordingly.	2.10
03/09/20	SKL	Review the latest Paysource cash activity re: Weekly Cash Report and categorize accordingly.	1.20
03/09/20	IA	Review cash transactions source files for the week ended 03/06.	1.20
03/10/20	SKL	Review and reconcile the latest Investment activity and update the prior week's cash summaries accordingly.	1.70
03/10/20	SKL	Reconcile the Jan GPO fees and update the January Customer Programs report accordingly.	1.30
03/10/20	SKL	Reconcile the January vendor chargebacks and fee for services and update the January Customer Programs report accordingly.	2.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/10/20	SKL	Prepare for and participate in meeting with J. Liceaga, O. Ingber (both TXP), and S. Lemack (AlixPartners) to discuss the latest IAC activity re: weekly cash report.	1.10
03/10/20	SKL	Finalize updates to the IAC summaries re: weekly cash reporting and update the deck accordingly.	1.80
03/10/20	SKL	Continue to make updates to the January Flash report re: headcount.	1.20
03/11/20	SKL	Update the Rhodes Cash Forecast with the latest cash actuals and prepare forecast-to-variance slides.	2.10
03/11/20	SKL	Update the Purdue Cash Forecast with the latest cash actuals and prepare forecast-to-variance slides.	2.40
03/11/20	SKL	Review of draft pipeline presentation for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	0.60
03/11/20	SKL	Finalize updates to the weekly cash report and circulate the deck for final sign-off and feedback.	2.40
03/11/20	SKL	Review the latest Pipeline report and begin updating the timeline slides accordingly.	1.10
03/11/20	IA	Review Paysource cash payments for the week ended 03/06 and updated actuals tracking report.	1.10
03/12/20	SKL	Continue to make updates to the latest Purdue timeline and circulate internally for final sign-off and feedback.	1.80
03/12/20	SKL	Update the latest Pipeline report to ensure consistent formatting throughout.	1.40
03/12/20	DS	Review and provide comments to S. Lemack (AlixPartners) on weekly cash report	1.70
03/13/20	SKL	Finalize updates to the weekly cash report and circulate to the team for final sign-off.	1.80
03/13/20	SKL	Update the Customer Programs report with the latest	2.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		feedback received from Christine Ostrowski discussion re: Private Insurance and Medicare Part D rebates.	
03/13/20	SKL	Prepare for and participate in Customer Programs discussion with C. Ostrowski (Purdue) and S. Lemack (AlixPartners).	0.60
03/13/20	SKL	Prepare the latest Customer Programs deck and circulate internally for final sign-off.	2.30
03/13/20	SKL	Review and reconcile the latest Cumberland funding's re: Medicare Part D and Private Insurance Program rebates and update the Customer Programs report accordingly.	1.90
03/16/20	SKL	Call with D. Samikkannu and S. Lemack (both AlixPartners) re: Customer Programs report review.	0.30
03/16/20	SKL	Working session with D. Samikkannu and S. Lemack (both AlixPartners) re: allocation of 3rd party rebate funding's and payments.	0.80
03/16/20	SKL	Finalize updates to the January Flash report and circulate to the AlixPartners team for final review.	1.10
03/16/20	SKL	Continue to finalize updates to the Purdue and Rhodes Private Insurance Program section of the Customer Programs Report.	2.30
03/16/20	SKL	Additional updates to the GPO section of the January Customer Programs Report.	1.10
03/16/20	SKL	Prepare additional sections to the Private Insurance and Medicare Part D section of the January Customer Programs Report and circulate to C. Ostrowski (Purdue) for final sign-off.	2.80
03/16/20	IA	Review Paysource payments for week ended 03/13	0.60
03/17/20	SKL	Finalize updates to the latest Pipeline deck and circulate to the AlixPartners team for final sign-off.	2.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/17/20	SKL	Finalize remaining updates to the January Customer Programs Report and circulate to the AlixPartners team for final sign-off.	2.40
03/17/20	SKL	Begin review of the latest weekly cash transactions and begin categorization of the EastWest bank transactions accordingly.	1.20
03/18/20	SKL	Review the February cash reports and to update and format for the February Monthly Operating Report.	2.40
03/18/20	SKL	Reconcile and put together the updated report re: February investment activity for the Monthly Operating Report and circulate to the TXP team for final sign-off.	2.70
03/18/20	SKL	Finalize reconciliation of the cash and investment activity for the month of February and circulate the updated information for the February Monthly Operating Report.	1.70
03/19/20	SKL	Review and reconcile the latest Paysource transactions and begin categorizing accordingly re: weekly cash reporting.	1.90
03/19/20	SKL	Finalize review of the latest investment activity and update the Purdue and Rhodes cash summaries accordingly.	1.40
03/19/20	SKL	Review and reconcile the latest IAC cash activity re: weekly cash reporting and circulate list of outstanding cash inquiries to E. Nowakowski (Purdue) and J. Liceaga (TXP).	2.00
03/19/20	DS	Review Rhodes Controller's commercial files underlying FY 2020 budget	1.80
03/19/20	DS	Update Rhodes cash flow model for sales forecasts by individual product	2.00
03/20/20	SKL	Prepare for and participate in Purdue workstream update call with the AlixPartners team.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/20/20	SKL	Reconcile the latest cash transaction information from J. Liceaga (TXP) and update the weekly cash report accordingly.	2.70
03/20/20	SKL	Finalize the weekly cash report and prepare updated list of outstanding items for E. Nowakowski (Purdue) re: weekly cash report.	2.10
03/20/20	SKL	Finalize the remaining updates for the January Flash report and circulate to J. Lowne and R. Aleali (both Purdue) for final review and sign-off.	1.10
03/20/20	SKL	Continue to review and finalize updates to the latest version of the Purdue Business Plan deck.	1.80
03/23/20	SKL	Review and reconcile the latest Accounts Receivable pulldown from SAP and begin categorizing and formatting the file to implement in the upcoming Rhodes 13-week cash forecast.	2.40
03/23/20	SKL	Finalize reconciliation of the latest fee applications filed by Retained Professionals and update the Retained Professional tracker accordingly.	2.30
03/23/20	SKL	Finalize reconciliation of the latest fee applications filed by Retained Professionals and update the Restructuring Professional tracker accordingly.	2.70
03/23/20	SKL	Prepare updated DSO and DPO analyses to be used in the upcoming Rhodes 13-week cash forecast.	1.90
03/23/20	IA	Review and provide comments to Purdue cash actuals report for week ended 03.13.2020	1.40
03/23/20	IA	Review recent Medicaid and commercial rebate payments through third party vendor.	1.10
03/24/20	IA	Review pay source payments for the week ended 03.20.2020	1.30
03/24/20	SKL	Finalize updates to the Cash Actuals report (week ended	1.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		03/13) and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	
03/24/20	SKL	Review and reconcile the latest East West cash report provided by J. Liceaga (TXP) and categorize the transactions accordingly.	2.10
03/24/20	SKL	Review and reconcile the latest Paysource transaction report and categorize the transactions accordingly.	1.80
03/24/20	SKL	Finalize review of the latest cash transaction reports and prepare list of open questions to J. Liceaga (TXP) and E. Nowakowski (Purdue).	0.40
03/24/20	SKL	Update the latest cash forecasts with the latest cash actuals and begin reviewing discrepancies between the forecast and actuals.	1.80
03/24/20	SKL	Continue to update the latest Rhodes 13-week cash forecast and begin making updates to the rebate section of the forecast.	1.80
03/24/20	JD	Review and provide comments on latest cash forecast to actual analysis.	0.50
03/25/20	SKL	Finalize updates to the IAC disbursement section of the latest Rhodes 13-week cash forecast.	1.20
03/25/20	SKL	Finalize updates to the IAC receipt section of the latest Rhodes 13-week cash forecast.	1.20
03/25/20	SKL	Begin rolling forward the previous Rhodes 13-week cash forecast and update the summary section of the latest Rhodes 13-week cash forecast.	2.30
03/25/20	SKL	Review and reconcile the latest Accounts Payable pulldown from SAP and begin categorizing and formatting the file to implement in the upcoming Rhodes 13-week cash forecast.	2.50
03/25/20	SKL	Prepare and finalize updates to the customer and other	2.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		receipt section of the latest Rhodes 13-week cash forecast.	
03/25/20	DS	Update product detail of sales budget in Rhodes cash forecast model, tying out to P&L	2.60
03/26/20	DS	Update cost by product in Rhodes cash flow model (revise for FY 2020 budget)	1.30
03/26/20	SKL	Continue to reconcile and prepare updated IAC disbursement/receipt summaries re: weekly cash reporting.	2.40
03/26/20	SKL	Finalize updates to the operating expense section of the latest Rhodes 13-week cash forecast.	2.60
03/27/20	SKL	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SKL	Finalize the latest forecast-to-actuals analysis for the Rhodes slides of the weekly cash report.	1.20
03/27/20	SKL	Prepare and finalize the weekly cash report deck and circulate to J. Lowne and R. Aleali (both Purdue) for final sign-off.	1.70
03/27/20	SKL	Update the Purdue and Rhodes cash summaries re: weekly cash actuals, based on the latest information provided by E. Nowakowski (Purdue) and J. Liceaga (TXP).	2.60
03/27/20	SKL	Finalize the latest forecast-to-actuals analysis for the Purdue slides of the weekly cash report.	1.50
03/27/20	IA	Analysis of historical Purdue net sales trends to inform updated collections forecast.	1.10
03/27/20	IA	Review cash actuals report for week ended 03/20/2020	0.70



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/27/20	IA	Update Purdue cash forecast customer collections based on company short term forecast and actual run rates.	1.20
03/27/20	JD	Review and provide comments on weekly cash forecast to actual analysis.	0.60
03/27/20	DS	Review of weekly cash report	0.40
03/30/20	IA	Recalculate outgoing benefit payments (LTRP, AIP and Retention) in the week of 04/03 to update payroll and benefit payment estimates for Purdue and Rhodes	1.40
03/30/20	IA	Modify Purdue cash forecast model for 13 week period starting with week ended 03/27, included actuals, and modified operating expense assumptions.	2.30
03/30/20	SKL	Review the latest East West cash transactions provided by J. Liceaga (TXP) and begin categorizing accordingly for the weekly cash report.	2.10
03/30/20	SKL	Review the latest Paysource cash transactions and begin categorizing accordingly for the weekly cash report.	1.60
03/30/20	SKL	Prepare an updated IAC transaction summary for Rhodes and Purdue and provide E. Nowakowski (Purdue) and J. Liceaga (TXP) with list of open questions.	1.80
03/30/20	SKL	Reconcile the latest investment activity and update the Purdue and Rhodes cash summaries accordingly re: weekly cash reporting.	0.70
03/30/20	SKL	Review and reconcile the latest Rhodes weekly sales report and prepare update for the company to review.	1.10
03/30/20	SKL	Review and reconcile the latest Purdue weekly sales report and prepare update for the company to review.	0.70
03/30/20	SKL	Finalize updates to the weekly cash reporting summaries based on the feedback received from E. Nowakowski (Purdue) and J. Liceaga (TXP).	1.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
03/31/20	SKL	Review and reconcile the latest fee applications filed on the docket for Restructuring Professionals and update the Restructuring forecast accordingly.	1.60
03/31/20	SKL	Review and reconcile the latest fee applications filed on the docket for Retained Professionals and update the Retained forecast accordingly.	1.40
03/31/20	SKL	Prepare and implement the latest Accounts Payable reconciliation into the Rhodes 13-week cash forecast.	1.40
03/31/20	SKL	Prepare and implement the latest Accounts Receivable reconciliation into the Rhodes 13-week cash forecast.	1.20
03/31/20	SKL	Begin refreshing the latest 13-week Rhodes cash forecast by pulling forward the cash actuals and 13-week summaries in the forecast.	1.40
03/31/20	SKL	Continue to update the latest 13-week Rhodes cash forecast by updating the operating expenses and payroll sections of the forecast.	2.20
03/31/20	DS	Update Rhodes cash flow model for FY 2020 budget details including detailed CoGS data as well as sales adjustments	1.30
Total			<b>199.20</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Cash Management  
Client/Matter # 012589.00103

## Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	165.50	515.00	85,232.50
David Samikkannu	13.90	690.00	9,591.00
Isabel Arana de Uriarte	18.20	690.00	12,558.00
Jesse DelConte	1.60	950.00	1,520.00
<b>Total Hours &amp; Fees</b>	<b>199.20</b>		<b>108,901.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/02/20	ADD	Review outstanding diligence request and follow up with relevant parties.	1.20
03/02/20	ADD	Compile diligence requests as of filing file date to support motion at request of Davis Polk	1.70
03/02/20	ADD	Compile and format documentation submitted in response to diligence request for processing and designation.	1.40
03/02/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	3.10
03/02/20	SJC	Redact information provided by Purdue/Rhodes in response to diligence requests for production under protective order (continued).	3.20
03/02/20	SJC	Review and redact 2015 financial update materials in preparation for processing an upload to data room.	1.70
03/02/20	IA	Follow up on approvals and final review of UCC diligence responses to business plan questions.	1.60
03/02/20	NAS	Consolidate data provided for 2YR lookback on payments to insiders and follow-up questions for TXP Payroll team.	1.10
03/03/20	NAS	Reconcile T&E data provided for purposes of 2YR lookback on payments to insiders requested by UCC.	1.80
03/03/20	NAS	Incorporate data received for Payroll, T&E, and Other Benefits into 2YR lookback to payments to insiders as requested by UCC.	2.70
03/03/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.20
03/03/20	SJC	Review and redact 2012 board meeting materials in preparation for processing an upload to data room.	3.00
03/03/20	SJC	Review and redact 2018 board meeting materials in preparation for processing an upload to data room.	1.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/03/20	ADD	Request approval to provide documents submitted in response to diligence requests to the data room.	0.60
03/03/20	ADD	Review and format files submitted in response to diligence requests in preparation for upload to data room.	2.40
03/03/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	3.10
03/03/20	ADD	Compile and provide files to DPW eDiscovery team for designation and Bates stamping	1.50
03/04/20	ADD	Compile and format files submitted in response to diligence requests in preparation for processing and designation.	2.10
03/04/20	ADD	Extract and review data room index in response to request from Davis Polk.	0.70
03/04/20	ADD	Review outstanding diligence request and follow up with relevant parties.	1.90
03/04/20	ADD	Request approval to upload documentation submitted in response to diligence request to the data room.	0.80
03/04/20	ADD	Review and redact third-part confidential information from previously posted cash value transfer diligence items for production under the protective order.	2.80
03/04/20	SJC	Review and redact 2017 board meeting materials in preparation for processing an upload to data room.	3.00
03/04/20	SJC	Review and redact 2016 board meeting materials in preparation for processing an upload to data room.	3.40
03/04/20	SJC	Review information provided by Purdue/Rhodes in response to diligence requests for production under protective order.	1.60
03/04/20	NAS	Review data provided by Purdue/TXP for purposes of 2YR	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		lookback on payments to insiders.	
03/05/20	NAS	Summarize payments to insiders over 2 years prior to filing as requested by UCC.	0.80
03/05/20	NAS	Analysis of fleet vehicle invoices for purposes of 2YR lookback on payments to insiders.	1.70
03/05/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.00
03/05/20	ADD	Update data room permissions to give access to documents to new groups.	1.40
03/05/20	ADD	Compile and format files submitted in response to diligence requests in preparation for processing and designation.	2.40
03/05/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) re: open diligence questions.	0.20
03/06/20	ADD	Review outstanding diligence requests, follow up with outstanding items, and update tracker accordingly.	1.80
03/06/20	ADD	Upload weekly production provided by Davis Polk eDiscovery team and permission files accordingly.	2.30
03/06/20	ADD	Reorganize data room to separate UCC and consenting / non-consenting states folders.	2.20
03/06/20	ADD	Research former employee job titles in response to diligence request.	1.50
03/06/20	NAS	Summarize payments to insiders over 2 years prior to filing as requested by UCC.	0.30
03/06/20	IA	Call with R. Silbert, R. Aleali (both Purdue), G. Sim (PJT), C. McMillian (Davis Polk), and I. Arana (AlixPartners) to discuss AG diligence.	0.50
03/09/20	NAS	Analyze monthly fleet vehicle invoices to determine amounts related to insiders over 2 years prior to filing.	3.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/09/20	NAS	Analysis of payments to insiders over 2 years prior to filing as requested by UCC.	1.80
03/09/20	IA	Follow up on UCC diligence responses to business plan questions.	1.30
03/09/20	ADD	Work with Intralinks support to determine method of filtering certain file types.	0.60
03/09/20	ADD	Compile and submit files to Davis Polk eDiscovery team for designation and processing.	0.50
03/10/20	ADD	Redact third-party confidential information from Board Minutes (2007-2008) in preparation for processing and production.	1.80
03/10/20	ADD	Compile and submit files to Davis Polk eDiscovery team for designation and processing.	0.80
03/10/20	ADD	Compile and format documents submitted in response to diligence request in preparation for approval and submission to Davis Polk.	2.40
03/10/20	ADD	Follow up on outstanding diligence requests with client contracts.	0.60
03/10/20	ADD	Call with Ad-Hoc committee advisors and A. DePalma (AlixPartners) to discuss business plan diligence requests	0.40
03/10/20	ADD	Submit request to client for new diligence items and follow up on outstanding items.	0.80
03/10/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss updates to the TXP information request tracker.	0.20
03/10/20	IA	Review files for submission in response to UCC diligence questions on business plan.	0.80
03/10/20	NAS	Correspondence with K. Laurel (Purdue) and D. Cabral (TXP) and analysis of data provided re: insider payroll over 2 years prior to filing.	2.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/10/20	NAS	Discussions with N. Simon (AlixPartners), E. Nowakowski, and E. Liesman (both Purdue) re: payment procedures for T&E and fleet vehicle invoices.	0.40
03/10/20	NAS	Consolidate list of payments to insiders over 2 years prior to filing and conform to SOFA reporting terminology.	1.50
03/10/20	IA	Follow up on UCC business plan diligence requests.	1.10
03/10/20	NAS	Analysis of T&E and fleet vehicle payments made to insiders over 2 years prior to filing as requested by UCC.	1.80
03/11/20	NAS	Consolidate and summarize all payments to insiders over 2 years prior to filing.	0.80
03/11/20	NAS	Analysis of personal income tax preparation invoices over 2 years prior to filing to determine services provided to insiders.	1.20
03/11/20	NAS	Draft preliminary report of payments to insiders over 2 years prior to filing (as requested by UCC) for internal review.	1.60
03/11/20	ADD	Follow up on outstanding diligence requests with client contracts.	1.70
03/11/20	ADD	Add new uses to Purdue data room at request of Davis Polk.	1.10
03/11/20	ADD	Redact third-party confidential information from board materials in preparation for designation and upload to VDR.	3.20
03/11/20	ADD	Call with Davis Polk and A. DePalma (AlixPartners) to discuss outstanding diligence requests.	0.80
03/11/20	ADD	Review documents redacted by teammate for confidential third party information in preparation for processing.	1.70
03/12/20	ADD	Compile outstanding diligence request into tracker at request of Davis Polk.	1.70



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/12/20	ADD	Submit request to client for new diligence items and follow up on outstanding items.	1.40
03/12/20	ADD	Research and provide update on outstanding UCC diligence items.	0.70
03/12/20	ADD	Remove users (Bayard attorneys) from project data room that no longer represent the UCC.	0.50
03/13/20	ADD	Attend AG Request Core team meeting call.	0.50
03/13/20	ADD	Redact third-party confidential information from Board Minutes (2007-2008) in preparation for processing and production.	2.80
03/13/20	ADD	Call with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) to discuss outstanding UCC diligence requests.	0.20
03/13/20	ADD	Add new users to Purdue dataroom at the request of UCC counsel.	0.40
03/13/20	ADD	Prepare and submit files to Davis Polk for processing (review or redaction and designation).	0.90
03/13/20	ADD	Follow up with client re: outstanding diligence requests.	0.90
03/13/20	ADD	Prepare files submitted in response to diligence requests for upload to data room.	1.60
03/13/20	NAS	Analysis of indemnification payment data for purposes of 2YR lookback on payments to insiders.	0.90
03/13/20	IA	Follow up on OCP monthly spend reporting.	0.60
03/13/20	MH	Call with M. Hartley (AlixPartners) and counsel to discuss OCP reporting variance and update to report.	0.50
03/14/20	ADD	Review diligence requests received by PJT	1.90
03/15/20	NAS	Analysis of indemnification payments made on behalf of Sackler family members for purposes of 2YR lookback on payments to insiders.	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/16/20	NAS	Revise report of payments to insiders over 2 years prior to filing as requested by UCC.	1.10
03/16/20	NAS	Quantify T&E reimbursements that were repaid by PRALP in order to exclude from 2YR lookback on payments to insiders.	1.30
03/16/20	SJC	Review and redact 2015 board meeting materials in preparation for processing an upload to data room.	3.00
03/16/20	SJC	Review and redact 2013 board meeting materials in preparation for processing an upload to data room.	3.00
03/16/20	SJC	Review and redact 2014 board meeting materials in preparation for processing an upload to data room.	2.00
03/16/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.10
03/16/20	ADD	Review and follow up with outstanding diligence request.	1.30
03/16/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.90
03/16/20	ADD	Review and redact mid-year and year-end financial presentations included as part of the board materials for 2018 in preparation for processing and upload to data room.	2.60
03/17/20	ADD	Review and summarize special committee requests posted in data room for Davis Polk.	1.20
03/17/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.10
03/17/20	ADD	Review and redact mid-year and year-end financial presentations included as part of the board materials for 2016 in preparation for processing and upload to data room.	2.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/17/20	ADD	Review and follow up with outstanding diligence request.	2.30
03/17/20	SJC	Review and redact 2010 board meeting materials in preparation for processing an upload to data room.	3.00
03/17/20	SJC	Review and redact 2011 board meeting materials in preparation for processing an upload to data room.	3.30
03/17/20	NAS	Adjust analysis of payments to insiders over 2 years prior to filing for repayments from PRALP.	1.90
03/17/20	NAS	Update summary of payments to insiders over 2 years prior to filing for review by Purdue and DPW.	0.80
03/17/20	JD	Review updated insider payment analysis going back 2 years. Provide comments re: same.	1.40
03/18/20	SJC	Review and redact 2009 board meeting materials in preparation for processing an upload to data room.	3.00
03/18/20	SJC	Review and redact 2009 board meeting materials in preparation for processing an upload to data room (continued).	3.00
03/18/20	ADD	Upload documents provided by DPW eDiscovery team to the data room.	1.10
03/18/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	1.70
03/18/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	0.90
03/18/20	ADD	Review and redact mid-year and year-end financial presentations included part of the board materials for 2017 in preparation for processing and upload to data room.	2.50
03/18/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/19/20	ADD	Review DOJ access to files in data room at request of Davis Polk.	0.80
03/19/20	ADD	Review file submitted previously shared materials prior to PO to determine need for processing and production.	1.00
03/19/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.20
03/19/20	ADD	Review and redact board materials from 2014 to 2015 in preparation for processing and upload to data room.	2.40
03/19/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/19/20	JD	Review proposed diligence request responses for potential valuation and solvency materials.	2.00
03/20/20	JD	Call with R. Aleali (Purdue) re: redaction process and diligence update.	0.30
03/20/20	ADD	Review and update data room permissions in response from a Committee requests.	2.10
03/20/20	ADD	Review and redact board materials for year 2015 in preparation for processing and production.	2.90
03/20/20	ADD	Review and follow up with outstanding diligence request.	1.70
03/23/20	ADD	Review and follow up with outstanding diligence request.	2.80
03/23/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.20
03/23/20	ADD	Review and redact minutes and decisions from 1999 to 2003 in preparation for processing and upload to data room.	3.20
03/23/20	JD	Review latest insider payment analysis going back 2 years.	0.60
03/23/20	JD	Review third party information redaction process.	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/23/20	NAS	Provide summary and circulate draft of 2YR lookback on payments to insiders to Purdue and DPW for review.	0.90
03/23/20	MH	Review proposed two year look back on insider payments.	1.30
03/23/20	MH	Call with legal operations analyst to reconcile spend reporting with Canadian counsel.	0.70
03/24/20	NAS	Revise 2YR payments to insider's report requested by UCC and respond to questions asked by J. Lowne (Purdue).	0.80
03/24/20	ADD	Prepare and upload files submitted in response to committee request and send to Davis Polk eDiscovery team,	2.40
03/24/20	ADD	Review and redact minutes and decisions from 2004 to 2006 in preparation for processing and upload to data room.	2.00
03/24/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	1.30
03/24/20	ADD	Review and follow up with outstanding diligence request.	1.70
03/25/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.90
03/25/20	ADD	Review and redact minutes and decisions from 2007 to 2011 in preparation for processing and upload to data room.	2.80
03/25/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room.	1.80
03/25/20	NAS	Investigate Rhodes Board director fees listed in 2YR lookback on insider payments following review by J. Lowne (Purdue).	1.30
03/25/20	NAS	Research inquiry from UCC re: additional family members with Purdue email addresses.	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/25/20	NAS	Revise report of payments to insiders over 2 years prior to filing following comments from J. Lowne (Purdue).	1.10
03/25/20	MH	Respond to questions from interested parties on additional family members and possible compensation payments.	0.80
03/26/20	IA	Review updated diligence tracker and DOJ requests.	1.10
03/26/20	IA	Review Avrio P&L allocations by innovation and updated growth assumptions.	1.40
03/26/20	NAS	Revisions to report of payments to insiders over 2 years prior to filing to include non-debtor to debtor cross-charges related to insider salaries.	1.20
03/26/20	JD	Review updated diligence trackers and latest diligence materials.	0.80
03/26/20	ADD	Request approval to process and produce files submitted in response to diligence request to data room .	3.10
03/26/20	ADD	Review and redact minutes and decisions from 2011 to 2015 in preparation for processing and upload to data room.	2.40
03/26/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/27/20	ADD	Call with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) to discuss outstanding diligence requests.	0.30
03/27/20	ADD	Call with A. DePalma (AlixPartners), Davis Polk, PJT and Purdue to discuss state attorney general requests.	0.50
03/27/20	ADD	Review and update date room permissions in response from a Committee requests.	2.40
03/27/20	ADD	Review and follow up with outstanding diligence request.	2.20
03/27/20	ADD	Review and redact minutes and decisions from 2016 to 2018 in preparation for processing and upload to data	2.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		room.	
03/27/20	NAS	Review transactions related to cross-charge of insider salaries from non-debtor to debtor entities to ensure accuracy of 2YR lookback on insider payments.	0.90
03/27/20	NAS	Discussion with M. Hartley and N. Simon (both AlixPartners) re: insider salary cross-charges from non-debtor to debtor entities.	0.30
03/27/20	MH	Discussion with N. Simon and M. Hartley (both AlixPartners) re: insider salary cross-charges from non-debtor to debtor entities.	0.30
03/27/20	MH	Review possible exceptions to the two year look back on insider payments.	2.10
03/30/20	MH	Create revised report on Ordinary Course Professionals to include additional requested information.	3.10
03/30/20	NAS	Evaluate cross-charge between Purdue and IAC related to payment to insiders for inclusion in 2YR lookback on insider payments.	1.20
03/30/20	ADD	Review and compile documentation in response to outstanding diligence requests to provide to Davis Polk eDiscovery team.	2.80
03/30/20	ADD	Request approval from client to release files to the Committees.	0.90
03/30/20	ADD	Review and update data room access for documents upload from previous production.	0.70
03/30/20	ADD	Download board materials and provide to AlixPartners eDiscovery team for upload to relativity platform.	0.50
03/31/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
03/31/20	ADD	Review outstanding diligence requests and follow up with	2.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
03/31/20	NAS	to obtain responsive files. Respond to follow-up questions from C. Robertson (DPW) and R. Aleali (Purdue) re: 2YR lookback on insider payments and submit final analysis to counsel.	0.30
<b>Total</b>			<b>259.00</b>



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Communication with Interested Parties  
Client/Matter # 012589.00104

## Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	150.50	515.00	77,507.50
Nate A Simon	38.70	515.00	19,930.50
Sam J Canniff	47.30	645.00	30,508.50
Isabel Arana de Uriarte	8.40	690.00	5,796.00
Michael Hartley	8.80	840.00	7,392.00
Jesse DelConte	5.30	950.00	5,035.00
<b>Total Hours &amp; Fees</b>	<b>259.00</b>		<b>146,169.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: U. S. Trustee / Court Reporting Requirements  
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
03/02/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.30
03/03/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.10
03/03/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.50
03/04/20	HK	Review vendor payables for potential contract rejection opportunities.	2.30
03/04/20	HK	Update status tracking documents for vendor trade agreements	1.20
03/04/20	MH	Call with J. Lowne, E. Ruiz (both Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss additional pre-petition vendor payments under the Critical Vendor Motion.	0.30
03/05/20	HK	Call with J. Lowne, E. Ruiz (both Purdue), M. Hartley, and H. Ku (both AlixPartners) to discuss additional pre-petition vendor payments under the Critical Vendor Motion.	0.30
03/05/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	1.60
03/06/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.10
03/06/20	MH	Update tracking report of payments to ordinary course professionals.	2.60
03/06/20	MH	Change the time source for payments to ordinary course professionals to even out payment patterns.	0.80
03/06/20	MH	Update the Monthly Operating Report for February payments to professionals.	1.10
03/06/20	MH	Reconcile tracking of payments to retained professionals,	2.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: U. S. Trustee / Court Reporting Requirements  
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		ordinary course professionals, and accounts payable control files.	
03/06/20	MH	Send kick off notice to all contributors to the Monthly Operating Report.	0.20
03/09/20	ADD	Research vendor relationship for conflict checks at request of Davis Polk.	1.20
03/10/20	MH	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss transition of responsibility for insider payments section of MOR.	0.40
03/10/20	MH	Update accounts payable sources of insider payments for the monthly operating report.	1.20
03/10/20	HK	Update status tracking documents for vendor trade agreements	1.60
03/10/20	NAS	Meeting with M. Hartley and N. Simon (both AlixPartners) to discuss transition of responsibility for insider payments section of MOR.	0.40
03/11/20	HK	Call with E. Ruiz (Purdue), M. Hartley, H. Ku (both AlixPartners), and other company representatives to discuss potential pre-petition royalties' obligations.	0.60
03/11/20	MH	Send updated data requests to all contributing parties for the insider portion of the February Monthly Operating Report.	1.30
03/11/20	MH	Update payroll information for insiders for February Monthly Operating Report.	0.50
03/12/20	NAS	Review requests sent and data provided for insider payments section of Feb 2020 MOR.	0.60
03/15/20	SKL	Call with S. Lemack and D. Samikkannu (both AlixPartners) re: client requests needed for deliverables	0.20
03/16/20	MH	Update accounts payable component of insider tracking	2.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: U. S. Trustee / Court Reporting Requirements  
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		report.	
03/16/20	DS	Call with D. Samikkannu and S. Lemack (both AlixPartners) re: Customer Programs report review	0.30
03/16/20	DS	Prepare detailed analysis on Med Part D and 3rd party vendors as part of Customer Programs report	2.20
03/16/20	DS	Review certain calculations in Customer Programs report	0.90
03/16/20	DS	Call with S. Lemack and D. Samikkannu (both AlixPartners) re: client requests needed for deliverables	0.20
03/17/20	DS	Review draft Customer Programs report and provide comments to S. Lemack (AlixPartners)	1.20
03/17/20	DS	Follow up with Head of Customer Programs (Purdue) re: updates and edits made to Customer Programs report	0.30
03/17/20	MH	Walk-through of MOR insider payments model with M. Hartley and N. Simon (both AlixPartners).	0.70
03/17/20	MH	Call with legal operations to review new, raw detail and discuss changes to Ordinary Course Professional tracking.	0.70
03/17/20	MH	Review proposed insider calculations for February Monthly Operating Report.	0.60
03/17/20	HK	Update status tracking documents for vendor trade agreements	1.10
03/17/20	NAS	Walk-through of MOR insider payments model with M. Hartley and N. Simon (both AlixPartners).	0.70
03/17/20	NAS	Review latest draft of insider payments section of MOR for accuracy.	0.20
03/18/20	NAS	Review latest draft of insider payments section of MOR for accuracy.	1.60
03/18/20	HK	Review available historical IAC licensing agreements.	2.30
03/18/20	MH	Incorporate cash reporting data into the insider report of	1.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: U. S. Trustee / Court Reporting Requirements  
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		the Monthly Operating Report.	
03/18/20	MH	Create proposed final insider report for the Monthly Operating Report.	0.90
03/18/20	DS	Correspondence with J. DelConte (AlixPartners) about key items to review in draft Customer Programs report	0.40
03/18/20	DS	Draft email with summary seeking approval from management for Customer Programs report	0.50
03/18/20	DS	Redact draft Customer Programs report prior to submission for production	1.40
03/19/20	NAS	Final review of insider payment section of Monthly Operating Report.	0.80
03/20/20	MH	Finalize and submit the Monthly Operating Report.	1.30
03/25/20	HK	Review company contracts data for sharing with Davis Polk.	1.30
03/25/20	HK	Review vendor invoices to confirm pre-petition/post-petition payables.	2.50
03/26/20	HK	Review company contracts data for sharing with Davis Polk.	2.60
03/26/20	HK	Provide additional detail to contracts repository to facilitate ability to search.	2.80
03/31/20	MH	Set up monthly template for Monthly Operating Report.	0.90
<b>Total</b>			<b>59.30</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: U. S. Trustee / Court Reporting Requirements  
Client/Matter # 012589.00105

## Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	1.20	515.00	618.00
Sam K Lemack	0.20	515.00	103.00
Hart Ku	27.20	515.00	14,008.00
Nate A Simon	4.30	515.00	2,214.50
David Samikkannu	7.40	690.00	5,106.00
Michael Hartley	19.00	840.00	15,960.00
<b>Total Hours &amp; Fees</b>	<b>59.30</b>		<b>38,009.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/01/20	DS	Calculate unallocated base costs from client's model	0.80
03/02/20	DS	Meeting with Avrio CFO and K. McCafferty (AlixPartners) re: base S&P spend and marketing scenarios	2.30
03/02/20	DS	Review FFS data set provided by Purdue financial analyst	0.60
03/02/20	KM	Meeting with Avrio CFO and D. Samikkannu (AlixPartners) re: base S&P spend and marketing scenarios	2.30
03/02/20	KM	Call with J. Turner (PJT), K. McCafferty, and R. Sublett (both AlixPartners) to discuss 10-year business plan assumptions	0.40
03/02/20	DS	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	DS	Meeting with J. Tran (Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40
03/02/20	JD	Meeting with J. Turner (PJT), J. Lowne, P. Strassburger (both Purdue), and J. DelConte (AlixPartners) re: OxyContin LOE assumptions.	1.10
03/02/20	JD	Call with Associate General Counsel re: business planning progress.	0.30
03/02/20	JD	Call with C. Robertson (Davis Polk), K. McCarthy, R. Aleali (both Purdue), and J. DelConte (AlixPartners) re: reporting expectations.	0.70
03/02/20	JD	Review detailed business planning materials and assumptions including product by product innovation forecasts and OTC market spending levels re: Avrio long term business plan.	2.80
03/02/20	JD	Partial attendance at meeting with J. Tran (Purdue), J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Avrio business plan assumptions.	
03/02/20	JD	Review and provide comments re: draft Avrio business plan presentation.	1.20
03/02/20	DS	Develop format for high-level scenarios in Avrio model	1.30
03/02/20	DS	Provide team with detailed workplan for day re: Avrio business plan	1.10
03/02/20	DS	Analyze Avrio operating model and provide comments to Avrio CFO	1.80
03/02/20	DS	Review Avrio CFO's cannibalization assumptions	1.60
03/02/20	RDS	Prepare slides to talk through Senokot gummy Nilson analysis	2.10
03/02/20	RDS	Call with J. Turner (PJT), K. McCafferty, and R. Sublett (both AlixPartners) to discuss 10-year business plan assumptions	0.40
03/02/20	RDS	Meeting with J. Tran (Purdue), D. Sammikkanu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) re: Avrio diligence questions	1.40
03/02/20	RDS	Discuss sales consumption data from Neilsen for Betadine	1.80
03/02/20	RDS	Review Avrio Gummy Nilsen data	0.70
03/02/20	RDS	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	RDS	Review and amendments to PJT and AlixPartners presentation for BoD	1.30
03/02/20	KM	Dashboard review	1.20
03/02/20	KM	Analysis re: forecasting models for generics portfolio long range planning	2.20
03/02/20	KM	Prepare suggested dashboard edits	0.40



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/02/20	KM	Research re: potential industry partners	1.70
03/02/20	KM	SWOT analysis re: potential industry partners	1.90
03/02/20	MH	Create accounts payable release file.	0.70
03/02/20	LJD	Review documents	0.70
03/02/20	LJD	Update call with J. Lowne (Purdue) and L. Donahue (AlixPartners)	0.50
03/02/20	HK	Update IAC diligence project status report for discussion with Davis Polk.	1.20
03/02/20	HK	Analyze European IAC G&A data to update Mundipharma IAC financial model.	2.10
03/02/20	HK	Analyze LAM IAC G&A data to update Mundipharma IAC financial model.	2.60
03/02/20	HK	Analyze Canadian IAC G&A data to update Mundipharma IAC financial model.	0.30
03/02/20	HK	Analyze corporate G&A data to update Mundipharma IAC financial model.	0.70
03/02/20	IA	Validate Purdue AIP payments by employee for Purdue and Rhodes based on court approval and latest active employee roster.	1.80
03/02/20	IA	Reconcile total AIP payments (Purdue and Purdue) to 2019 accruals and approved court amounts.	2.10
03/02/20	IA	Follow up on commercial leases and support documents in preparation for upcoming hearing.	1.10
03/02/20	IA	Review updated Avrio PL allocations file between base business and innovations.	1.70
03/02/20	IA	Review company short term cash forecast to compare to 13 week forecast and update fee for service credit assumptions.	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/02/20	IA	Discussion with I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) re: presentation materials for Avrio board meeting	0.80
03/02/20	NAS	Create plan for Mundipharma diligence priorities for week of 3/2.	0.60
03/02/20	NAS	Analysis of Purdue IQVIA data to determine what data should be requested for purposes of Mundipharma diligence.	0.80
03/02/20	NAS	Analysis of Mundipharma G&A costs by region outlined in financial statements provided by Management Revisions.	0.50
03/02/20	NAS	Analysis of price/volume data provided by Mundipharma to assess forward-looking projections.	2.80
03/02/20	NAS	Provide overview to J. DelConte (AlixPartners) of historical Mundipharma Consumer Health performance.	0.40
03/02/20	GJK	Update and coordination of diligence for Mundipharma	1.50
03/02/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.30
03/03/20	JD	Review draft business planning materials re: branded opioids, PHI and pipeline assets and update associated work plan and meeting timelines.	2.30
03/03/20	JD	Review and provide comments on the latest professional fee forecast and check forecast against the docket and fee apps filed to date.	0.70
03/03/20	JD	Meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to discuss Rhodes ten-year budget changes	0.50
03/03/20	JD	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: long term planning for Rhodes.	0.30
03/03/20	GJK	Call with I. McClatchey (Norton Rose) and G. Koch	1.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners) re: updates on London Mundipharma Deutsche Bank, LEK and exec meetings	
03/03/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss current status of Mundipharma diligence process.	0.30
03/03/20	NAS	Analysis of Purdue IQVIA data to inform data request for Mundipharma diligence.	1.50
03/03/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss current status of Mundipharma diligence process.	0.30
03/03/20	GJK	Analysis re: price x volume information	2.00
03/03/20	IA	Follow up on OCP spend reporting.	0.40
03/03/20	IA	Discuss and follow up on request for validation of 2019 benefit plan accruals and estimate for 2020 with C. Destefano (Purdue) and I. Arana (AlixPartners)	2.40
03/03/20	IA	Follow up on commercial leases requests in preparation for hearing.	1.30
03/03/20	IA	Review Avrio products - Kiwi and Ginger - study and results.	1.70
03/03/20	IA	Call with C. Destefano (Purdue), J. Teo (Willis Towers Watson), and I. Arana (AlixPartners) to discuss data set provided on historical and estimated benefit payments by employee	0.60
03/03/20	IA	Call with C. Destefano (Purdue) and I. Arana (AlixPartners) and to discuss bonus files for AIP payments.	0.50
03/03/20	IA	Review Rhodes Tech and Rhodes Pharma calculated bonus by employee files to validate AIP 2020 approved payments.	1.90
03/03/20	IA	Follow up on reporting from HR and updated Purdue voluntary terminations report,	1.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/03/20	IA	Review questions received from Willis Towers Watson on court approved AIP and LTRP payments.	0.60
03/03/20	HK	Update IAC diligence project status report for discussion with Davis Polk.	1.20
03/03/20	HK	Update Mundipharma business plan analysis with revise product category sales trends.	2.60
03/03/20	LJD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business planning progress and work plan going forward.	0.70
03/03/20	MH	Create accounts payable release file.	0.70
03/03/20	MH	Attend call with legal operations to review changes to the invoice release process.	0.50
03/03/20	MH	Arrange for a special hold on payments to an equipment lessor on advice from counsel.	0.40
03/03/20	KM	Dashboard process planning	1.10
03/03/20	KM	Generics pipeline projections with SME	0.60
03/03/20	KM	Prepare Rhodes Tech scenario breakdown	1.40
03/03/20	KM	Workstream planning	0.50
03/03/20	KM	Call with D. Lundie, D. Fogel, J. Lowne (Purdue), J. Turner, R. Schnitzler (PJT), K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic / sponsor steps for Rhodes Technology asset	0.90
03/03/20	KM	Discussion with SME re: Rhodes Tech closure model	0.80
03/03/20	KM	Rhodes performance tracking	0.60
03/03/20	KM	Discussion with SME re: long range forecasting models for generics industry	0.80
03/03/20	KM	Prepare for and attend meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(all AlixPartners) to discuss Rhodes ten-year budget changes	
03/03/20	KM	Create preliminary 10-year plan budget scenarios for Rhodes	1.60
03/03/20	RDS	Work planning for Rhodes headcount reductions	0.60
03/03/20	RDS	Update market share analysis for Rhodes Gx products	0.70
03/03/20	RDS	Work through Rhodes Pharma implementation planning for R&D headcount	0.60
03/03/20	RDS	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes 10 year business plan.	0.40
03/03/20	RDS	Call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: long term planning for Rhodes.	0.30
03/03/20	RDS	Revise workplan ahead of D. Lundie meeting 3/4/2020	0.40
03/03/20	RDS	Meeting with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss Rhodes implementation planning - Coventry site costs for budget base case	1.00
03/03/20	RDS	Conversation with D. Fogel (Purdue) to discuss Upside scenario for Coventry budget upside case	0.90
03/03/20	RDS	Call with D. Lundie, D. Fogel, J. Lowne (Purdue), J. Turner, R. Schnitzler (PJT), K. McCafferty (AlixPartners) to discuss strategic / sponsor steps for Rhodes Technology asset	0.90
03/03/20	RDS	Meeting with J. Lowne, D. Fogel (both Purdue), J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to discuss Rhodes ten-year budget changes	0.50
03/03/20	RDS	Determine next steps for Avrio business plan	0.40
03/03/20	RDS	Review Rhodes Budget assumptions and Wilson, NC Assumptions	2.60
03/03/20	DS	Model base sales realization scenarios across product	2.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		families	
03/03/20	DS	Model benchmark S&P override toggle across product families	2.80
03/03/20	DS	Model cost of sales realization across product families	1.60
03/03/20	DS	Build scenario control panel for base products in Avrio model	1.90
03/03/20	JD	Partial participation in call with J. Turner (PJT), J. DelConte, and R. Sublett (both AlixPartners) re: Rhodes 10 year business plan.	0.20
03/04/20	DS	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	JD	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	DS	Meeting with J. Lowne (Purdue), I. Arana, and D. Samikkannu (both AlixPartners) to review updated Avrio dashboard.	0.50
03/04/20	DS	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	DS	Correspondence with Rhodes financial analyst re: customer programs files sent	0.30
03/04/20	DS	Analyze Betadine Gargle data sent by Avrio	1.20
03/04/20	DS	Model upside scenarios for base products business	2.10
03/04/20	DS	Model downside and benchmark scenarios for base products business for Avrio	2.00
03/04/20	DS	Develop dynamic model for S&P fluctuations in Avrio model	2.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/04/20	RDS	Outline and shell an investment teaser for Rhodes Tech asset	1.50
03/04/20	RDS	Changes to the Base/Lo/Hi scenarios for Rhodes business plan	0.40
03/04/20	RDS	Gather market research to position coventry asset within the wider API manufacturing landscape	0.30
03/04/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning for Rhodes turnaround plan	1.10
03/04/20	RDS	Review agenda for RELT meetings and prepare slides to discuss implementation progress for each workstream	0.60
03/04/20	RDS	Prepare for Avrio dashboard meeting with J. Lowne (Purdue) later today	0.20
03/04/20	RDS	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	RDS	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	KM	Prepare Rhodes Tech teaser outline	1.40
03/04/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Rhodes Tech closure model options	0.60
03/04/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning for Rhodes turnaround plan	1.10
03/04/20	KM	Rhodes implementation planning with AlixPartners Partners team	1.10
03/04/20	KM	Deck planning and outline re: Rhodes Tech strategic partnerships	1.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/04/20	KM	Slides creation re: Rhodes Tech strategic partnerships	2.70
03/04/20	KM	Review of teaser deck with K. McCafferty, and R. Sublett (both AlixPartners)	0.30
03/04/20	KM	Market trends and forecast research and analysis	1.40
03/04/20	MH	Create accounts payable release file.	0.70
03/04/20	MH	Advise client on vendor who threatened to end calibration support over nonpayment of pre-petition.	0.90
03/04/20	LJD	Review draft decks for business plan and comments	1.80
03/04/20	LJD	Prepare for and attend call with J. Turner, J. O'Connell (both PJT), J. Lowne (Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Thursday meeting agenda.	0.60
03/04/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.40
03/04/20	IA	Meeting with J. Lowne (Purdue), I. Arana, and D. Samikkannu (both AlixPartners) to review updated Avrio dashboard.	0.50
03/04/20	IA	Discuss and follow up on requests for information re: AIP and LTRP approved amounts with D. Sims (Willis Towers Watson) and I. Arana (AlixPartners)	1.30
03/04/20	IA	Follow up on pending payments to benefit vendors.	0.60
03/04/20	IA	Follow up on calculation questions re: Rhodes AIP bonus amounts.	0.80
03/04/20	IA	Update Avrio scorecard to incorporate comments from management.	1.30
03/04/20	IA	Follow up on weekly sales by product reports.	0.40
03/04/20	IA	Review updated January flash report.	1.10
03/04/20	IA	Review and discuss final Purdue and Rhodes Pharma AIP	0.60



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		payment files with C. Destefano (Purdue) and I. Arana (AlixPartners)	
03/04/20	GJK	Coordination re: Mundipharma including open diligence items, and price x volume	2.00
03/04/20	NAS	Analysis of data templates and subsequent correspondence with FTI re: Mundipharma IQVIA data requests.	0.40
03/04/20	NAS	Assess current state of Mundipharma business plan model and additional modifications that can be made.	0.40
03/04/20	NAS	Catch up call with J. DelConte, N. Simon (both AlixPartners), J. Turner and R. Schnitzler (both PJT) re: business plan.	0.50
03/04/20	NAS	Initial analysis of Purdue business plan slides.	0.30
03/04/20	IA	Call with I. Arana, D. Samikkannu, J. DelConte, and R. Sublett (all AlixPartners) to continue to iterate Avrio business plan presentation.	0.60
03/04/20	IA	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	JD	Prepare for and participate in Managed Care marketing meeting with B. Shank, M. Ronning (both Purdue), J. DelConte, and S. Lemack (both AlixPartners).	1.20
03/04/20	JD	Catch up call with J. DelConte, N. Simon (both AlixPartners), J. Turner and R. Schnitzler (both PJT) re: business plan.	0.50
03/04/20	JD	Meeting with J. Lowne, T. Garvey, B. Weingarten (all Purdue), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio scorecard.	0.50
03/04/20	JD	Call with J. Turner, J. O'Connell (both PJT), J. Lowne (Purdue), L. Donahue, and J. DelConte (both AlixPartners)	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: Thursday meeting agenda.	
03/04/20	JD	Review and provide comments on draft branded opioid, PHI and pipeline asset slides for the ultimate business plan presentation.	1.70
03/04/20	JD	Correspondence with KCC and C. MacDonald (Purdue) re: vendor forms.	0.30
03/04/20	JD	Edit HRT overview presentation to share with the committee advisors.	0.80
03/05/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan questions.	0.60
03/05/20	JD	Call with J. Turner (PJT) and J. DelConte (AlixPartners) re: open business plan questions.	0.30
03/05/20	JD	Prepare for and participate in a meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	2.00
03/05/20	JD	Review market access customer presentation, provide comments, and correspondence with Associate General Counsel re: same.	1.10
03/05/20	JD	Review unbilled and accrued professional fee amounts and correspondence with R. Brown (Purdue) re: same.	0.50
03/05/20	JD	Update and send out agenda prior to meeting with DPW, AlixPartners, PJT and management.	0.30
03/05/20	JD	Review and provide comments on draft Avrio business plan slides.	1.30
03/05/20	JD	Draft responses to questions from the UCC re: Avrio lease assumption and correspondence with Davis Polk and management re: same.	0.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/05/20	NAS	Review draft Board presentation related to Purdue business plan.	2.20
03/05/20	NAS	Provide update to G. Koch (AlixPartners) re: status of Mundipharma diligence and business plan model.	0.30
03/05/20	GJK	Calls with Brian Bromberg (FTI) and G. Koch (AlixPartners) re: follow up on P&V, model	2.00
03/05/20	IA	Meeting with D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), and J. Tran (Purdue) re: open items and status updates	0.20
03/05/20	IA	Calculate estimated 2021 LTRP payments and outstanding grants by employee under current program.	2.70
03/05/20	IA	Final review and updated summary of AIP payments to Purdue employees.	1.30
03/05/20	IA	Create detailed file that shows insider and non insider split for estimated and agreed 2020 LTRP payments, for comparison to estimated 2021 payments.	2.20
03/05/20	IA	Follow up on executive bio information requested by legal (R Aleali)	0.70
03/05/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.10
03/05/20	HK	Review current status of Mundipharma business plan model.	1.80
03/05/20	LJD	Prepare for and participate in a meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: case progress and go forward planning.	2.40
03/05/20	LJD	Review draft slide deck for input into business plan	2.50
03/05/20	LJD	Review and comment on customer leave behind	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/05/20	MH	Call with supply chain management to discuss treatment of vendors re: caps in their trade agreements.	0.30
03/05/20	MH	Create accounts payable release file.	0.70
03/05/20	MH	Research new pre-petition invoices for vendor with a trade agreement to determine proper treatment.	0.70
03/05/20	KM	Market trends and forecast research and analysis	1.70
03/05/20	KM	Slide creation re: Rhodes Tech strategic partnerships "teaser" deck	1.90
03/05/20	KM	Analysis and slides creation re: DEA quota trends for core opioids	2.10
03/05/20	RDS	Review of RELT communication and provide commentary on the ten-year plan thoughts from D. Lundie (Purdue).	0.50
03/05/20	RDS	Meeting with D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), and J. Tran (Purdue) re: open items and status updates	0.20
03/05/20	RDS	Schedule turnaround team meetings for next week in Rhode Island	0.50
03/05/20	RDS	Correspondence with D. Fogel (Purdue) and J. DelConte (AlixPartners) re: Low/Base/High scenario analysis for Rhodes Pharma x	0.70
03/05/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to talk Low scenario implications	0.50
03/05/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic partnerships presentation for Rhodes Tech	0.40
03/05/20	RDS	Review Rhodes RELT agenda	0.60
03/05/20	RDS	Slide preparation - Avrio Dulcolax case study	0.80
03/05/20	DS	Meeting with D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), and J. Tran (Purdue) re: open items and	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		status updates	
03/05/20	DS	Begin modeling innovation bottoms up data for Betadine innovation	2.30
03/05/20	DS	Begin modeling for Senokot the detailed innovation scenarios	1.40
03/05/20	DS	Correspondence with R. Sublett (AlixPartners) re: Betadine Gargle data received from client	0.40
03/05/20	DS	Review category spending and retail dollars data provided by Avrio management	1.40
03/05/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss strategic partnerships presentation for Rhodes Tech	0.40
03/05/20	KM	Edit and formatting re: Rhodes Tech strategic partnerships "teaser" deck	0.90
03/05/20	KM	Review of Rhodes Tech partnership opportunity	0.60
03/06/20	KM	Rhodes implementation planning for review sessions	0.80
03/06/20	KM	Analysis and market research re: SWOT analysis for Rhodes Tech strategic partnerships "teaser"	1.50
03/06/20	KM	Agendas and actions lists for Rhodes implementation planning for review sessions	1.20
03/06/20	KM	Key executives from potential partners analysis	1.70
03/06/20	KM	Slide creation re: Rhodes Tech strategic partnerships "teaser" deck	0.70
03/06/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss customer and product profitability for Rhodes Pharma products	0.20
03/06/20	DS	Review detailed Canadian Betadine Gargle data sent by Avrio management	1.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/06/20	DS	Analyze Rhodes budget files sent by Rhodes management	2.20
03/06/20	DS	Correspondence with S. Lemack (AlixPartners) re: next steps re: Rhodes budget files	0.30
03/06/20	DS	Review Gummy external comps and benchmarks	1.40
03/06/20	DS	Call with D. Samikkannu (AlixPartners), J. Tran (Purdue), and marketing analyst re: Betadine case study	0.80
03/06/20	DS	Call with J. Tran, R. Brown (Purdue), D. Samikkannu, and R. Sublett (both AlixPartners) to discuss beta fine throat gargle case study	0.80
03/06/20	RDS	Comments to updated Avrio dashboard	0.30
03/06/20	RDS	Call with J. Tran, R. Brown (Purdue), D. Samikkannu, and R. Sublett (both AlixPartners) to discuss beta fine throat gargle case study	0.80
03/06/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss customer and product profitability for Rhodes Pharma products	0.20
03/06/20	RDS	Correspondence with Rhodes team re: customer and product profitability analysis and corresponding implementation plan.	0.60
03/06/20	MH	Create accounts payable release file.	0.70
03/06/20	MH	Update status of legal vendors in all payment and reporting systems on advice from legal operations.	1.30
03/06/20	LJD	Review various files for budget input and edit/comment	2.60
03/06/20	HK	Review new uploads to Mundipharma due diligence data site.	1.40
03/06/20	HK	Review draft business plan model to draft summaries on sales trends in Canada.	1.10
03/06/20	IA	Review received Avrio competitive Gummy data.	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/06/20	IA	Discuss draft Avrio scorecard with J. Lowne (Purdue) and I. Arana (AlixPartners)	0.50
03/06/20	IA	Update Avrio scorecard to incorporate latest comments from management.	1.70
03/06/20	IA	Call with C. DeStefano (Purdue), I. Arana (AlixPartners), and Willis Towers Watson to discuss numbers on benefit program proposal overview.	0.60
03/06/20	IA	Review actual and estimated amounts presented in benefit programs proposal to be reviewed with CEO and prepared by Willis Tower Watson	2.30
03/06/20	IA	Discuss Avrio open items for business plan presentation and assigned updates.	0.60
03/06/20	GJK	Call with I. McClatchey (Norton Rose) and G. Koch (AlixPartners) re: follow up on Friday legal calls	1.30
03/06/20	JD	Conversation with R. Schnitzler (PJT) and J. DelConte (AlixPartners) re: business plan and Avrio meeting on Monday.	0.50
03/06/20	JD	Update draft responses to UCC questions on Avrio lease and correspondence with management and Davis Polk re: same.	0.60
03/06/20	JD	Review draft pipeline slides and provide comments on missing elements and potential adjustments to existing slides.	1.80
03/06/20	JD	Review and provide comments on draft PHI slides and compare financial information in the slides back to the PHI diligence responses given to the various committee advisors.	1.30
03/06/20	JD	Conversations with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Rhodes business plan sensitivities. Correspondence with PJT re: same.	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/06/20	JD	Review and provide comments on final customer presentation.	0.30
03/06/20	JD	Review and provide comments on the latest Avrio scorecard.	0.40
03/07/20	DS	Follow up with Avrio management re: further Canadian Betadine Gargle data	0.30
03/08/20	DS	Refresh numbers for draft deck reflecting Avrio CFO's latest allocations	1.30
03/08/20	DS	Update cannibalization assumptions and re-run analysis on commercial products	1.60
03/08/20	DS	Correspondence with J. Tran (Purdue) re: gummy comps	0.30
03/08/20	DS	Draft introductory slides to frame discussion for presentation	1.10
03/08/20	RDS	Avrio Slide creation - observations, risks and opportunities	0.70
03/08/20	RDS	Avrio Slide creation - Betadyne case study	1.10
03/08/20	IA	Update Avrio business plan slides for review with management.	1.80
03/09/20	IA	Review insider estimated approved benefit payments as requested by human resources to be submitted to WTW.	0.60
03/09/20	IA	Review latest version of Avrio allocated PL file showing the split of base business and innovations.	1.70
03/09/20	IA	Review Emerson savings backup presentation to inform restated Avrio historical financials.	0.80
03/09/20	IA	Meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	2.00
03/09/20	LJD	Catch up call with L. Donahue and J. DelConte (both	0.70



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		AlixPartners) re: business plan progress.	
03/09/20	MH	Create accounts payable release file.	0.70
03/09/20	MH	Create monthly analysis of pre-petition accounts payable for reclassification to "subject to compromise"	3.80
03/09/20	JD	Prepare for and attend meeting with J. Lowne, J. Tran (both Purdue), J. Turner, R. Schnitzler (both PJT), J. DelConte, D. Samikkannu, R. Sublett, and I. Arana (all AlixPartners) re: Avrio business plan presentation.	2.00
03/09/20	JD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: business plan progress.	0.70
03/09/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.30
03/09/20	JD	Analysis of Avrio business plan and historical sales and promotion spend trends including creating sensitivity analyses at various different spend levels.	1.70
03/09/20	JD	Meeting with J. Lowne, M. Kesselman, R. Brown (all Purdue), T. Melvin (PJT), and J. DelConte (AlixPartners) re: professional fee forecasts.	0.50
03/09/20	JD	Review and provide draft comments to PJT draft business plan board presentation.	1.10
03/09/20	JD	Review draft Rhodes Pharma and Rhodes Tech sensitivities for business plan presentation.	0.40
03/09/20	JD	Provide comments on draft Avrio presentation.	0.70
03/09/20	JD	Finalize Avrio lease assumption questions to be posted to the data room.	0.60
03/09/20	GJK	Call with N. Simon and G. Koch (both AlixPartners) to provide update on Mundipharma diligence status and set priorities for week of 3/9.	0.40
03/09/20	GJK	Call with I McClatchey (Norton Rose) to discuss	1.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/09/20	GJK	Mundipharma diligence and next steps	0.30
03/09/20	GJK	Call with B. Bromberg (FTI) and G. Koch (AlixPartners) to discuss diligence requests	2.50
03/09/20	IA	Mundipharma diligence - key questions, documents reviews, next steps	1.20
03/09/20	NAS	Edit slides to be reviewed with J. Lowne, B. Weingarten, J. Tran (all Purdue), R. Schnitzler, and J. Turner (both PJT)	0.40
03/09/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to provide update on Mundipharma diligence status and set priorities for week of 3/9.	0.50
03/09/20	RDS	Review Purdue business plan slides for Board proposed by PJT.	2.00
03/09/20	RDS	Meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	1.60
03/09/20	RDS	Avrio slide creation - edits from meeting with J. Lowne (Purdue) and changes to the S&P bridge for legacy commercial products	2.00
03/09/20	RDS	Call with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project management update for Rhodes Pharma pipeline turnaround plan	1.90
03/09/20	RDS	Meeting with R. Shamblen, J. Freidricksen, D. Fogel (all Purdue), R Sublett, and K. McCafferty (both AlixPartners) re: Rhodes Tech strategic partnerships "teaser"	1.10
03/09/20	RDS	Slide creation - Avrio analysis from Nielsen sensitivity on senokot and colace marketing spend	0.80
03/09/20	RDS	Slide creation - Avrio innovation payback and enterprise	

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		value creation	
03/09/20	ADD	Update Purdue vendor master spreadsheet.	0.60
03/09/20	DS	Prepare for and attend meeting with J. Lowne, B. Weingarten, J. Tran (all Purdue), D. Samikkannu, I. Arana, J. DelConte, and R. Sublett (all AlixPartners) to discuss board presentation on Avrio health	2.00
03/09/20	DS	Work on revised presentation (marketing spend scenarios, evaluating S&P spend)	2.10
03/09/20	DS	Update Avrio model with J. Tran's (Purdue) revised numbers	1.40
03/09/20	DS	Review draft materials in preparation for meeting	1.40
03/09/20	DS	Updates to draft materials based on Purdue CFO's comments	0.60
03/09/20	DS	Correspondence with Aviro marketing manager re: Gargle data sent	0.30
03/09/20	DS	Analyze marketing spend scenarios provided by Nielsen	2.40
03/09/20	DS	Review Purdue CFO's list of comments to proposed materials	0.90
03/09/20	DS	Review and correspondence with Avrio CFO re: working capital assumptions	1.20
03/09/20	KM	Itinerary planning and adjustment	0.50
03/09/20	KM	Analysis and market research re: API forecast for core opioids	2.20
03/09/20	KM	Slide creation re: Rhodes Tech partnership teaser	0.90
03/09/20	KM	Review and analysis re: Rhodes Pharma resource allocation	0.90
03/09/20	KM	Slide creation re: Rhodes Tech partnership teaser	1.10
03/09/20	KM	Call with V. Mancinelli, K. Kolar, D. Ebere, D. Fogel (all	2.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project management update for Rhodes Pharma pipeline turnaround plan	
03/09/20	KM	Prepare for and attend meeting with R. Shamblen, J. Freidricksen, D. Fogel (all Purdue), R Sublett, and K. McCafferty (both AlixPartners) re: Rhodes Tech strategic partnerships "teaser"	1.90
03/09/20	KM	API market research	0.40
03/09/20	KM	Call with K. McCafferty (AlixPartners) and D. Fogel (Purdue) re: implementation review process for this week	0.10
03/09/20	KM	Document edits re: Rhodes Tech strategic partnerships "teaser"	0.80
03/10/20	KM	Meeting with V. Mancinelli, B. Thebeau, D. Fogel (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma CPP implementation	1.50
03/10/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: overall implementation progress and 10-year budget	0.50
03/10/20	KM	Document revisions re: Rhodes Tech strategic partnerships	1.10
03/10/20	KM	Preparation for Org structure discussions	0.40
03/10/20	KM	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing organizational changes implementation planning (partial attendance)	1.70
03/10/20	KM	Call with A. Soma, D. Fogel, R. Shamblan (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes tech R&D implementation planning.	1.40
03/10/20	KM	Review and analysis re: Rhodes Pharma partnership	0.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		opportunities	
03/10/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes Pharma R&D implementation planning and Rhodes board presentation materials	1.00
03/10/20	KM	Deck pages re: Rhodes Tech teaser	1.60
03/10/20	KM	Preparation for CPP meeting	0.30
03/10/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss aggregated implementation plans for Rhodes	0.50
03/10/20	DS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to review and update draft slides	0.60
03/10/20	DS	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing organizational changes implementation planning	2.20
03/10/20	DS	Draft list of detailed follow up items on Avrio budget, based on model outputs	1.20
03/10/20	DS	Work on Betadine subproducts part of Avrio model	2.70
03/10/20	DS	Make Avrio model dynamic re: S&P spend and innovation products detail	2.80
03/10/20	RDS	Meeting with V. Mancinelli, B. Thebeau, D. Fogel (all Purdue) K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma CPP implementation	1.50
03/10/20	RDS	Historical Avrio spend with combined Purdue previously unallocated costs	0.40
03/10/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: overall implementation progress and 10-year budget	0.50
03/10/20	RDS	Slide creation - Avrio historical financials	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/10/20	RDS	Slide creation - Avrio Colace & Senokot media / S&P spend / savings analysis	0.80
03/10/20	RDS	Attend call with D. McGuire, D. Fogel, R. Shamblan, A. Soma (all Purdue), K. McCafferty, D Samikkannu, and R. Sublett (both AlixPartners) to discuss manufacturing organizational changes implementation planning	2.20
03/10/20	RDS	Call with A. Soma, D. Fogel, R. Shamblan (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes tech R&D implementation planning.	1.40
03/10/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) to discuss aggregated implementation plans for Rhodes	0.50
03/10/20	RDS	Correspondence with D. Lundie (Purdue) re: work stream planning updates	0.40
03/10/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss Rhodes Pharma R&D implementation planning and Rhodes board presentation materials	1.00
03/10/20	RDS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to review and update draft slides	0.60
03/10/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: RELT meeting and presentation.	0.20
03/10/20	NAS	Meeting with J. DelConte and N. Simon (both AlixPartners) to review Purdue business plan slides prepared by company and discuss revisions.	0.90
03/10/20	NAS	Discussion with J. DelConte, N. Simon (both AlixPartners), R. Schnitzler, and J. Turner (both PJT) re: draft Purdue business plan presentation for Board.	0.50
03/10/20	NAS	Updates to Mundipharma diligence process including country manager meetings and KPMG workplan status.	0.50
03/10/20	IA	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/10/20	IA	AlixPartners) to review and update draft slides	0.50
03/10/20	GJK	Call with AHC and I. Arana (AlixPartners) to discuss open diligence requests.	1.10
03/10/20	GJK	Call with I. McClatchey (Norton Rose), G. Koch, and J. DelConte (both AlixPartners) re: follow up	2.50
03/10/20	GJK	Mundipharma P V review.	1.00
03/10/20	JD	Budget sales comparison for Mundipharma (provided by T Martin - Huron)	0.40
03/10/20	JD	Follow up with the company re: open vendor payment issues.	1.30
03/10/20	JD	Review Adhanisa pre-read materials. Provide comments re: same.	0.50
03/10/20	JD	Review final Ad Hoc Committee diligence responses and diligence materials.	0.90
03/10/20	JD	Review and provide comments on draft materials for Rhodes Executive Leadership Team meeting.	0.90
03/10/20	JD	Meeting with N. Simon and J. DelConte (both AlixPartners) to review Purdue business plan slides prepared by company and discuss revisions.	0.50
03/10/20	JD	Discussion with N. Simon, J. DelConte (both AlixPartners), R. Schnitzler, and J. Turner (both PJT) re: draft Purdue business plan presentation for Board.	0.60
03/10/20	JD	Review comments from J. Lowne (Purdue) on the draft Avrio presentation and review Avrio analysis for potential responses.	0.20
03/10/20	JD	Call with I. McClatchey (Norton Rose), G. Koch, and J. DelConte (both AlixPartners) re: follow up (partial attendance)	0.20
03/10/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners)	

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: RELT meeting and presentation.	
03/10/20	MH	Create accounts payable release file.	0.70
03/10/20	MH	Update all professional release table to reflect updates from legal operations on retention status.	0.90
03/10/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: case progress.	1.10
03/10/20	IA	Review submitted files and follow up on questions re: Rhodes merit increases.	1.40
03/10/20	IA	Follow up on pending payments to benefit vendors.	0.50
03/10/20	IA	Review updated retention tracker for Purdue employees.	1.30
03/10/20	IA	Update Avrio business plan presentation slides.	2.10
03/11/20	HK	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	LJD	Prepare for and attend business plan call for LOE, history on ANDA challenges and BP implications with C. Landau, J. Lowne, M. Ronning (Purdue), J. DelConte and L. Donahue (both AlixPartners).	1.50
03/11/20	LJD	Prepare for and attend meeting with C. Landau, J. Lowne, M. Ronning (all Purdue), R. Schnitzler, J. Turner (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: Adhansia projections.	1.70
03/11/20	LJD	Review staffing protocol and comment	0.40
03/11/20	MH	Call with E. Ruiz (Purdue), M. Hartley, H. Ku (both AlixPartners), and other company representatives to discuss potential pre-petition royalties' obligations.	0.60
03/11/20	MH	Create accounts payable release file.	0.70
03/11/20	JD	Continue analysis of Avrio forecasted S&P spending. Review modeling to date.	0.70



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/11/20	JD	Review of draft pipeline presentation for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	0.60
03/11/20	JD	Meeting with J. Lowne, C. Landau, M. Ronning (all Purdue), and J. DelConte (AlixPartners) re: customer outreach.	0.50
03/11/20	JD	Attend business plan call for LOE, history on ANDA challenges and BP implications with C. Landau, J. Lowne, M. Ronning (all Purdue), J. DelConte and L. Donahue (both AlixPartners).	1.00
03/11/20	JD	Meeting with C. Landau, J. Lowne, M. Ronning (all Purdue), R. Schnitzler, J. Turner (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: Adhansia projections.	1.00
03/11/20	JD	Review OxyContin LOE and Adhansia presentations prior to meetings later this afternoon. Provide comments re: same.	0.80
03/11/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/11/20	JD	Conversation with J. Lowne, E. Ruiz (both Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: business plan scenarios.	0.50
03/11/20	GJK	Mundipharma sales comparisons, including file from FTI	2.50
03/11/20	GJK	Mundipharma diligence coordination including discussions with FTI	1.50
03/11/20	GJK	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	IA	Review updated Avrio PL allocations file for base and innovation products.	1.00
03/11/20	IA	Review Avrio February sales report to be incorporated	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		into Dashboard.	
03/11/20	IA	Review updated employee demographic and bonuses file prepared by human resources.	1.70
03/11/20	IA	Update business plan slides for Avrio board presentation to include refreshed financials.	2.30
03/11/20	IA	Update Avrio dashboard to incorporate comments from management.	1.30
03/11/20	IA	Follow up on pending payments to benefit providers through third party vendor.	0.60
03/11/20	IA	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	IA	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70
03/11/20	NAS	Review updates to Mundipharma diligence process including new data requests and KPMG tax workstream update.	0.70
03/11/20	NAS	Review of draft pipeline presentation for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	0.60
03/11/20	NAS	Prepare for diligence call with L. Lee (Mundipharma Korea).	0.40
03/11/20	NAS	Diligence call with L. Lee (Mundipharma Korea), G. Koch, and N. Simon (both AlixPartners).	1.00
03/11/20	RDS	Call with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss months two dashboard update status and commentary	0.80
03/11/20	RDS	Slide creation - Avrio valuation and cash flow over time	1.20
03/11/20	RDS	Slide creation - Avrio historical financial observations	0.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/11/20	RDS	Slide creation - Avrio commercial S&P bridge & financial projection observations	1.10
03/11/20	RDS	Slide creation - teaser for Rhodes Tech partnership and strategic opportunities conversations	2.00
03/11/20	RDS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70
03/11/20	RDS	Slide creation - Avrio case study for senokot gummy	0.80
03/11/20	RDS	Coordination of Avrio slide preparation - AlixPartners team	0.40
03/11/20	RDS	Slide creation - Avrio summary of innovation product launches and time / line chart to profitability / ROI	2.00
03/11/20	RDS	Avrio business plan presentation edits	0.50
03/11/20	RDS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	RDS	Correspondence with AlixPartners team about data requests from Mundipharma	0.20
03/11/20	DS	Revise Avrio model for base products numbers and numerous tabs	1.50
03/11/20	DS	Revise analysis on cannibalization and assumed base growth	1.40
03/11/20	DS	Put together analysis on laxative market and market share / growth rates	2.20
03/11/20	DS	Tie-out Avrio model to Avrio CFO's latest budget to ensure balances	2.60
03/11/20	DS	Review latest draft of Avrio materials	0.20
03/11/20	DS	Meeting with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss Avrio presentation materials	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/11/20	DS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to finalize Avrio presentation materials before sharing with PJT	0.50
03/11/20	KM	Review of February dashboard	0.20
03/11/20	KM	Dashboard edits	0.80
03/11/20	KM	Call with N. Davis, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss months two dashboard update status and commentary	0.80
03/11/20	KM	Research and analysis re: partnership API locations and competitive advantages	1.70
03/11/20	KM	Document editing and slide creation re: Rhodes Tech teaser	2.10
03/11/20	KM	Slide creation re: Rhodes Tech teaser	1.30
03/11/20	KM	Key Execs list for partnerships discussions	1.40
03/12/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation planning workstream progress and plan for board presentation materials	1.80
03/12/20	KM	Rhodes Tech partnership list and review to Rhodes Tech executive team	0.80
03/12/20	KM	Call with R. Shamblen, P. Cheng, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation plans for Rhodes Tech turnaround	1.90
03/12/20	KM	Analysis re: Rhodes Tech implementation timeline	0.30
03/12/20	KM	Call with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: debrief and Rhodes Tech planning	0.20
03/12/20	KM	CPP analysis for Rhodes Pharma	0.80
03/12/20	KM	Outline of Rhodes presentation to Board slides	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	KM	CPP implementation sequencing	0.60
03/12/20	DS	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	DS	Meeting with marketing analyst re: Betadine Gargle	0.20
03/12/20	DS	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	DS	Correspondence with S. Lemack (AlixPartners) re: status of Customer Programs report	0.30
03/12/20	DS	Assemble analysis on projected business plan cut into 3 types of product families	2.40
03/12/20	DS	Revise slide on commercial products cannibalization and growth rates	1.10
03/12/20	DS	Put together financial analysis on historical - transition - budget, explaining trends and implications	2.20
03/12/20	RDS	Assemble and communicate daily workplan for Avrio business planning team	0.10
03/12/20	RDS	Review Purdue Canada financials for input to US Avrio business plan	0.40
03/12/20	RDS	Rhodes board material outline and agenda for D. Lundie (Purdue) call to discuss	0.40
03/12/20	RDS	Review Rhodes Tech R&D Implementation planning workstream and assemble comments for call with management	0.60
03/12/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review	1.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		implementation planning workstream progress and plan for board presentation materials	
03/12/20	RDS	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	RDS	Call with Avrio management to discuss betadine gargle data.	0.30
03/12/20	RDS	Slide creation - Betadine throat gargle case study	0.90
03/12/20	RDS	Avrio workstream implementation planning and S&P cutbacks	0.40
03/12/20	RDS	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	DS	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	RDS	Call with R. Shamblen, P. Cheng, A. Soma (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to review implementation plans for Rhodes Tech turnaround	1.90
03/12/20	RDS	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	RDS	Communication with BIC re: Avrio data to support business plan assumptions	0.20
03/12/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30
03/12/20	RDS	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	NAS	Assess current status of Mundipharma diligence process and coordinate with other advisors.	1.00
03/12/20	NAS	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/12/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: current status of Mundipharma diligence process and takeaways from recent diligence calls.	0.30
03/12/20	NAS	Compare sales data across iterations of Mundipharma business plan to assess changes in trends and categorizations.	0.80
03/12/20	IA	Update executive bios presentation as requested by legal in response to DOJ request.	1.70
03/12/20	IA	Review September to February OCP spend report and follow up on open items.	1.80
03/12/20	IA	Follow up on pending payments through third party vendor Benefit focus.	0.40
03/12/20	IA	Update Avrio business plan presentation slides.	2.80
03/12/20	IA	Meeting with J. Tran (Purdue), D. Samikkannu, J. DelConte, R. Sublett, and I. Arana (all AlixPartners) to review operating model for Avrio.	0.50
03/12/20	IA	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	IA	Prepare for and attend call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio.	1.70
03/12/20	IA	Review competitive brand and market share data for	1.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Avrio category competitors.	
03/12/20	GJK	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/12/20	GJK	Discussion with N. Simon and G. Koch (both AlixPartners) re: current status of Mundipharma diligence process and takeaways from recent diligence calls.	0.30
03/12/20	GJK	Follow up on Canada gargle product with I. McClatchey (Norton Rose) and also pull relevant info for business planning team	0.50
03/12/20	GJK	Mundipharma diligence planning	2.50
03/12/20	JD	Call with J. Tran (Purdue), J. DelConte, I. Arana, D. Samikkannu, and R. Sublett (all AlixPartners) to discuss updated 3.11.20 budget and S&P and G&A changes from January budget - diligence detailed operating model for Avrio. Partial attendance.	1.10
03/12/20	JD	Meeting with B. Weingarten (Purdue) and J. DelConte (AlixPartners) re: Avrio business plan.	0.60
03/12/20	JD	Meeting with R. Schnitzler, J. Turner (both PJT), J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: Avrio business plan.	0.50
03/12/20	JD	Call with R. Sublett and J. DelConte (both AlixPartners) re: go forward business plan process.	0.30
03/12/20	JD	Call with D. Consla (Davis Polk), and J. DelConte (AlixPartners) re: general Chapter 11 timeline.	0.20
03/12/20	JD	Review pipeline asset presentation and provide comments to management.	0.60
03/12/20	JD	Review draft Chapter 11 timeline and create Chp. 11 glossary page to be provided to various managed care customers.	1.50



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/12/20	MH	Create accounts payable release file.	0.70
03/12/20	MH	Analyze reporting options for tracking of professional payments using different date sources.	2.40
03/12/20	MH	Call with M. Hartley (AlixPartners) and counsel to review options to finalize the Ordinary Course Professional report.	0.50
03/12/20	LJD	Review decks for business plan presentation and comment	0.90
03/12/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.10
03/12/20	HK	Diligence call with F. Bernard (Mundipharma Central/Eastern Europe), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.00
03/13/20	HK	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/13/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.70
03/13/20	LJD	Call with company management re: staffing update and working on locations	0.30
03/13/20	LJD	Coordination call with T. Coleman (PJT)	0.60
03/13/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners)	0.40
03/13/20	MH	Create accounts payable release file.	0.70
03/13/20	MH	Call with M. Hartley (AlixPartners) and legal operations to discuss ordinary course exceptions and identify better data source.	0.70
03/13/20	MH	Revise all professional payment reporting to align with Team Connect data source.	2.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/13/20	JD	Review and provide comments to management on the updated Adhansia slides.	0.50
03/13/20	JD	Review, provide comments and edit the latest Avrio business plan slides.	1.40
03/13/20	JD	Review and provide comments on the January flash report.	0.40
03/13/20	JD	Review historical PBGC correspondence and open diligence questions.	0.70
03/13/20	JD	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business planning progress.	0.20
03/13/20	JD	Call with J. Lowne and others (all Purdue) and J. DelConte (AlixPartners) re: business planning open items and scheduled time to finish.	0.50
03/13/20	JD	Prepare for and participate in a call with R. Aleali, E. Ruiz (both Purdue), S. Brecher (Davis Polk), and J. DelConte (AlixPartners) re: PBGC response.	0.50
03/13/20	GJK	Mundipharma model review and coordination	2.20
03/13/20	GJK	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/13/20	IA	Review proposed benefit program overview presentation.	0.80
03/13/20	IA	Review updated employee demographic information source file submitted by human resources.	1.20
03/13/20	IA	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/13/20	IA	Update Avrio slides for business plan presentation to client.	1.60
03/13/20	IA	Review cash report for week ended 03/13.	1.30
03/13/20	IA	Review monthly flash report and follow up on open items for January.	1.40
03/13/20	NAS	Prepare for Mundipharma Japan diligence call.	0.30
03/13/20	NAS	Diligence call with S. Kimura (GM, Mundipharma Japan), G. Koch, N. Simon, H. Ku (all AlixPartners), and other Mundipharma diligence advisors.	1.50
03/13/20	RDS	Aggregate Avrio slides and provide final edits for distribution to management team	1.50
03/13/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to recap implementation meetings and plan for next weeks	1.10
03/13/20	RDS	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	RDS	Review of latest Avrio 3.11.2020 operating plan adjustments	1.00
03/13/20	RDS	Slide creations - Avrio opening methodology walk through	0.60
03/13/20	RDS	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma R&D turnaround plan	1.80
03/13/20	RDS	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma CPP discussions	1.00
03/13/20	RDS	Review latest slides for J. Lowne (Purdue) presentation	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/13/20	RDS	Review of market research for Avrio / consumer health businesses	1.10
03/13/20	DS	Participate in a call with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners) re: latest Avrio business plan deck.	0.60
03/13/20	DS	Refine consumer health comparative analysis, utilizing CapIQ data	1.10
03/13/20	DS	Edit Senokot Kiwi scenario analysis for Avrio business plan	0.90
03/13/20	DS	Enhance Avrio working capital analysis for use of business plan presentation	1.20
03/13/20	DS	Enhance Avrio working capital analysis for use of business plan Create appendix detailed pro forma historical analysis of gross profit and S&P components	2.20
03/13/20	KM	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Eber (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma R&D turnaround plan	1.80
03/13/20	KM	Review of CPP analysis	0.20
03/13/20	KM	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss update implementation planning for Rhodes Pharma CPP discussions	1.00
03/13/20	KM	Analysis re: CPP implementation plan	0.30
03/13/20	KM	Analysis and restructuring of the CPP implementation plan	0.90
03/13/20	KM	Summary of implementation progress for discussion with D. Lundie (Purdue)	0.70
03/13/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to recap implementation meetings and	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		plan for next weeks.	
03/13/20	KM	Analysis re: Rhodes Pharma allocation of resources and key execs	1.20
03/14/20	RDS	Review Rhodes quality organization implementation plans	0.60
03/14/20	RDS	Review J. Lowne (Purdue) comments to Avrio presentation materials	0.30
03/14/20	JD	Review comments from J. Lowne (Purdue) to draft Avrio business plan presentation.	0.60
03/15/20	LJD	Review correspondence	0.30
03/15/20	LJD	Review and discuss Oxycontin patent overview slides	0.70
03/15/20	IA	Update Avrio business plan slides to reflect latest comments from management.	2.40
03/15/20	IA	Update Avrio dashboard to show February net sales by brand by product.	1.10
03/15/20	IA	Consolidate update slides from AlixPartners and PJT for Avrio business plan presentation for review by management.	0.70
03/15/20	RDS	Review PJT slides for Avrio presentation	0.30
03/15/20	RDS	Slide presentation edits for Monday Avrio presentation	0.90
03/15/20	RDS	Review latest comments from Purdue CFO to Avrio materials	0.30
03/15/20	DS	Correspondence with J. DelConte (AlixPartners) re: cannibalization assumptions in analysis	0.20
03/15/20	DS	Follow up with Head of Finance (Purdue) re: G&A assumptions in business plan beyond 2020	0.30
03/15/20	DS	Incorporate Purdue CFO's comments into Avrio business plan deck	2.40
03/16/20	DS	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and	1.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	
03/16/20	DS	Correspondence with Head of Finance (Purdue) re: historical period needed for market share data	0.20
03/16/20	DS	Draft workplan and share with I. Arana (AlixPartners) and Head of Finance (Purdue) re: completing draft of Avrio business plan materials	0.50
03/16/20	DS	Working session with D. Samikkannu and S. Lemack (both AlixPartners) re: allocation of 3rd party rebate funding's and payments	0.80
03/16/20	DS	Update Avrio business plan draft materials with comments from Purdue CFO	0.80
03/16/20	DS	Draft detailed list of to-do items based on Avrio business plan meeting	1.30
03/16/20	DS	Review of historical market share data sent by Head of Finance Avrio	0.70
03/16/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	0.20
03/16/20	KM	Meeting with J. Norhtington, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Quality organization implementation plan.	1.00
03/16/20	KM	Slide creation re: CPP implementation plan	0.80
03/16/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) re: customer classification for hydroprophone analysis	0.10
03/16/20	KM	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Ebere, (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updates to implementation planning for Rhodes Pharma R&D turnaround plan	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/16/20	KM	Analysis and slide creation re: CPP implementation plan	0.80
03/16/20	KM	Meeting with V. Mancinelli, K. Kolar, D. Eber, D. Fogel (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes Pharma implementation plan review	1.10
03/16/20	KM	Call with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	0.60
03/16/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	1.70
03/16/20	KM	Call with R. Haberman, D. Fogel, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Hydromorphone CPP analysis needs and requirements	0.80
03/16/20	KM	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updated CPP implementation plan	0.50
03/16/20	KM	Analysis re: hydromorphone volume by customer	1.10
03/16/20	KM	Gap analysis re: Rhodes Pharma R&D implementation plan	0.70
03/16/20	RDS	Meeting with J. Norhtington, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Quality organization implementation plan.	1.00
03/16/20	RDS	Call with V. Mancinelli, D. Fogel, R. Thebeau (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updated CPP implementation plan	0.50
03/16/20	RDS	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/16/20	RDS	Call with V. Mancinelli, D. Fogel, K. Kolar, D. Eber, (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss updates to implementation planning for Rhodes Pharma R&D turnaround plan	1.10
03/16/20	RDS	Assemble AlixPartners version of shortened Avrio business plan presentation	0.30
03/16/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	0.60
03/16/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma R&D implementation to budget headcount bridge	1.70
03/16/20	RDS	Call with R. Haberlin, D. Fogel, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Hydromorphone CPP analysis needs and requirements	0.80
03/16/20	RDS	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio and Rhodes business plan progress.	0.40
03/16/20	RDS	Analysis of Dilaudid AG CPP (Purdue)	0.80
03/16/20	RDS	Assemble slides for RELT meeting to discuss Rhodes Pharma CPP	0.60
03/16/20	RDS	Call with K. McCafferty and R. Sublett (both AlixPartners) re: customer classification for hydroprophone analysis	0.10
03/16/20	IA	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	IA	Draft executive committee bios and job history as requested by DOJ.	2.60
03/16/20	IA	Update Purdue retention tracker to include updated	1.80



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		demographic information and latest additions to program.	
03/16/20	IA	Update AIP and LTRP database to include updated 2020 demographic data by employee, as requested by WTW.	1.40
03/16/20	HK	Review IAC projected balance sheet data.	1.60
03/16/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.20
03/16/20	LJD	Catch up call with L. Donahue and J. DelConte (both AlixPartners) re: case work stream coordination and business plan progress.	0.40
03/16/20	LJD	Review and comment on interim fee app	0.60
03/16/20	LJD	Review draft avrio business plan presentation and comment	1.50
03/16/20	MH	Create accounts payable release file.	0.70
03/16/20	JD	Call with J. Lowne, B. Weingarten, J. Tran, E. Ruiz and others (all Purdue), J. DelConte, D. Samikkannu, I. Arana, R. Sublett (all AlixPartners), R. Schnitzler, J. Turner and others (all PJT) to discuss the Avrio business plan presentation	1.20
03/16/20	JD	Call with J. DelConte and R. Sublett (both AlixPartners) re: Avrio and Rhodes business plan progress.	0.40
03/16/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Avrio business plan.	0.20
03/16/20	JD	Correspondence with J. Tran and J. Lowne (both Purdue) re: open Avrio questions.	0.40
03/16/20	JD	Review and provide comments on draft Avrio business plan analysis and presentation.	2.00
03/16/20	JD	Correspondence with C. Robertson (Davis Polk) and J. Turner (PJT) re: Nalmefene consultant.	0.30
03/16/20	JD	Create tracker and forecast for restructuring professional	2.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		fees and compare to latest business plan forecast.	
03/16/20	JD	Review draft Oncology business plan presentation.	1.10
03/16/20	GJK	Call with I. McClatchy (Norton Rose) re: Mundipharma diligence	2.50
03/16/20	GJK	Mundipharma document review	1.00
03/17/20	GJK	Mundipharma diligence, planning and analysis including next steps with/without Deutsche Bank meetings	3.00
03/17/20	NAS	Revise branded opioid and Adhansia business plan slides in advance of Board meeting.	2.60
03/17/20	IA	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan presentation	0.40
03/17/20	JD	Review and work on latest Avrio business plan presentation.	1.00
03/17/20	JD	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	JD	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/17/20	JD	Review Ad Hoc committee due diligence questions, proposed responses and materials provided to date.	0.80
03/17/20	JD	Call with J. DelConte (AlixPartners) and J. Lowne (Purdue) re: Avrio business plan presentation progress.	0.60
03/17/20	JD	Update and finalize generic Chapter 11 timeline for the commercial group and their customer outreach.	1.50
03/17/20	JD	Review draft version of the Oncology asset analysis. Review draft Oncology presentation. Provide comments	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: same.	
03/17/20	MH	Research signed trade agreement to ensure proper UCC approval and correct accounts payable controls.	0.40
03/17/20	MH	Rebuild the Ordinary Course Professional report to tie to details from Team Connect.	2.90
03/17/20	MH	Build algorithm to assign correct period and category to Team Connect billing details for Ordinary Course Professional tracking.	2.70
03/17/20	MH	Create accounts payable release file.	0.70
03/17/20	MH	Prepare for call with legal operations on Ordinary Course Professional tracking.	1.10
03/17/20	LJD	Review deck for Wednesday presentation and discussion	1.50
03/17/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.20
03/17/20	HK	Review IAC projected cash flow data.	2.10
03/17/20	IA	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	IA	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/17/20	IA	Follow up on pending payments to benefit vendors.	0.30
03/17/20	IA	Update Avrio slides to reflect changes requested by management.	1.90
03/17/20	RDS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan presentation	0.40
03/17/20	RDS	Work on RELT meeting presentation for Rhodes Pharma	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		CPP	
03/17/20	RDS	Slide creation - Avrio presentation S&P, net sales CAGR bridge	0.70
03/17/20	RDS	Meeting with K. McCafferty and R. Sublett (both AlixPartners) re: implementation planning	0.70
03/17/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning workstreams ahead of RELT workshop Wednesday / Thursday	1.80
03/17/20	RDS	Review latest turn of Avrio presentation materials and aggregate comments	0.20
03/17/20	RDS	Meeting with R. Haberin, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: CPP analysis and financial impact	0.70
03/17/20	RDS	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	RDS	Modeling of CPP scenarios for Rhodes	0.30
03/17/20	RDS	Analysis of pro forma bridge for historical Avrio financials	0.50
03/17/20	RDS	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to assemble questions for RELT meetings for D. Lundie (Purdue)	2.40
03/17/20	RDS	Avrio presentation tweaks ahead of pre-read	1.60
03/17/20	DS	Call with D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to discuss changes to Avrio business plan presentation	0.40
03/17/20	DS	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		due diligence responses.	
03/17/20	KM	Analysis re: CPP approach and impact	1.20
03/17/20	KM	Slide creation re: CPP approach and impact	0.90
03/17/20	KM	Meeting with K. McCafferty and R. Sublett (both AlixPartners) re: implementation planning	0.70
03/17/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss implementation planning workstreams ahead of RELT workshop Wednesday / Thursday	1.80
03/17/20	KM	Meeting with R. Haberin, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: CPP analysis and financial impact	0.70
03/17/20	KM	Slide edits re: CPP financial impact	0.30
03/17/20	KM	Meeting with K. McCafferty and R. Sublett (both AlixPartners) to assemble questions for RELT meetings for D. Lundie (Purdue)	2.40
03/17/20	KM	Reconciliation re: Rhodes Pharma R&D implementation plan	0.40
03/17/20	DS	Call re: Avrio presentation progress with J. DelConte, R. Sublett, D. Samikkannu, and I. Arana (all AlixPartners).	0.80
03/17/20	DS	Prepare pro forma historical Avrio analysis incorporating adjustments along the P&L	2.40
03/17/20	DS	Revise Avrio business plan materials for revised numbers	1.80
03/17/20	DS	Call with Head of Finance (Purdue) re: pro forma historical adjustments	0.80
03/17/20	DS	Revise Avrio working capital / free cash flow analysis for updated working capital assumptions developed with Purdue CFO	1.30
03/17/20	DS	Revise AlixPartners's Avrio model for new set of numbers	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/17/20	DS	Review analysis on SG&A and G&A changes to plan	0.80
03/17/20	DS	Create a "Pre-Read" version of Avrio business plan materials and send to Purdue CFO	0.80
03/17/20	ADD	Participate in a call with J. Lowne, D. Fogel (both Purdue), T. Melvin, J. Turner (both PJT), K. Knechtel (FTI), H. Schenk (Houlihan), J. DelConte, D. Samikkannu, A. DePalma, and I. Arana (all AlixPartners) re: business plan due diligence responses.	1.10
03/18/20	DS	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	DS	Conform CFO's latest version of Avrio business plan deck with March 17 numbers	1.90
03/18/20	KM	RELT implementation planning	1.00
03/18/20	KM	Call with M. Hartley and K. McCafferty (both AlixPartners) re: Rhodes EI program activities	0.30
03/18/20	KM	Rhodes implementation milestones and budgeted impact summary	0.90
03/18/20	KM	Meeting with D. Fogel (Purdue) K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes implementation milestones and budgeted impact	0.50
03/18/20	KM	Review Rhodes project review meeting materials	0.30
03/18/20	KM	Rhodes project review meeting hosted by D. Lundie (Purdue)	4.00
03/18/20	KM	Meeting with D. Lundie (Purdue) and K. McCafferty (AlixPartners) re: RELT meeting preparation	0.50
03/18/20	KM	Background and incremental analyses re: RELT meeting	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		preparation	
03/18/20	KM	Call with J. Lowne, D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to preview updated scenario planning for five-year plan	0.60
03/18/20	RDS	Assemble Gantt chart to guide budget variance discussion with RELT	1.70
03/18/20	RDS	Meeting with D. Fogel (Purdue) K. McCafferty and R. Sublett (both AlixPartners) re: Rhodes implementation milestones and budgeted impact	0.50
03/18/20	RDS	Rhodes Executive Leadership Team (RELT) R&D meeting (virtual/WebEx)	3.60
03/18/20	RDS	Assemble summary document for D. Lundie (Purdue) to guide discussions at day 2 of the RELT	1.00
03/18/20	RDS	Address Avrio presentation questions	0.60
03/18/20	RDS	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	RDS	Recap D. Lundie (Purdue) and RELT R&D Discussion	0.20
03/18/20	RDS	Call with J. Lowne, D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to preview updated scenario planning for five-year plan	0.60
03/18/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss board slide outline	0.10
03/18/20	IA	Follow up on pending payments to benefit vendors.	0.40
03/18/20	IA	Update Executive committee bios and job history based on job descriptions provided by human resources, as requested by DOJ.	1.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/18/20	IA	Follow up on updated Purdue budget files to be incorporated into Purdue cash forecast.	0.30
03/18/20	IA	Update Avrio business plan slides to include latest updated financials.	1.40
03/18/20	IA	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.10
03/18/20	LJD	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback.	0.60
03/18/20	LJD	Participate in call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, M. Ronning (all Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Oncology asset forecast.	1.60
03/18/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: catch up on business planning and case progress.	0.40
03/18/20	LJD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau (both Purdue), J. DelConte and L. Donahue (AlixPartners) re: PHI and Pipeline asset forecasts.	1.10
03/18/20	MH	Research new pre-petition invoice for trade agreement vendor to determine correct payment treatment.	0.50
03/18/20	MH	Create accounts payable release file.	0.70
03/18/20	MH	Call with M. Hartley and K. McCafferty (both AlixPartners) re: Rhodes EI program activities	0.30



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/18/20	JD	Participate in call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, M. Ronning (all Purdue), L. Donahue, and J. DelConte (both AlixPartners) re: Oncology asset forecast.	1.60
03/18/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne (Purdue), and J. DelConte (AlixPartners) re: Oncology forecast.	0.50
03/18/20	JD	Call with R. Schnitzler (PJT) and J. DelConte (AlixPartners) re: business plan issues.	0.20
03/18/20	JD	Review draft customer programs motion and provide comments.	0.30
03/18/20	JD	Review updated Avrio business plan presentation.	0.80
03/18/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: catch up on business planning and case progress.	0.40
03/18/20	JD	Call with C. Landau, J. Lowne, B. Weingarten and other management (all Purdue), J. Turner, R. Schnitzler and others (all PJT), L. Donahue, J. DelConte, D. Samikkannu, I. Arana, and R. Sublett (all AlixPartners) to present Avrio board materials and solicit feedback	0.60
03/18/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau (both Purdue), J. DelConte and L. Donahue (AlixPartners) re: PHI and Pipeline asset forecasts.	0.70
03/18/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: Oncology forecast.	0.30
03/18/20	NAS	Revise branded opioid and Adhansia business plan slides for Board presentation.	0.70
03/18/20	GJK	Court call re: Purdue filing and implications for IAC diligence	3.00
03/18/20	GJK	Follow up post Court call, including priority steps and messaging	1.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/19/20	GJK	Call with G. Koch (AlixPartners), I. McClatchy (Norton Rose), and B. Bromberg (FTI) re: Mundipharma diligence process	2.00
03/19/20	GJK	Follow up and document review per FTI and Huron emails	1.60
03/19/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to provide update on latest developments in Mundipharma diligence process.	0.40
03/19/20	NAS	Review of new files posted in Mundipharma diligence data room, including guide to accounting treatment.	1.30
03/19/20	NAS	Correspondence with B. Bromberg (FTI) and analysis of data provided re: new data from Mundipharma/Huron.	0.70
03/19/20	NAS	Meeting with J. DelConte, N. Simon, and S. Lemack (all AlixPartners) to discuss revisions to Purdue business plan slides for upcoming Board meeting.	0.90
03/19/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to provide update on latest developments in Mundipharma diligence process.	0.40
03/19/20	NAS	Inventory of available Mundipharma data and analysis of how data can be incorporated into Mundipharma business plan model.	0.90
03/19/20	NAS	Revise Purdue business plan slides for upcoming Board meeting following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	0.40
03/19/20	JD	Participate in a call with C. Landau, M. Kesselman, J. Lowne (all Purdue), M. Huebner, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell (both PJT), J. DelConte, and L. Donahue (both AlixPartners) re: case update and go forward planning call.	1.20
03/19/20	JD	Meeting with J. DelConte, N. Simon, and S. Lemack (all AlixPartners) to discuss revisions to Purdue business plan	0.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		slides for upcoming Board meeting	
03/19/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan questions.	0.20
03/19/20	JD	Review draft Opioid, PHI and Pipeline presentation edits. Provide comments re: same.	1.00
03/19/20	JD	Review and edit draft HRT presentation and draft court declaration in order to prepare it to be shared with outside advisors.	1.80
03/19/20	JD	Review and provide comments re: draft January flash report.	0.70
03/19/20	JD	Call with J. Turner (PJT) and J. DelConte (AlixPartners) re: go forward Thursday meetings.	0.30
03/19/20	MH	Create accounts payable release file.	0.70
03/19/20	MH	Call with counsel to discuss next steps on legal firm that may have exceeded the OCP cap.	0.40
03/19/20	LJD	Prepare for and attend update call with advisors and management	1.20
03/19/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.30
03/19/20	SKL	Meeting with J. DelConte, S. Lemack, and N. Simon (all AlixPartners) to discuss revisions to Purdue business plan slides for upcoming Board meeting.	0.90
03/19/20	SKL	Begin review of the latest version of the Purdue business plan slides and begin updating accordingly to ensure consistent format throughout.	2.10
03/19/20	IA	Review position history and job descriptions submitted for executive committee members as requested by legal in response to DOJ request.	1.20
03/19/20	IA	Update Avrio business plan slides to reflect financials	1.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		adjusted for innovation growth in outer years of forecast.	
03/19/20	IA	Review updated Avrio business plan presentation, now including updated slides showing latest financials	1.60
03/19/20	IA	Review follow up questions on Avrio business plan slides received from management.	1.10
03/19/20	RDS	Rhodes Executive Leadership Team meeting with R. Shamblen, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue), K. McCafferty and R. Sublett (both AlixPartners) to discuss turnaround implementation plans	3.90
03/19/20	RDS	Updated RELT review slides for David Lundie	0.30
03/19/20	RDS	Recap on RELT meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) and design next steps for big four management meetings	1.00
03/19/20	RDS	Slide creation - shell for Rhodes Board materials, dashboard and Appendix slides	2.20
03/19/20	RDS	Correspondence with R. Schnitzler (PJT) re: Avrio financials	0.30
03/19/20	RDS	Slide creation - Rhodes board presentation financial scenario modeling and bridges	0.90
03/19/20	RDS	Slide creation - Rhodes board presentation; Butrans market share and impact to Rhodes budget	1.80
03/19/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	1.30
03/19/20	KM	Rhodes Executive Leadership Team meeting with R. Shamblen, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue), K. McCafferty and R. Sublett (AlixPartners) to discuss turnaround implementation plans.	3.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/19/20	KM	Recap on RELT meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) and design next steps for big four management meetings	1.00
03/19/20	KM	Deck outline and storyline re: Rhodes presentation to the Board	2.00
03/19/20	KM	Analysis and slide creation re: Rhodes presentation to the Board	1.40
03/19/20	KM	Analysis variance re: Rhodes presentation to the Board	1.60
03/19/20	DS	Update Avrio business plan deck for latest numbers	1.10
03/19/20	DS	Call with Head of Finance (Purdue) re: cost structure prior to current sales/operations provider	0.40
03/19/20	DS	Correspondence with PJT re: providing latest numbers in business plan	0.30
03/20/20	DS	Review latest draft of Avrio deck and provide revised copy to management, PJT	1.30
03/20/20	DS	Update Avrio deck to include detail on retail sales	0.20
03/20/20	DS	Further revise Avrio business plan deck based on comments from Head of Finance (Purdue)	1.50
03/20/20	KM	Storyboard and planning re: Rhodes presentation to the Board	0.60
03/20/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss revised board presentation.	1.40
03/20/20	KM	Butrans edits re: Rhodes presentation to the Board	0.70
03/20/20	KM	Call with N. Davis (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss dashboard updates	0.40
03/20/20	KM	Coordination and correspondence re: status of Rhodes turnaround implementation planning	0.30
03/20/20	KM	Deck edits and improvements re: Rhodes presentation to	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		the Board	
03/20/20	KM	Partnership analysis re: Rhodes presentation to the Board	0.60
03/20/20	KM	Deck edits re: Rhodes presentation to the Board	0.50
03/20/20	KM	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials	1.10
03/20/20	KM	Dashboard slide creation and updates re: Rhodes presentation to the Board	0.40
03/20/20	RDS	Slide creation - Rhodes board presentation; Butrans Appendix detail	1.00
03/20/20	RDS	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials	1.10
03/20/20	RDS	Continue edits to board presentation for Rhodes board materials and Rhodes Tech partnership update and implementation Gantt chart	2.20
03/20/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss revised board presentation	1.40
03/20/20	RDS	Slide creation - low/base/high and plant closure slides	0.50
03/20/20	RDS	Call with N. Davis (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss dashboard updates	0.40
03/20/20	RDS	Review and changes to Avrio board presentation per updated 3.17.20 financial update	0.60
03/20/20	IA	Review submitted additional job descriptions for executive committee members and update summary file in response to DOJ diligence request	2.40
03/20/20	IA	Review updated AIP and LTRP database created for Willis Towers Watson and update with new hires eligible for payments in 2021	1.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/20/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.60
03/20/20	LJD	Prepare for and attend opioid assumptions for revenue sensitivities call with management and advisors	1.10
03/20/20	MH	Create accounts payable release file.	0.70
03/20/20	JD	Conference call with J. DelConte, N. Simon (both AlixPartners), J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, and M. Kesselman (all Purdue) to review branded opioid business plan.	1.20
03/20/20	JD	Call with J. DelConte (AlixPartners), J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT) re: Adhansia LOE.	0.50
03/20/20	JD	Call with J. Lowne, D. Fogel, D. Lundie (all Purdue), J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) to preview board presentation materials.	1.10
03/20/20	JD	Review and provide comments on the branded opioid business plan presentation.	0.70
03/20/20	JD	Review and provide comments on the Rhodes business plan presentation and analysis.	0.70
03/20/20	JD	Review final January flash report to send out for approval to post.	0.40
03/20/20	JD	Catch up call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
03/20/20	NAS	Assess data received from Mundipharma to-date and determine how to bridge between data sources in business plan model.	1.10
03/20/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: key outputs from Mundipharma business plan model for interim report.	0.80
03/20/20	NAS	Create list of action items and determine best approach	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		towards revising Mundipharma model following discussion with G. Koch (AlixPartners).	
03/20/20	NAS	Conference call with J. DelConte, N. Simon (both AlixPartners), J. Turner, R. Schnitzler (both PJT), J. Lowne, C. Landau, and M. Kesselman (all Purdue) to review branded opioid business plan.	1.20
03/20/20	NAS	Revise Mundipharma business plan model to incorporate G&A and indirect R&D.	2.30
03/20/20	NAS	Reconcile P&L line items included in two types of Mundipharma P&Ls provided by Management Revisions and incorporate those which are missing in business plan model.	3.40
03/20/20	NAS	Summarize findings from revisions to-date to Mundipharma business plan model for G. Koch (AlixPartners).	0.50
03/20/20	GJK	Catch up call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
03/20/20	GJK	Mundipharma diligence and analysis	2.30
03/20/20	GJK	Mundipharma diligence coordination and planning	1.50
03/20/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: key outputs from Mundipharma business plan model for interim report.	0.80
03/21/20	IA	Review April retention payments information by employee to be submitted by HR to payroll.	0.60
03/21/20	RDS	Updates to Avrio board presentation including J. Lowne, J. Tran (both Purdue) updates to language and projections	0.90
03/21/20	DS	Further revise Avrio business plan deck and send to management and PJT	1.10
03/22/20	DS	Review CFO's comments on Avrio draft deck	0.50



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/22/20	IA	Update executive bios and add position timeline tables to slides in executive committee summary file in response to DOJ diligence request	1.70
03/22/20	JD	Review and provide comments on the latest Adhansia presentation before tomorrow's meetings.	1.10
03/23/20	JD	Review and provide comments on different Adhansia financial sensitivities.	0.80
03/23/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.30
03/23/20	JD	Call with J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: Adhansia business plan.	0.50
03/23/20	JD	Call with J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner, R. Schnitzler, J. O'Connell (all PJT), L. Donahue, and J. DelConte (both AlixPartners) re: Adhansia business plan.	0.70
03/23/20	JD	Review and provide comments on updated Avrio analysis and forecast.	0.80
03/23/20	JD	Call with J. Lowne, C. Landau, D. Lundie (all Purdue), J. Turner, R. Schnitzler (both PJT), R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes business plan.	1.00
03/23/20	JD	Meeting with J. Lowne (Purdue), J. Turner, R. Schnitzler (both PJT), and J. DelConte (AlixPartners) re: final business plan presentation.	0.30
03/23/20	JD	Review latest Rhodes slides.	0.20
03/23/20	JD	Call with C. Landau, D. Lundie, M. Kesselman, J. Lowne, D. Fogel (all Purdue), J. DelConte, and R. Sublett (all AlixPartners) to present the Gx business plan.	1.40
03/23/20	JD	Review and comment on Adhansia projections, scenario	1.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		analyses and draft presentation.	
03/23/20	JD	Review final January flash report and correspondence with R. Aleali (Purdue) re: same.	0.40
03/23/20	GJK	Mundipharma diligence and projection planning	3.00
03/23/20	GJK	Mundipharma sales trends and markets review	2.50
03/23/20	NAS	Set priorities and action items related to Mundipharma diligence for week of 3/23.	0.90
03/23/20	NAS	Review prior Purdue business plan presentations to Board for purposes of drafting materials for upcoming Board meeting.	0.30
03/23/20	NAS	Draft and send follow-up questions to S. Jamieson (Management Revisions) re: Mundipharma data provided.	1.20
03/23/20	NAS	Pull data from source files and revise Mundipharma business plan model to include functionality for intercompany eliminations.	2.10
03/23/20	NAS	Add P&Ls for adjusting journal entries and central functions to Mundipharma business plan model.	3.00
03/23/20	IA	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Avrio VP Finance re: updating business plan numbers	0.30
03/23/20	IA	Update executive bios and employment history overview deck in response to DOJ request.	1.70
03/23/20	IA	Review updated innovation PLs for Avrio reallocating growth reductions to Senokot gummies.	1.20
03/23/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.60
03/23/20	MH	Create accounts payable release file.	0.70
03/23/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan and team coordination.	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/23/20	LJD	Preview adhansia plan	1.10
03/23/20	LJD	Review correspondence	0.50
03/23/20	DS	Meeting with D. Samikkannu, I. Arana (both AlixPartners), and Avrio VP Finance re: updating business plan numbers	0.30
03/23/20	DS	Create schedule summarizing topline changes to prior plan	1.20
03/23/20	DS	Update model for revised numbers	2.70
03/23/20	DS	Review revised numbers in detail providing comments to VP Finance	2.90
03/23/20	DS	Review and provide comments to S. Lemack (AlixPartners) on weekly cash report	0.90
03/23/20	DS	Draft detailed email to VP Finance (Purdue) re: further changes needed to be made with revised numbers	0.70
03/23/20	KM	Edits for Rhodes deck for Board meeting	0.70
03/23/20	KM	Analysis of recent IQVIA data and methylphenidate market share data	0.60
03/23/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: methylphenidate analysis	0.40
03/23/20	KM	Analysis and slide creation re: change in methylphenidate market	1.90
03/23/20	KM	Call with D. Fogel, D. Lundie (both Purdue), R. Sublett and K. McCafferty (AlixPartners) re. Rhodes presentation to the Board and C. Landau (Purdue) discussion	1.80
03/23/20	KM	Update presentation re: Rhodes presentation to the Board and C. Landau (Purdue) discussion	0.90
03/23/20	KM	Dashboard slide development re: Rhodes presentation to the Board and C. Landau (Purdue) discussion	1.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/23/20	KM	Call with D. Fogel, D. Lundie, J. Lowne, C. Landau, M. Kesselman, B. Weingarten (all Purdue), and K. McCafferty (AlixPartners) re: Rhodes deck for presentation to the Board	1.00
03/23/20	KM	Board deck edits re: Rhodes deck for presentation to the Board	0.90
03/23/20	RDS	Assemble materials for call with C. Landau (Purdue)	1.10
03/23/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: methylphenidate analysis	0.40
03/23/20	RDS	Call with C. Landau, D. Lundie, M. Kesselman, J. Lowne, D. Fogel (all Purdue), J. DelConte, and R. Sublett (all AlixPartners) to present the Gx business plan	1.40
03/23/20	RDS	Update dashboard and sensitivity analysis for Rhodes business plan	0.90
03/23/20	RDS	Correspondence re: updated Rhodes budget figures	0.50
03/23/20	RDS	Update to Rhodes board presentation to reflect Methylphenidate and changes to the pipeline	0.50
03/23/20	RDS	Avrio financial restatements	0.20
03/23/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss Methylphenidate	0.50
03/23/20	RDS	Update presentation to reflect Methylphenidate forecast updates	2.30
03/23/20	RDS	Call with D. Fogel, D. Lundie (both Purdue), R. Sublett and K. McCafferty (both AlixPartners) re. Rhodes presentation to the Board and C. Landau (Purdue) discussion	1.80
03/23/20	RDS	Call with J. Lowne, C. Landau, D. Lundie (all Purdue), J. Turner, R. Schnitzler (both PJT), R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: Rhodes	1.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan.	
03/24/20	RDS	Review changes to board presentation by D. Lundie (Purdue)	0.50
03/24/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss management changes to board presentation	1.50
03/24/20	RDS	Edits to board presentation for Rhodes	1.20
03/24/20	RDS	Review amended Avrio board presentation and update executive summary version	1.50
03/24/20	RDS	Execute D. Lundie (Purdue) edits to Rhodes board presentation	0.40
03/24/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to review changes to Rhodes board presentation	0.40
03/24/20	RDS	Draft email outreach drafts for potential strategic partners to Rhodes Tech	1.60
03/24/20	RDS	Changes to Rhodes Tech teaser presentation	0.80
03/24/20	RDS	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	RDS	Review Rhodes business plan assumptions	0.50
03/24/20	KM	Call with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss management changes to board presentation	1.50
03/24/20	KM	Rhodes org synergies implementation plan and targeting	0.60
03/24/20	KM	Rhodes budget cash flow bridge analysis	0.90
03/24/20	KM	Slide edits re: Rhodes implementation progress and Board report	0.80
03/24/20	KM	Coordination of Rhodes partnership planning effort	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/24/20	KM	Analysis and review of Butrans and Methylphenidate impact to budget	1.90
03/24/20	KM	Board deck edits re: Rhodes deck for presentation to the Board	0.80
03/24/20	KM	Slide editing for Board deck	0.80
03/24/20	KM	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	KM	Deck edits re: Rhodes implementation progress and Board report	0.50
03/24/20	DS	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Wang (PJT) re: revised numbers	0.30
03/24/20	DS	Incorporate next draft of numbers into business plan model	2.20
03/24/20	DS	Bridge changes in last 3 set of management's numbers and provide to PJT	1.80
03/24/20	DS	Draft analysis supporting topline change in Avrio business plan	1.10
03/24/20	DS	Revise latest version of Avrio deck and send for internal review	1.00
03/24/20	LJD	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	MH	Create accounts payable release file.	0.70
03/24/20	MH	Research petition status on bonus payments to contracted sales force.	0.80
03/24/20	HK	Update IAC diligence tracker with additions to the diligence data site.	0.30
03/24/20	IA	Review insider payments based on latest estimate of LTI	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		grant factors.	
03/24/20	IA	Review latest Avrio PL allocations by innovation adjusted for Gummies growth.	1.40
03/24/20	IA	Update Avrio slides based on latest Avrio PL allocations by innovation adjusted for Gummies growth.	1.40
03/24/20	NAS	Evaluate current state of Mundipharma business plan model and plan out revisions.	0.40
03/24/20	NAS	Review latest draft of Adhansia presentation for Purdue management for summary slides to go to Board.	0.60
03/24/20	NAS	Prepare for Mundipharma diligence status update call with PJT.	0.30
03/24/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) to discuss status of Mundipharma diligence/model and discuss scenarios to run.	0.50
03/24/20	NAS	Create plan to implement specific scenarios in Mundipharma business plan model following discussion with PJT.	0.20
03/24/20	NAS	Create consolidated tab in Mundipharma business plan model for all commercial regions, central costs, and intercompany eliminations/adjustments.	1.20
03/24/20	NAS	Document data sources for all inputs to Mundipharma business plan model, build check functionality relative to raw data, and resolve all discrepancies.	2.80
03/24/20	IA	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Wang (PJT) re: revised numbers	0.30
03/24/20	GJK	Mundipharma report outline review	1.50
03/24/20	GJK	Mundipharma trends analysis	2.00
03/24/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), J. Turner,	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		R. Schnitzler, and J. Arsic (all PJT) to discuss status of Mundipharma diligence/model and discuss scenarios to run.	
03/24/20	JD	Correspondence with C. Landau and J. Lowne (both Purdue) re: questions from Duff & Phelps.	0.70
03/24/20	JD	Review and provide comments on final branded opioid presentation.	1.00
03/24/20	JD	Review latest draft PHI and pipeline slides for incorporation into the overall board business plan presentation.	0.80
03/24/20	JD	Review updated draft Adhansia slides and provide comments re: same.	0.50
03/24/20	JD	Update call with L. Donahue, J. DelConte, K. McCafferty, and R. Sublett (all AlixPartners) to review Rhodes board presentation	1.50
03/24/20	JD	Review 3 statement model incorporating the latest updated business plans to analyze the consolidated cash flows in conjunction with public health initiatives layered in in order to compare plan to January forecast.	1.80
03/25/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan progress.	0.20
03/25/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan update.	0.60
03/25/20	JD	Review latest Rhodes business plan updates.	1.00
03/25/20	JD	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: DOJ responses.	0.50
03/25/20	JD	Review updated Avrio slides.	0.50



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/25/20	JD	Review and reconcile Rhodes presentation against financial model.	0.60
03/25/20	JD	Review diligence materials re: third party valuations.	0.80
03/25/20	JD	Review Syneos master service agreement re: force majeure clause.	0.30
03/25/20	GJK	Mundipharma report notes and scenario planning	2.00
03/25/20	GJK	Project coordination and planning	1.00
03/25/20	GJK	Mundipharma diligence and analysis	2.00
03/25/20	NAS	Review and revise Adhansia slides provided by Purdue for materials related to upcoming Board meeting.	1.20
03/25/20	NAS	Review and revise branded opioid business plan slides provided by Purdue in advance of Board meeting.	2.80
03/25/20	NAS	Revise Public Health Initiatives business plan slides in advance of Purdue Board meeting.	0.30
03/25/20	IA	Review comments received from J. Lowne (Purdue) on Avrio business plan presentation.	0.90
03/25/20	IA	Review updated P&L file for Avrio and update board presentation to include latest comments from management.	1.70
03/25/20	IA	Follow up on PJT questions related to adjacent innovations in Avrio business plan.	0.40
03/25/20	IA	Review wages motion agreement documents and summarize backup to non-executive retention payments by employee per management's request.	1.30
03/25/20	IA	Review voluntary resignations report submitted by human resources.	0.30
03/25/20	IA	Review and update Avrio business plan presentation based on comments from AlixPartners team.	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/25/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.80
03/25/20	MH	Create accounts payable release file.	0.70
03/25/20	MH	Add insurance vendor to approved release list.	0.30
03/25/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: business plan update.	0.60
03/25/20	LJD	Review and comment on Rhodes partnership teaser	0.70
03/25/20	DS	Review latest draft of Avrio deck and send to fellow advisors	1.10
03/25/20	DS	Call with VP Finance (Purdue) and D. Samikkannu (AlixPartners) re: previous sales broker and cost structure	0.50
03/25/20	KM	Creation of Smartsheet implementation tracker	0.40
03/25/20	KM	Deck edits and improvements re: Rhodes presentation to the Board for D. Lundie	0.40
03/25/20	KM	Rhodes cash flow bridge revisions	0.90
03/25/20	KM	Rhodes R&D implementation plan update and analysis	0.80
03/25/20	KM	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss latest updates to Rhodes board presentation	1.90
03/25/20	KM	Call with D. Lundie, R. Shamblan, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) for update on Rhodes Tech partnership workstream	1.50
03/25/20	KM	Rhodes Tech implementation plan update and analysis - 5x24 ops	0.50
03/25/20	KM	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	KM	Build Rhodes presentation to the Board for D. Lundie (Purdue)	2.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/25/20	RDS	Update Rhodes work stream workplan	0.40
03/25/20	RDS	Implementation gantt chart creation	0.60
03/25/20	RDS	Further edits to board slides for Rhodes presentation	1.50
03/25/20	RDS	Review and provide thoughts against J. Lowne (Purdue) commentary to the Avrio board presentation slides.	0.30
03/25/20	RDS	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss latest updates to Rhodes board presentation	1.90
03/25/20	RDS	Call with D. Lundie, R. Shamblan, D. Fogel (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) for update on Rhodes Tech partnership workstream	1.50
03/25/20	RDS	Call with R. Sublett, K. McCafferty, and J. DelConte (all AlixPartners) re: updated Rhodes business plan slides.	0.90
03/25/20	RDS	Assemble longer form board presentation for contextual backup	1.10
03/25/20	RDS	Call with R. Schnitzler (PJT) and R. Sublett (AlixPartners) to discuss Avrio and Rhodes business plan presentation	0.40
03/25/20	RDS	Review Rhodes Tech partnership rationale	1.40
03/26/20	RDS	Meeting with D. Lundie, D. McGuire, D. Fogel, R. Shamblen, V. Mancinelli, J. Doyle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes deck and initiatives for BOD	1.50
03/26/20	RDS	Call with Rhodes senior leadership team R. Shamblen, D. Lundie, V. Mancinelli, D. Fogel, D. McGuire, J. Northington (all Purdue) and R. Sublett (AlixPartners) to present board slides	1.50
03/26/20	RDS	Prepare presentation breakdown for Rhodes board deck	0.60
03/26/20	RDS	Correspondence with PJT re: board presentation to discuss business planning	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/26/20	RDS	Partnership presentation for Noramco teaser	2.80
03/26/20	RDS	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) to discuss headcount reductions targets for Rhodes organization	0.20
03/26/20	RDS	Assemble board backup story to bridge from various approved budget approvals	1.60
03/26/20	RDS	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	RDS	Call with D. Fogel, D. Lundie (both Purdue), and R. Sublett (AlixPartners) to discuss headcount reductions	0.20
03/26/20	RDS	Meeting with D. Fogel, M. Sisoda, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma market dynamics / forecasting / competitive landscape	1.00
03/26/20	KM	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: edits and financial update for Rhodes presentation to the Board for D. Lundie	0.40
03/26/20	KM	Rhodes Tech workforce reduction Smartsheet implementation plan development	0.80
03/26/20	KM	Meeting with D. Fogel, M. Sisoda, N. Davis (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Pharma market dynamics / forecasting / competitive landscape	1.00
03/26/20	KM	Rhodes Tech 5x24 operations implementation plan development on smartsheet	0.50
03/26/20	KM	Meeting with D. Lundie, D. McGuire, D. Fogel, R.	1.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Shamblen, V. Mancinelli, J. Doyle (all Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes deck and initiatives for BOD	
03/26/20	KM	Rhodes Tech implementation plan health and status updates	0.30
03/26/20	DS	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Tran (Purdue) to discuss latest version of board presentation	0.40
03/26/20	KM	Edits to Rhodes BOD presentation	0.40
03/26/20	KM	Research and analysis for Rhodes Tech teaser	1.80
03/26/20	KM	Rhodes Tech teaser for Noramco partnership discussion	0.70
03/26/20	KM	Partnership teaser analysis and development	2.30
03/26/20	JD	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00
03/26/20	DS	Call with VP Finance (Purdue) and D. Samikkannu (AlixPartners) to review revised numbers	0.80
03/26/20	LJD	Prepare for and attend call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, J. DelConte (all AlixPartners) re: case progress update and planning call.	1.20
03/26/20	LJD	Update call with J. Dubel (board member)	0.50
03/26/20	MH	Research vendor with additional invoices beyond trade agreement amount.	0.80
03/26/20	MH	Create accounts payable release file.	0.70
03/26/20	SKL	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/26/20	SKL	Continue to update the latest version of the Business Planning/Pipeline deck in preparation for tomorrow's discussion with J. DelConte and N. Simon (both AlixPartners)	2.50
03/26/20	SKL	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, S. Lemack, and N. Simon (all AlixPartners).	1.20
03/26/20	IA	Update operating expenses assumptions in Purdue cash forecast based on run rates.	1.20
03/26/20	IA	Call with D. Samikkannu, I. Arana (both AlixPartners), and J. Tran (Purdue) to discuss latest version of board presentation	0.40
03/26/20	IA	Review updated Avrio model and CAGR breakeven point.	0.70
03/26/20	IA	Draft Avrio innovation break even analysis per requests by management to be included in business plan presentation.	1.80
03/26/20	NAS	Revise Mundipharma business plan model to incorporate price/volume data provided by company.	2.10
03/26/20	NAS	Prepare for walk-through of latest draft of Purdue business plan slides with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.00
03/26/20	NAS	Revise list of Mundipharma diligence requests to be sent to Huron (Mundipharma financial advisor).	0.60
03/26/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to prepare for Mundipharma diligence discussion with Huron and other Mundipharma diligence advisors.	0.30
03/26/20	NAS	Mundipharma diligence process discussion with Huron (financial advisor to Mundipharma), G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic (both PJT), and other Mundipharma diligence advisors (FTI, HL, Province,	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Jefferies).	
03/26/20	NAS	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/26/20	GJK	Mundipharma project coordination, including prep for calls and alignment with other advisors	2.50
03/26/20	GJK	Mundipharma sales trends/analysis	2.00
03/26/20	GJK	Mundipharma diligence process discussion with Huron (financial advisor to Mundipharma), G. Koch, N. Simon (both AlixPartners), J. Turner, J. Arsic (both PJT), and other Mundipharma diligence advisors (FTI, HL, Province, Jefferies).	0.60
03/26/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to prepare for Mundipharma diligence discussion with Huron and other Mundipharma diligence advisors	0.30
03/26/20	GJK	Call with J. O'Connell, R. Schnitzler, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman (both Purdue), L. Donahue, G. Koch, J. DelConte (all AlixPartners) re: case progress update and planning call.	1.00
03/26/20	JD	Call with J. Turner (PJT), K. McCafferty, J. DelConte, and R. Sublett (all AlixPartners) re: aggregated Purdue business plan	0.80
03/26/20	JD	Walk-through of latest draft of Purdue business plan slides for Board of Directors with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/26/20	JD	Review updated and edited branded opioid, adhasnia, pipeline and PHI slides prior to call with team and compare against previous versions.	1.50
03/26/20	JD	Review additional Rhodes background business plan	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		slides.	
03/26/20	JD	Review and update Avrio innovation breakeven analysis.	0.80
03/26/20	JD	Review final version of HRT Naloxone agreement prior to distribution.	0.50
03/27/20	JD	Catch up with J. Lowne (Purdue), R. Schnitzler, J. Turner (both PJT), and J. DelConte (AlixPartners) re: business plan progress.	0.50
03/27/20	JD	Review the latest version of the Board presentation from David Lundie.	0.60
03/27/20	GJK	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	GJK	IAC update with PJT and DPW to discuss DPW reaching out to family counsel re: DB meetings	0.30
03/27/20	GJK	Mundipharma model review and planning	3.20
03/27/20	GJK	Mundipharma consumer products review	2.50
03/27/20	JDH	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	RC	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	NAS	Build revised Mundipharma sales scenario (through Product Contribution line) for Europe, LAM, and Canada	2.90



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		regions.	
03/27/20	NAS	Check and reconcile figures resulting from revised sales case scenario in Mundipharma business plan model.	2.10
03/27/20	NAS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	NAS	Summarize findings from revised sales case scenario in Mundipharma business plan model for G. Koch (AlixPartners).	1.30
03/27/20	NAS	Build revised sales scenario in Mundipharma business plan model below Product Contribution line item.	1.90
03/27/20	IA	Discussion with J. Wang (PJT) and I. Arana (both AlixPartners) on Avrio updated financials.	0.40
03/27/20	IA	Review and update innovation break even analysis for Avrio.	1.10
03/27/20	IA	Update Avrio slides to include latest comments from management and updated financials.	1.40
03/27/20	IA	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SKL	Finalize updates to the Purdue Business Plan/Pipeline slides and circulate to the AlixPartners team for final sign-off.	1.30
03/27/20	HK	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K.	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	
03/27/20	LJD	Call with J. Dubel (board member)	0.40
03/27/20	LJD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	MH	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	MH	Create accounts payable release file.	0.70
03/27/20	MFR	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	KM	Storyboard and planning re: Rhodes presentation to the Board	1.20
03/27/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Rhodes business plan slides for the board	0.80
03/27/20	KM	Meeting with R. Shamblen, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech partnership outreach - general and noramco	2.00
03/27/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes BOD presentation	1.50
03/27/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty	0.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners) re: Rhodes headcount and organizational restructuring targets	
03/27/20	KM	Rhodes Tech partnership outreach - edits and outreach for Cambrex, Alcaliber and Hikma	1.60
03/27/20	KM	Rhodes Tech partnership outreach - master teaser improvement	1.00
03/27/20	KM	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	RDS	Review headcount reductions from finance reductions with D. Fogel (Purdue)	0.30
03/27/20	RDS	Meeting with R. Shamblen, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Tech partnership outreach - general and noramco	2.00
03/27/20	RDS	Review and correct presentation changes to the Rhodes Board presentation from J. Lowne (Purdue)	1.30
03/27/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes BOD presentation	1.50
03/27/20	RDS	Review and send board presentation slides to Purdue aggregator	0.30
03/27/20	RDS	Assemble partnership discussion emails with strategic insights to tease conversation	1.50
03/27/20	RDS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	RDS	Correspondence with J. Tran (Purdue) re: Betadine throat	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		gargle	
03/27/20	RDS	PowerPoint edits to teaser presentation framing Rhodes Tech	0.50
03/27/20	ADD	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/28/20	RDS	Review and provide comments to the PJT aggregated board business plan presentation	0.70
03/28/20	RDS	Call with J. Turner, R. Schnitzler (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) to discuss aggregated board presentation	0.80
03/28/20	KM	Participate in a call with R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) re: draft Board deck (Partial Participation).	0.60
03/28/20	IA	Call with J. Turner, R. Schnitzler (both PJT), J. DelConte, R. Sublett, K. McCafferty, and I. Arana (all AlixPartners) to discuss updated board deck.	0.80
03/28/20	NAS	Revise Purdue opioid business plan slides for Board of Directors following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.20
03/28/20	GJK	Mundipharma diligence - balance sheet/cash forecast	2.00
03/28/20	JD	Review and provide comments on initial PJT draft of Board business plan presentation.	2.50
03/28/20	JD	Participate in a call with R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty, I. Arana and R. Sublett (all AlixPartners) re: draft Board deck.	0.80
03/29/20	JD	Create slides for the Board deck on G&A and Medical	2.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Affairs.	
03/29/20	NAS	Revise Adhansia business plan slides for Board of Directors following discussion with J. DelConte, N. Simon, and S. Lemack (all AlixPartners).	1.70
03/29/20	NAS	Build full P&L split by Consumer Health and Ethical businesses in Mundipharma business plan model.	1.90
03/29/20	RDS	Review of updated board slides and correspondence with PJT advisors	0.60
03/30/20	RDS	Construct new slides for aggregated business plan deck that encompasses better context for Rhodes business plan	1.70
03/30/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project Windsor financials and forecasting performance	1.10
03/30/20	RDS	Slide creation - industry overview of generics and impact on Rhodes business	1.80
03/30/20	RDS	Slide creation - historical Rhodes revenue execution against budget	0.90
03/30/20	RDS	Slide creation - update management levers to implement turnaround plan and impact on the budget	2.10
03/30/20	RDS	Meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	1.70
03/30/20	RDS	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan post business plan meeting.	0.70
03/30/20	RDS	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		slides.	
03/30/20	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan post business plan meeting.	0.70
03/30/20	KM	Revenue analysis re: Project Windsor - Rhodes business plan outline for Board	1.90
03/30/20	KM	Deck creation re: Project Windsor - Rhodes business plan outline for Board	2.70
03/30/20	KM	Slide creation re: Project Windsor - Rhodes business plan outline for Board	1.10
03/30/20	KM	Rhodes implementation planning follow up and progress tracking	0.80
03/30/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: project Windsor financials and forecasting performance	1.10
03/30/20	KM	Board deck review with Purdue executive team	1.00
03/30/20	KM	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan slides.	0.60
03/30/20	JD	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: discuss next steps and coordinate plan post business plan meeting.	0.70
03/30/20	JD	Correspondence with C. MacDonald (Purdue) re: professional fee payments.	0.20
03/30/20	JD	Correspondence with E. Kardos (AlixPartners) re: Purdue confidentiality agreements.	0.20
03/30/20	JD	Review and provide comments to the consolidated business plan presentation.	3.30
03/30/20	JD	Review and provide comments on the latest weekly sales	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		report update and compare sales levels to previous versions.	
03/30/20	JD	Review R&D and legal fee forecasts for 2020-2024 period and provide comments re: same.	0.70
03/30/20	JD	Review OCP payment tracking information prior to filing a report with the court, compare amounts against original forecasts and provide comments re: same.	1.10
03/30/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) re: Mundipharma model walk through and variance on sales	1.40
03/30/20	NAS	Build comparison of Mundipharma management's revised sales forecast relative to December 2019 version and analyze key takeaways.	2.50
03/30/20	NAS	Review Mundipharma product classifications in data provided to ensure alignment across data sources.	0.50
03/30/20	NAS	Prepare product line-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.80
03/30/20	IA	Review comments from J. Lowne (Purdue) to Avrio board deck slides.	0.80
03/30/20	IA	Follow up on March source data (invoiced sales, consumption, market share) for Avrio Dashboard, to be shown as part of Avrio board update.	0.30
03/30/20	NAS	Build standalone product class scenarios in Mundipharma business plan model in advance of conversation with PJT.	2.40
03/30/20	GJK	Document review for opportunities to utilize balance sheet and cash flow info	2.00
03/30/20	GJK	Review of VDD documents re: Ethical breakdown	2.00
03/30/20	GJK	Product analysis - analgesics and CH	2.50
03/30/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) re:	1.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/30/20	JD	Mundipharma model walk through and variance on sales	
03/30/20	JD	Conversation with L. Donahue and J. DelConte (both AlixPartners) re: business plan update and case planning.	0.50
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: business plan presentation.	0.30
03/30/20	JD	Meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	1.70
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: sync up post business plan review meeting.	0.10
03/30/20	JD	Call with J. Lowne (Purdue) and J. DelConte (AlixPartners) re: open business plan issues.	0.40
03/30/20	JD	Conversation with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan slides.	0.60
03/30/20	IA	Draft Purdue corporate operating expense overview slides including details on R&D, legal, and bankruptcy costs.	2.60
03/30/20	MH	Call with M. Hartley (AlixPartners), legal operations, and Canadian counsel to review changes to payments to ensure compliance with Ordinary Course Professional limits.	0.80
03/30/20	MH	Create accounts payable release file.	0.70
03/30/20	LJD	Prepare for and attend meeting with T. Coleman, J. O'Connell, R. Schnitzler, J. Turner (all PJT), L. Donahue, J. DelConte, R. Sublett (all AlixPartners), C. Landau, J. Lowne, M. Kesselman, and D. Lundie (all Purdue) re: Board business plan presentation review.	2.50
03/30/20	LJD	Conversation with L. Donahue and J. DelConte (both	0.50



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/31/20	MH	AlixPartners) re: business plan update and case planning. Call with M. Hartley (AlixPartners), supply chain manager, and large sales force contractor to review pre-petition invoices.	0.90
03/31/20	MH	Create accounts payable release file.	0.70
03/31/20	MH	Create second accounts payable release file on request.	0.50
03/31/20	MH	Advise purchasing manager of procedure to amend the existing trade agreement with a vendor.	0.40
03/31/20	IA	Update corporate slides in business plan board presentation based on comments from J. Lowne (Purdue)	1.60
03/31/20	IA	Update Purdue 13 week cash forecast customer collections, restructuring fees and retained professional fees.	2.70
03/31/20	IA	Update Avrio dashboard for March invoiced sales data.	1.10
03/31/20	IA	Update Avrio dashboard for March consumption and market share data.	1.80
03/31/20	GJK	Mundipharma diligence report planning	2.20
03/31/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to align on discussion topics and prepare for 3/31 Mundipharma model and sales update meeting with PJT.	0.30
03/31/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to prep for PJT walk through and review of Mundipharma diligence responses on variances between March 2020 and OB sales	1.00
03/31/20	GJK	Call with PJT to review draft of model	1.00
03/31/20	NAS	Prepare region-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.40
03/31/20	NAS	Prepare agenda and discussion points related to Mundipharma model and management's sales update for	1.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		3/31 call with PJT.	
03/31/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to align on discussion topics and prepare for 3/31 Mundipharma model and sales update meeting with PJT.	0.30
03/31/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to prep for PJT walk through and review of Mundipharma diligence responses on variances between March 2020 and OB sales	1.00
03/31/20	NAS	Build list of action items following 3/31 Mundipharma discussion with PJT.	0.30
03/31/20	NAS	Build product line-level standalone case in Mundipharma business plan model for 3/31 discussion with PJT.	1.10
03/31/20	NAS	Check product line-level standalone case in Mundipharma business plan model against management forecast and resolve any discrepancies.	1.80
03/31/20	JD	Conversation with J. DelConte (AlixPartners) and R. Silbert (Purdue) re: PHI plans and disclosure to various stakeholders.	0.20
03/31/20	JD	Conversation with J. DelConte (AlixPartners) and J. Lowne (Purdue) re: business plan presentation.	0.10
03/31/20	JD	Review latest inbound requests from the Ad Hoc Committee and proposed responses and review correspondence from T. Melvin (PJT) and E. Ruiz (Purdue) re: same.	0.60
03/31/20	JD	Review proposed UCC diligence responses and proposed responses to HRT specific questions.	0.40
03/31/20	JD	Review mark up of pipeline assets section of the business plan presentation and provide comments re: same.	0.50
03/31/20	JD	Review comments to Board presentation executive summary.	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/31/20	JD	Review updated Adhansia section.	0.40
03/31/20	JD	Review proposed diligence responses to various outstanding UCC requests.	0.30
03/31/20	JD	Review corporate expense forecasts and create presentation slides and create summary slide for Board presentation.	1.50
03/31/20	JD	Review updated Rhodes business plan slides and provide comments re: same.	0.80
03/31/20	JD	Review updated draft corporate expense slides and provide comments re: same.	0.60
03/31/20	JD	Review and provide comments to the updated Avrio business plan presentation.	0.50
03/31/20	JD	Review and provide comments on updated Opioid section of the business plan presentation.	0.70
03/31/20	JD	Review and provide comments on the updated Adhansia section of the business plan presentation and review previous iterations of that section and previous Adhansia Board presentations.	1.10
03/31/20	JD	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
03/31/20	JD	Correspondence with R. Schnitzler (PJT) re: Rhodes slides.	0.40
03/31/20	KM	Rhodes implementation strategy and impact to budget for Board presentation	0.60
03/31/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: impact of Oxy-APAP and Oxy-IR rebid	2.00
03/31/20	KM	Meeting with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes	0.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Board deck refinement	
03/31/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation executive summary for Rhodes	1.00
03/31/20	KM	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation for Rhodes	1.10
03/31/20	KM	Rhodes Board deck restructuring for executive team	1.90
03/31/20	KM	Rhodes implementation plan timeline update	0.40
03/31/20	KM	Rhodes Board deck edits	0.90
03/31/20	KM	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
03/31/20	RDS	Call with J. DelConte, R. Sublett, and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.20
03/31/20	RDS	Review and turn comments to new format board presentation on Avrio business plan	0.10
03/31/20	RDS	Update board presentation	1.50
03/31/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation for Rhodes	1.10
03/31/20	RDS	Meeting with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: Rhodes Board deck refinement	0.60
03/31/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty, and R. Sublett (both AlixPartners) to discuss board presentation executive summary for Rhodes	1.00
03/31/20	RDS	Review customer, product profitability analysis for additional marginal products	1.20
03/31/20	RDS	Turn comments from J. Lowne (Purdue) to board	0.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
03/31/20	RDS	presentation slides for Rhodes Meeting with D. Fogel (Purdue), K. McCafferty, and R. Sublett (both AlixPartners) re: impact of Oxy-APAP and Oxy-IR rebid	2.00
<b>Total</b>			<b><u>1,155.50</u></b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Business Analysis & Operations  
Client/Matter # 012589.00106

## Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.50	515.00	1,287.50
Sam K Lemack	9.00	515.00	4,635.00
Hart Ku	40.40	515.00	20,806.00
Nate A Simon	92.70	515.00	47,740.50
David Samikkannu	139.10	690.00	95,979.00
Isabel Arana de Uriarte	144.90	690.00	99,981.00
Jon D Hecht	0.80	690.00	552.00
Ryan D Sublett	201.70	735.00	148,249.50
Michael Hartley	44.70	840.00	37,548.00
Gabe J Koch	93.30	840.00	78,372.00
Mark F Rule	0.80	910.00	728.00
Jesse DelConte	142.50	950.00	135,375.00
Kevin M McCafferty	200.50	950.00	190,475.00
Richard Collura	0.80	1,090.00	872.00
Lisa Donahue	41.80	1,195.00	49,951.00
<b>Total Hours &amp; Fees</b>	<b>1,155.50</b>		<b>912,551.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Executory Contracts  
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
03/03/20	JD	Correspondence with R. Aleali and J. Doyle (both Purdue) re: lease extensions.	0.30
03/25/20	JD	Correspondence with H. Ku (AlixPartners) and Davis Polk re: contract database.	0.30
03/31/20	JD	Conversation with J. DelConte (AlixPartners), C. Robertson (Davis Polk), and R. Aleali (Purdue) re: executory contract assumption process.	0.50
Total			<b>1.10</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Executory Contracts  
Client/Matter # 012589.00108

## Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	1.10	950.00	1,045.00
<b>Total Hours &amp; Fees</b>	<b>1.10</b>		<b>1,045.00</b>



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Special Projects  
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
03/04/20	JKL	QCing production (WIN001) and PDF export settings.	0.90
03/04/20	KG	Stage, process and load documents to Relativity, update/overlay data and index for search/retrieval, and batch document as requested.	0.40
03/04/20	KG	Create requested PDFs for production.	1.90
03/05/20	KG	Create first set of PDFs for production.	0.80
03/05/20	KG	Process and load document to Relativity. Update/overlay data and index for search/retrieval. Batch document as requested.	0.40
03/05/20	JKL	QCing production (WIN002) and PDF export settings.	0.90
03/06/20	JKL	QCing PDF export deliverable. Delivering PDF export.	1.00
03/06/20	KG	Create second set of PDFs for production.	1.30
03/17/20	KG	Create fourth set of PDFs for production.	1.40
03/20/20	KG	Create fifth set of PDFs for production.	2.60
03/30/20	KG	Stage and process data for loading to Relativity, export and import data into Relativity, perform quality control review of data loaded to hosting environment, generate TIF images, update/overlay data and index for search/retrieval, and create review batches.	1.80
Total			<b>13.40</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Special Projects  
Client/Matter # 012589.00110

## Fee Recap:

Consultant	Hours	Rate	Amount
Kristina Galbraith	10.60	645.00	6,837.00
Jay K Lynn	2.80	950.00	2,660.00
<b>Total Hours &amp; Fees</b>	<b>13.40</b>		<b>9,497.00</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Retention and Engagement Administration  
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
03/30/20	LCV	Review current NDA.	0.20
Total			<b>0.20</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Retention and Engagement Administration  
Client/Matter # 012589.00112

## Fee Recap:

Consultant	Hours	Rate	Amount
Laurie C Verry	0.20	510.00	102.00
<b>Total Hours &amp; Fees</b>	<b>0.20</b>		<b>102.00</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Fee Statements and Fee Applications  
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
03/02/20	JD	Review draft January professional fees.	2.60
03/03/20	TB	Correspondence with K. Sundt (AlixPartners) re: professional fees covered for interim fee application.	0.30
03/03/20	TB	Preparation of fifth monthly fee statement and exhibits for January 2020.	1.40
03/03/20	TB	Continue preparation of fifth monthly fee statement and exhibits for January 2020.	1.20
03/03/20	KAS	Correspondence with T. Brewer (AlixPartners) re: professional fees covered for interim fee application.	0.30
03/04/20	KMD	Preparation of professional fees for February 2020	1.40
03/04/20	TB	Preparation of initial schedule workbook for first interim fee application.	3.00
03/04/20	TB	Continue preparation of initial schedule workbook for first interim fee application.	1.70
03/05/20	TB	Update fee application status chart.	0.90
03/05/20	TB	Preparation of initial schedule workbook for first interim fee application.	2.80
03/05/20	JD	Review and finalize January fee statement prior to sending off to Davis Polk to file.	0.30
03/05/20	JD	Review and edit the draft narratives for the interim fee statement.	0.50
03/05/20	KMD	Preparation of professional fees for February 2020	0.90
03/05/20	KAS	Review draft 5th monthly fee application and respond to T. Brewer (AlixPartners) re: same.	0.50
03/05/20	DS	Write professional services summary for interim fee statement	1.80
03/06/20	KMD	Preparation of professional fees for February 2020	1.00
03/06/20	TB	Continue preparation of Interim and exhibit A.	1.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Fee Statements and Fee Applications  
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
03/06/20	TB	Preparation of Exhibit A for first interim fee application	3.00
03/06/20	LMB	Review and revise first interim fee application and supporting schedules	1.40
03/07/20	TB	Preparation of interim fee application and exhibits.	3.60
03/07/20	TB	Continue preparation of interim fee application and exhibits.	3.00
03/08/20	TB	Review court docket	0.20
03/09/20	LMB	Review and revise first interim fee application, cover page	0.40
03/09/20	JD	Draft portion of the interim fee application.	0.80
03/10/20	KMD	Preparation of professional fees for February 2020	2.30
03/11/20	KMD	Preparation of professional fees for February 2020	3.40
03/11/20	KAS	Review 1st interim fee application.	0.70
03/11/20	TB	Final preparation of First Interim and exhibits.	3.70
03/12/20	KMD	Preparation of professional fees for February 2020	3.00
03/12/20	KMD	Continue preparation of professional fees for February 2020	1.20
03/13/20	JD	Review and provide comments on first interim fee application.	1.00
03/14/20	TB	Update First Interim Application with exhibits.	1.00
03/16/20	TB	Update First Fee Application.	1.40
03/16/20	JD	Review and revise final fee application and correspondence with T. Brewer (AlixPartners) re: final edits.	0.60
03/16/20	JD	Final review of interim fee application.	0.30
03/26/20	KMD	Preparation of professional fees for March 2020	2.60
03/28/20	KMD	Preparation of professional fees for March 2020	2.30
<b>Total</b>			<b>58.10</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Fee Statements and Fee Applications  
Client/Matter # 012589.00113

## Fee Recap:

Consultant	Hours	Rate	Amount
Kiera M Davids	18.10	415.00	7,511.50
Tammy Brewer	28.80	450.00	12,960.00
Lisa Marie Bonito	1.80	450.00	810.00
Kaitlyn A Sundt	1.50	510.00	765.00
David Samikkannu	1.80	690.00	1,242.00
Jesse DelConte	6.10	950.00	5,795.00
<b>Total Hours &amp; Fees</b>	<b>58.10</b>		<b>29,083.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Court Hearings  
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
03/02/20	JD	Dial in to Court hearing.	0.30
03/03/20	RDS	Review court filings (mediation approval, compensation and PHI) for Rhodes business plan ramifications	0.90
03/18/20	JD	Participate in the court hearing telephonically.	3.00
03/18/20	RC	Dial into a portion of the preliminary injunction hearing.	1.50
03/24/20	JD	Participate in Purdue Board meeting.	1.60
Total			<b>7.30</b>



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Court Hearings  
Client/Matter # 012589.00114

## Fee Recap:

Consultant	Hours	Rate	Amount
Ryan D Sublett	0.90	735.00	661.50
Jesse DelConte	4.90	950.00	4,655.00
Richard Collura	1.50	1,090.00	1,635.00
<b>Total Hours &amp; Fees</b>	<b>7.30</b>		<b>6,951.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/02/20	RC	Review related party information included in the debtors audited financial statements.	1.20
03/02/20	RC	Call with J. Dougherty (Haug Partners) and R. Collura (AlixPartners) to discuss status of information and data requests from TXP.	1.10
03/02/20	RC	Review information and data requests for TXP and prepare for call with TXP's counsel.	0.50
03/02/20	RC	Review available tax information and tax returns for debtor entities.	1.00
03/02/20	RC	Review intercompany schedules and payments to IACs.	0.80
03/02/20	RC	Review information gathered in response to requests made by the UCC.	1.30
03/02/20	RC	Review tax and rent information included in the Debtors' audited financial statements.	0.80
03/02/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation between SOFA schedules and draft intercompany and non-cash transfers report.	0.40
03/02/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	2.50
03/02/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation between SOFA schedules and draft intercompany and non-cash transfers report.	0.40
03/02/20	MFR	Review and analysis of Purdue SOFA schedules.	2.20
03/02/20	MFR	Review and analysis of transfers between Purdue and Purdue Canada.	1.80
03/03/20	MFR	Review and analysis of the accounting and support documentation related to transfers between Purdue and Purdue Canada / Adlon.	2.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/03/20	MFR	Preparation for and conference call with E. Nowakowski (Purdue), M. Rule, and F. Silva (both AlixPartners) re: follow-up questions on draft intercompany and non-cash transfers report.	1.20
03/03/20	MFR	Review outstanding information requests related to Report 1B (the non-cash transfers report).	0.20
03/03/20	MFR	Review, analysis and reconciliation of SOFA schedules and Report 1B (the non-cash transfers report).	2.70
03/03/20	FOS	Conference call with E. Nowakowski (Purdue), M. Rule, and F. Silva (both AlixPartners) re: follow-up questions on draft intercompany and non-cash transfers report.	0.70
03/03/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	2.50
03/03/20	MH	Attend call with R. Collura and M. Hartley (both AlixPartners) to discuss status of tax research.	0.40
03/03/20	RC	Call with M. Hartley and R. Collura (both AlixPartners) to discuss tax information and related analysis.	0.40
03/03/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of information requests.	0.50
03/03/20	RC	Review documentation gathered in response to the UCC's information requests.	1.70
03/03/20	RC	Review documentation related tax returns and tax calculations in response to requests from Davis Polk.	1.40
03/03/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of information requests.	0.50
03/04/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	3.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/04/20	FOS	Discussion with M. Rule and F. Silva (both AlixPartners) re: SOFA schedules.	0.20
03/04/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report (continued).	2.80
03/04/20	MFR	Discussion with M. Rule and F. Silva (both AlixPartners) re: SOFA schedules.	0.20
03/04/20	MFR	Review and analysis of Purdue transfers since 9/15/18.	2.90
03/05/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups to draft intercompany and non-cash transfers report.	0.20
03/05/20	MFR	Review of transfers and supporting documentation for transfers between Purdue and Mundipharma EDO GmbH.	2.10
03/05/20	MFR	Review of transfers and supporting documentation for transfers between Purdue and Mundipharma EDO GmbH.	2.30
03/05/20	MFR	Email to Davis Polk re: transfers between Purdue and Mundipharma EDO GmbH.	0.20
03/05/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups to draft intercompany and non-cash transfers report.	0.20
03/05/20	FOS	Compose email to K. Shibuya (AlixPartners) re: follow-ups to Mundipharma EDO services provided to Purdue.	0.10
03/05/20	FOS	Analyze data re: reconciliation between SOFA schedules / SAP and draft intercompany and non-cash transfers report.	1.50
03/05/20	MH	Review 2008 and 2009 tax distributions against tax returns.	2.30
03/05/20	RC	Review correspondence from the UCC's advisors related to requests for tax information.	0.20

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/05/20	RC	Review correspondence from the UCC's advisors related to requests for information related to payments to insiders.	0.10
03/05/20	RC	Review distribution related documentation gathered in response to requests from the UCC's advisors.	1.80
03/05/20	RC	Review tax documentation gathered in response to requests from the UCC's advisors.	0.70
03/06/20	RC	Review IAC payment information.	0.80
03/06/20	RC	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfer of value report.	0.40
03/06/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of diligence requests.	0.40
03/06/20	FOS	Compose emails to A. DePalma (AlixPartners) re: Accounts Payable reconciliation to cash distributions.	0.10
03/06/20	FOS	Compose emails to K. Shibuya (AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.10
03/06/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.20
03/06/20	MFR	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfer of value report.	0.40
03/06/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-ups on draft intercompany and non-cash transfers report.	0.20
03/06/20	MFR	Review and analysis of accounts payable report related to Purdue and Rhodes	3.20
03/06/20	MFR	Communication with A. Lutchen, B. Chen, M. Clarens, E.	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Kim (all Davis Polk), and M. Rule (AlixPartners) re: transfers between Purdue and Mundipharma EDO and discussion with M. Rule and F. Silva (both AlixPartners) re: the same.	
03/06/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss status of diligence requests.	0.40
03/09/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss updates to the information requests tracker.	0.30
03/09/20	ADD	Upload files to data room requested by various parties and permission the documents accordingly.	1.00
03/09/20	ADD	Develop a list of material to provide to everyone when added to the VDR.	0.70
03/09/20	ADD	Call with A. DePalma, and R. Collura (both AlixPartners) to discuss building tracker for outstanding TXP requests .	0.20
03/09/20	ADD	Research and compile all TXP tax request to develop tracker at request of Davis Polk.	2.30
03/09/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners), and Davis Polk diligence team to discuss outstanding TXP requests and potential next steps.	0.50
03/09/20	ADD	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests	0.50
03/09/20	MFR	Call with A. Lutchen, B. Chen (both Davis Polk), M. Rule, and F. Silva (both AlixPartners) re: transfers between Purdue and Mundipharma EDO	0.20
03/09/20	MFR	Review and analysis of supporting accounting documentation related to payments between Purdue and Purdue Pharma Technologies	1.80
03/09/20	MFR	Review and analysis of supporting accounting documentation related to payments between Purdue and	1.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		foreign IACs related to OxyContin royalties.	
03/09/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report/UCC Requests.	0.10
03/09/20	MFR	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50
03/09/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report/UCC Requests.	0.10
03/09/20	FOS	Compose email to K. Shibuya (AlixPartners) re: Mundipharma EDO services support.	0.20
03/09/20	FOS	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50
03/09/20	FOS	Call with A. Lutchen, B. Chen (both Davis Polk), M. Rule, and F. Silva (both AlixPartners) re: transfers between Purdue and Mundipharma EDO	0.20
03/09/20	RC	Review various information requests and prepare for call with Davis Polk.	0.40
03/09/20	RC	Call with A. DePalma, R. Collura (both AlixPartners), and Davis Polk diligence team to discuss outstanding TXP requests and potential next steps.	0.50
03/09/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss building tracker for outstanding TXP requests.	0.20
03/09/20	RC	Review information request tracker and provide comments.	0.40
03/09/20	RC	Call with A. DePalma, R. Collura, M. Rule, and F. Silva (all AlixPartners) to discuss AP Reconciliation to Report 1B and new UCC requests.	0.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss updates to the information requests tracker.	0.30
03/09/20	RC	Review the UCC's requests for royalty and licensing agreements.	0.20
03/09/20	RC	Review non-cash transfer report and supporting schedules.	1.20
03/10/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss updates to the TXP information request tracker.	0.20
03/10/20	RC	Review and update TXP and PRA LP information request tracker.	1.10
03/10/20	RC	Review communications with Haug Partners and update TXP and PRA LP information request tracker.	1.10
03/10/20	RC	Review documents related organizational structure.	0.70
03/10/20	RC	Review documents gathered in response to requests from the UCC.	1.20
03/10/20	RC	Review and analysis of documents related to organizational changes.	0.70
03/10/20	RC	Review available tax documentation related to debtor entities.	1.40
03/10/20	RC	Review and analysis of intercompany transactions.	1.60
03/10/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20
03/10/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.20
03/10/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.20
03/10/20	MFR	Review, analysis and organization of workpapers related	2.80



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/10/20	MFR	to payments between Purdue and One Stamford Reality. Review and analysis of accounts payable extract from SAP.	0.80
03/10/20	ADD	Review data room access and update permissions at direction of Davis Polk.	1.20
03/11/20	MFR	Review and analysis of accounts payable extract from SAP.	1.30
03/11/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	2.60
03/11/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.70
03/11/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.40
03/11/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.30
03/11/20	FOS	Call with M. Rule and F. Silva(both AlixPartners) re: status of draft intercompany and non-cash transfers report.	0.40
03/11/20	FOS	Update tracker re: follow-up items on draft intercompany and non-cash transfers report.	0.50
03/11/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	2.00
03/11/20	RC	Review documents and respond to email from Province re: ownership structure.	0.30
03/11/20	REO	Reconcile Transfer pricing deck re: cash and non-cash transfers of value examined by the AlixPartners team to MDL report.	1.00
03/12/20	RC	Review various supporting documentation related to the	0.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		cash transfers of value report in response to requests from the UCC.	
03/12/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests for supporting documentation related to the cash transfers of value report.	0.50
03/12/20	RC	Review documentation gathered in response to distribution related requests from the UCC.	1.30
03/12/20	RC	Review requests from the UCC related to royalty agreements.	0.20
03/12/20	RC	Review non-cash transfer of value report support schedules and documentation.	1.30
03/12/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	3.00
03/12/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report (continued).	3.00
03/12/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.20
03/12/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.40
03/12/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and One Stamford Reality.	3.20
03/12/20	MFR	Review and analysis of accounts payable extract from SAP.	1.60
03/12/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss requests for supporting documentation related to the cash transfers of value report.	0.50
03/12/20	ADD	Upload diligence production to the Purdue data room and update document permissions.	0.80
03/13/20	MFR	Review, analysis and organization of workpapers related	2.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to payments between Purdue and One Stamford Reality.	
03/13/20	MFR	Review and analysis of accounts payable extract from SAP.	2.20
03/13/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.40
03/13/20	MFR	Review and analysis of licensing agreements related to UCC request.	2.10
03/13/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report.	3.00
03/13/20	FOS	Analyze data re: accounts payable extract versus draft intercompany and non-cash transfers report (continued).	2.70
03/13/20	RC	Call with R. Collura (AlixPartners) and M. Sharp (Purdue) to discuss response to questions related to the cash transfers of value report.	0.10
03/13/20	RC	Review special committee related work and respond to requests from Davis Polk.	0.20
03/13/20	RC	Review cash transfers of value report and respond to questions from Purdue.	0.30
03/15/20	RC	Review and respond to questions from Davis Polk related to the cash transfers of value report.	0.30
03/15/20	RC	Review information related to reimbursements from PRA LP and communicate with team.	0.50
03/16/20	RC	Call with R. Collura and N. Simon (both AlixPartners) to discuss analysis of payments to insiders.	0.30
03/16/20	RC	Review analysis of payments to insiders.	0.70
03/16/20	RC	Review draft response to additional requests for information from the UCC's advisors and provide comments.	0.60
03/16/20	RC	Review and analysis of pre-petition transaction with IACs.	1.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/16/20	RC	Review tax distribution documentation and related analysis.	1.20
03/16/20	KS	Review transactions and related documents related to Mundipharma EDO.	1.70
03/16/20	NAS	Call with R. Collura and N. Simon (both AlixPartners) to discuss analysis of payments to insiders.	0.30
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report (continued).	3.00
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report (continued).	1.70
03/16/20	FOS	Compose email to K. Shibuya (AlixPartners) re: access to SAP/Ariba.	0.10
03/16/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: Accounts Payable extract reconciliation to draft intercompany and non-cash transfers report.	0.20
03/16/20	FOS	Analyze and reconcile SAP accounts payable data extract re: draft intercompany and non-cash transfers report.	3.00
03/16/20	MFR	Review and analysis of licensing agreements related to UCC request and email response to R. Collura (AlixPartners) re: same.	2.40
03/16/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: Accounts Payable extract reconciliation to draft intercompany and non-cash transfers report.	0.20
03/16/20	MFR	Review and respond to emails from K. Shibuya (AlixPartners) re: payments between Purdue and Mundipharma EDO.	0.40
03/16/20	MFR	Review and analysis of examples of supporting documentation for payments between Purdue and	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Mundipharma EDO.	
03/16/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.80
03/17/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.10
03/17/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	2.30
03/17/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.60
03/17/20	MFR	Review and analysis of licensing agreements related to UCC request and provide additional response to R. Collura (AlixPartners).	2.80
03/17/20	NAS	Correspondence with intercompany payment investigation team M. Rule, F. Silva, N. Simon, and R. Collura (all AlixPartners) re: UCC data requests.	0.40
03/17/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss the recent diligence requests from the UCC's advisors and related responses.	0.50
03/17/20	RC	Review and comment on responses to UCC's advisors' requests for agreements between the Debtors and IACs.	0.70
03/17/20	RC	Review support documentation gathered in response to various financial information requests received from the UCC's advisors.	0.80
03/17/20	RC	Review updated draft of schedule of payments to insiders and provide comments.	1.10
03/17/20	RC	Review additional diligence requests made by the UCC's advisors.	0.40

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/17/20	RC	Review and analysis pre-petition transactions with IACs.	1.30
03/17/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss the recent diligence requests from the UCC's advisors and related responses.	0.50
03/18/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC request status	0.20
03/18/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), J. McClammy, M. Clarens, C. Oluwole (all Davis Polk), and J. Dougherty (Haug Partners) to discuss status of TXP's responses to information requests.	0.50
03/18/20	RC	Review tracking list of requests to TXP and prepare for call with TXP's outside counsel.	0.60
03/18/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), J. McClammy, M. Clarens, C. Oluwole (all Davis Polk), and J. Dougherty (Haug Partners) to discuss status of TXP's responses to information requests.	0.50
03/18/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.20
03/18/20	RC	Review documentation related to the distribution's analysis based on call with TXP's counsel.	0.80
03/18/20	RC	Review and analysis of tax related information in connection with responding to requests from the UCC's advisors.	1.20
03/18/20	KS	Review inter-company transactions and related attached documents.	1.80
03/18/20	MFR	Review and analysis of licensing agreements related to UCC request and provide additional response to R. Collura (AlixPartners).	1.80
03/18/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma	1.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Technologies	
03/18/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of SAP accounts payable extract to draft intercompany and non-cash transfers report.	0.80
03/18/20	MFR	Review and respond to emails with K. Shibuya (AlixPartners) re: payments between Purdue and Mundipharma EDO and analysis of attached documentation and support.	1.90
03/18/20	MFR	Draft email to A. Lutchen (Davis Polk) re: analysis of supporting documentation of payments between Purdue and Mundipharma EDO.	0.40
03/18/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.80
03/18/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of SAP accounts payable extract to draft intercompany and non-cash transfers report.	0.80
03/18/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report.	3.00
03/18/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report (continued).	2.00
03/19/20	FOS	Analyze and reconcile SAP Accounts Payable data extract re: draft intercompany and non-cash transfers report (continued).	1.20
03/19/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: status of reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
03/19/20	FOS	Analyze and reconcile SAP Accounts Payable data extract	3.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		re: draft intercompany and non-cash transfers report.	
03/19/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	2.10
03/19/20	MFR	Review of audited financial statements for information re: related intercompany payments	0.80
03/19/20	MFR	Call with R. Collura and M. Rule (both AlixPartners) to discuss intercompany and non-cash transfers of value report and requests from the UCC's advisors.	0.70
03/19/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	2.70
03/19/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.40
03/19/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: status of reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
03/19/20	SJC	Review of EX-US requests (continued).	1.80
03/19/20	SJC	Review of EX-US requests.	3.10
03/19/20	RC	Call with R. Collura and M. Rule (both AlixPartners) to discuss intercompany and non-cash transfers of value report and requests from the UCC's advisors.	0.70
03/19/20	RC	Review documentation related to the intercompany and non-cash transfers of value report.	1.30
03/20/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss staffing requirements for UCC request for supporting documentation.	0.40
03/20/20	RC	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfers of value	0.50



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/20/20	RC	report and responses to the UCC's discovery requests. Call with S. Canniff and R. Collura (both AlixPartners) to discuss distributions analysis and approach for gathering additional documentation in response to the UCC's requests.	0.40
03/20/20	RC	Review and respond to requests from the UCC's advisors.	0.30
03/20/20	SJC	Call with S. Canniff and R. Collura (both AlixPartners) to discuss distributions analysis and approach for gathering additional documentation in response to the UCC's requests.	0.40
03/20/20	MFR	Call with M. Rule and R. Collura (both AlixPartners) to discuss intercompany and non-cash transfers of value report and responses to the UCC's discovery requests.	0.50
03/20/20	MFR	Review and analysis of licensing agreements related to UCC request.	1.10
03/20/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and Purdue Pharma Technologies	2.10
03/20/20	MFR	Call with E. Ruiz (Purdue), M. Rule, and F. Silva (both AlixPartners) re: intercompany licensing agreements.	0.20
03/20/20	MFR	Review latest status of open items.	0.50
03/20/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.30
03/20/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.10
03/20/20	FOS	Call with E. Ruiz (Purdue), M. Rule, and F. Silva (both AlixPartners) re: intercompany licensing agreements.	0.20
03/20/20	FOS	Analyze and reconcile SAP Accounts Payable data extract	3.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/20/20	ADD	re: draft intercompany and non-cash transfers report. Call with A. DePalma and R. Collura (both AlixPartners) to discuss staffing requirements for UCC request for supporting documentation.	0.40
03/23/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/23/20	FOS	Reconcile Accounts Payable SAP data extract re: draft intercompany and non-cash transfers report.	7.20
03/23/20	MFR	Review and analysis of license agreement related to Israel.	0.60
03/23/20	MFR	Review and analysis of examples of Report 1A documentation provided to the UCC.	2.60
03/23/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/23/20	MFR	Review of emails from R. Collura and A. DePalma (both AlixPartners) re: UCC information requests and provide responding email.	0.30
03/23/20	MFR	Review of email from E. Ruiz (Purdue) re: licensing agreements. Provided responding email.	0.20
03/23/20	MFR	Review latest UCC information requests and available information.	0.70
03/23/20	MFR	Review and respond to emails from R. Collura (AlixPartners) re: the UCC's request for licensing agreements.	0.20
03/23/20	MFR	Review and production of documents responsive to the UCC request for royalty payment information.	1.30
03/23/20	MFR	Correspondence with R. Collura and A. DePalma (both	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		AlixPartners) re: licensing agreements.	
03/23/20	SJC	Call with R. Collura and S. Canniff (all AlixPartners) to discuss additional work to perform in response to the UCC's information requests.	0.50
03/23/20	SJC	Meeting with J. Hecht and S. Canniff (both AlixPartners) to discuss compiling distribution support and SAP walk through.	0.50
03/23/20	SJC	Compile distribution support for UCC request.	3.40
03/23/20	SJC	Compile distribution support for UCC request (continued).	3.10
03/23/20	RC	Review initial sample selections made by the UCC's advisors re: cash distributions.	1.00
03/23/20	RC	Communicate with TXP's counsel re: follow-up for responses to information requests.	0.10
03/23/20	RC	Communicate with Davis Polk re: requests made to TXP's counsel	0.20
03/23/20	RC	Review documentation related to transactions with IACs in connection with responding to information requests.	0.80
03/23/20	RC	Review information response tracker related to requests made to TXP's counsel.	0.20
03/23/20	RC	Call with R. Collura and S. Canniff (all AlixPartners) to discuss additional work to perform in response to the UCC's information requests.	0.50
03/23/20	RC	Call with R. Collura and J. DelConte (both AlixPartners) to discuss license agreements and related responses to the UCC's requests.	0.50
03/23/20	RC	Review documentation related to the UCC's requests for royalty rate information	0.40
03/23/20	RC	Review documentation related to report 1b in response to requests from the UCC's advisors.	1.10

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/23/20	RC	Review available licensing agreements and communicate with the UCC's advisors.	0.30
03/23/20	RC	Review information related to royalty and licensing agreements in response to requests made by the UCC's advisors.	0.60
03/23/20	JDH	Collection of supporting documentation related to distributions.	3.20
03/23/20	JDH	Conference with Purdue IT.	2.40
03/23/20	JDH	Meeting with J. Hecht and S. Canniff (both AlixPartners) to discuss compiling distribution support and SAP walk through	0.50
03/24/20	JDH	Meeting with J. Hecht and S. Canniff (both AlixPartners) to walk through SAP and supporting documents for distributions.	1.00
03/24/20	JDH	Call with Purdue IT re: SAP access.	0.70
03/24/20	JDH	Documentation support for distributions (continued).	3.00
03/24/20	JDH	Documentation support for distributions.	3.40
03/24/20	RC	Review information provided by TXP's counsel and communicate with team re: next steps.	0.70
03/24/20	RC	Review information related to property and withholding taxes provided by TXP's outside counsel.	0.30
03/24/20	RC	Review asset and trust information provided by counsel of the Sacklers.	1.10
03/24/20	RC	Review and analysis of transactions with IACs in response to requests from the UCC's advisors.	0.80
03/24/20	RC	Review information and provide list of requests for royalty and license agreements to Davis Polk.	0.60
03/24/20	RC	Review compensation information related to requests received from the UCC's advisors.	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/24/20	RC	Review royalty rate information requests received from the UCC's advisors and communicate with AlixPartners team on next steps.	0.40
03/24/20	RC	Review and communicate with the AlixPartners team re: information requests related to transactions with IACs.	0.30
03/24/20	RC	Review and analysis of payments to IACs.	0.90
03/24/20	RC	Communicate with Davis Polk re: outstanding requests for information from TXP/PRA LP.	0.20
03/24/20	SJC	Meeting with J. Hecht and S. Canniff (both AlixPartners) to walk through SAP and supporting documents for distributions.	1.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements.	3.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements (continued).	3.00
03/24/20	SJC	Compilation and analysis of 2017 distribution support from SAP in addition to review of supporting bank statements (continued).	1.00
03/24/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data to draft report.	0.30
03/24/20	MFR	Review and respond to emails from the UCC re: the proposed information request to Bates White	1.10
03/24/20	MFR	Review and respond to emails from R. Collura (AlixPartners) re: documentation provided to the UCC.	0.30
03/24/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/24/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	2.80
03/24/20	FOS	Call with A. DePalma and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/24/20	FOS	Reconcile Accounts Payable SAP data extract re: draft intercompany and non-cash transfers report.	4.90
03/24/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable SAP data to draft report.	0.30
03/24/20	ADD	Call with A. DePalma and F. Silva (both AlixPartners) re: reconciliation of Accounts Payable SAP data extract to draft intercompany and non-cash transfers report.	0.30
03/25/20	ADD	Call with A. DePalma and J. DelConte (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.30
03/25/20	ADD	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding requests from the UCC.	0.60
03/25/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.50
03/25/20	FOS	Extract data from SAP re: accounts receivable for debtor entities.	2.50
03/25/20	FOS	Analyze SAP accounting records re: cash payments for services provided by Mundipharma International Ltd (USA) to Purdue.	2.50
03/25/20	FOS	Compose email to N. Simon (AlixPartners) re: IAC cash payments.	0.10
03/25/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.60

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/25/20	MH	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding requests from the UCC.	0.60
03/25/20	MH	Initial research into historical property tax payment records.	1.70
03/25/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	2.20
03/25/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses	1.20
03/25/20	MFR	Discussion with M. Rule and R. Collura (both AlixPartners) re: case status and UCC requests.	0.30
03/25/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.50
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP.	3.00
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP (continued).	3.00
03/25/20	SJC	Review of bank statements supporting 2017 distributions as well as compiling and evaluating related distribution support from SAP (continued).	1.50
03/25/20	RC	Review support for tax distributions and calculations of such.	1.40
03/25/20	RC	Call with R. Collura, M. Hartley, and A. DePalma (all AlixPartners) to discuss real estate and tax withholding requests from the UCC.	0.60
03/25/20	RC	Discussion with M. Rule and R. Collura (both AlixPartners)	0.30

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		re: case status and UCC requests.	
03/25/20	JD	Call with A. DePalma and J. DelConte (both AlixPartners) to discuss status of outstanding UCC diligence requests.	0.30
03/25/20	JDH	Documentation support for distributions.	3.00
03/25/20	JDH	Documentation support for distributions (continued).	1.10
03/25/20	JDH	Documentation support for distributions (continued).	2.80
03/25/20	JDH	Documentation support for distributions (continued).	3.00
03/25/20	RC	Review support documentation related to distributions requests from the UCC.	1.00
03/25/20	RC	Review updated analysis of payments to insiders.	0.80
03/25/20	RC	Review information provided by TXP's counsel.	0.50
03/25/20	RC	Review and analysis of intercompany transaction support.	0.80
03/25/20	RC	Review documentation related to transaction with IACs.	0.60
03/26/20	RC	Call with M. Hartley and R. Collura (both AlixPartners) to prepare for call with Davis Polk re: tax distributions analysis.	0.50
03/26/20	RC	Review and analysis of documents related to tax distributions.	1.60
03/26/20	RC	Call with R. Collura and M. Hartley (AlixPartners) and E. Kim and A. Whisenant (Davis Polk) to discuss tax distribution analysis and next steps.	0.60
03/26/20	RC	Review information provided by TXP related to compensation.	0.70
03/26/20	RC	Review and analysis of tax information related to the debtor entities.	1.30
03/26/20	RC	Review tax distributions and related support.	1.30
03/26/20	JDH	Documentation support for distributions (continued).	3.00



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/26/20	JDH	Documentation support for distributions.	3.30
03/26/20	JDH	Documentation support for distributions (continued).	2.10
03/26/20	NAS	Correspondence with M. Hartley (AlixPartners) re: follow-up question related to Cash Transfers of Value investigation report.	0.80
03/26/20	SJC	Compilation and analysis of 2016 distribution support from SAP in addition to review of supporting bank statements (continued).	2.10
03/26/20	SJC	Compilation and analysis of 2016 distribution support from SAP in addition to review of supporting bank statements.	3.00
03/26/20	SJC	Compilation and analysis of 2016 distribution support from SAP in addition to review of supporting bank statements (continued).	0.80
03/26/20	MH	Call with M. Hartley and R. Collura (both AlixPartners) to prepare for call with Davis Polk re: tax distributions analysis.	0.50
03/26/20	MH	Call with R. Collura and M. Hartley (AlixPartners) and E. Kim and A. Whisenant (Davis Polk) to discuss tax distribution analysis and next steps.	0.60
03/26/20	MH	Initial research into availability of payroll information for administrative support in equity owner offices.	0.90
03/26/20	MH	Prepare for call with counsel on tax distribution calculations.	1.20
03/26/20	MH	Call with M. Hartley (AlixPartners) and counsel to review progress on validating tax distribution calculations against financial results.	0.90
03/26/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.70

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/26/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	3.20
03/27/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and MIL USA.	2.70
03/27/20	MFR	Review of open items related to intercompany and non-cash transfers report.	0.80
03/27/20	MH	Additional research on historical pay records for equity owner administrative costs.	0.70
03/27/20	MH	Initial research on historical payroll tax withholding amounts.	1.30
03/27/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: UCC information requests.	0.30
03/27/20	FOS	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	FOS	Analyze cash payment records re: services provided by Mundipharma International Ltd. (US) to Purdue.	0.90
03/27/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: UCC information requests.	0.30
03/27/20	SJC	Conference call with L. Donahue, R. Collura, A. DePalma, J. DelConte, G. Koch, M. Rule, I. Arana, M. Hartley, N. Simon, S. Caniff, S. Lemack, J. Hecht, F. Silva, H. Ku, K. McCafferty, R. Sublett (all AlixPartners) re: weekly AlixPartners team update call.	0.80
03/27/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP (continued).	2.90
03/27/20	SJC	Review of bank statements supporting 2016 distributions	3.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		as well as compiling and evaluating related distribution support from SAP.	
03/27/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP (continued).	0.70
03/27/20	JDH	Documentation support for distributions.	3.50
03/27/20	JDH	Documentation support for distributions (continued).	3.60
03/27/20	RC	Review support documentation related distributions analysis.	1.40
03/27/20	RC	Review family counsel materials re: holding companies and trust structure.	1.30
03/27/20	RC	Review information compiled in response to requests made by the UCC's advisors.	1.50
03/30/20	RC	Review documentation and follow-up with TXP's outside counsel re: status of information requests.	0.70
03/30/20	RC	Review accounting activity related to transactions with IACs.	1.20
03/30/20	RC	Review analysis of payments to insiders.	0.60
03/30/20	RC	Review information related to rent expense and property taxes.	0.50
03/30/20	RC	Review information related to withholding taxes.	0.60
03/30/20	RC	Review information related to requests for compensation and benefits	0.50
03/30/20	JDH	Documentation support for distributions (continued).	5.50
03/30/20	JDH	Documentation support for distributions.	3.00
03/30/20	SJC	Compiling supporting documentation for tax distributions 2010-2018.	2.50
03/30/20	SJC	Review of bank statements supporting 2016 distributions	3.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		as well as compiling and evaluating related distribution support from SAP (continued).	
03/30/20	SJC	Review of bank statements supporting 2016 distributions as well as compiling and evaluating related distribution support from SAP.	3.00
03/30/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	5.00
03/30/20	MH	Create revised report on Ordinary Course Professionals to include additional requested information.	0.60
03/30/20	MFR	Review and analysis of accounts payable extract from SAP and reconcile to intercompany and non-cash transfers report analyses.	1.40
03/30/20	MFR	Review of audited financial statements for information re: related intercompany payments	1.80
03/30/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and P.F. Laboratories.	2.80
03/31/20	MFR	Review, analysis and organization of workpapers related to payments between Purdue and P.F. Laboratories.	2.80
03/31/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
03/31/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report (continued)	3.00
03/31/20	MH	Create template for presentation of tax distribution history.	1.60
03/31/20	SJC	Review and compilation of distribution support for samples selected by Province.	3.00
03/31/20	SJC	Review and compilation of distribution support for samples selected by Province (continued).	3.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
03/31/20	SJC	Review and compilation of distribution support for samples selected by Province (continued).	2.00
03/31/20	JDH	Documentation support for distributions (continued).	2.30
03/31/20	JDH	Documentation support for distributions (continued).	3.00
03/31/20	JDH	Documentation support for distributions	3.00
03/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC diligence items.	0.60
03/31/20	RC	Communicate with Province re: requests for information.	0.10
03/31/20	RC	Review and analysis of additional information related to Ex-US distributions.	1.20
03/31/20	RC	Review available bank records and communicate with Davis Polk.	0.30
03/31/20	RC	Review cash flow information related to Ex-US distributions.	1.30
03/31/20	RC	Review support related to the intercompany and non-cash transfers of value report.	1.40
03/31/20	RC	Review status of information responses to various diligence requests from the UCC.	0.50
03/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding UCC diligence items.	0.60
<b>Total</b>			<b>441.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Forensic Analysis  
Client/Matter # 012589.00115

## Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	1.00	420.00	420.00
Andrew D DePalma	12.30	515.00	6,334.50
Nate A Simon	1.50	515.00	772.50
Sam J Canniff	58.10	645.00	37,474.50
Kyoko Shibuya	3.50	645.00	2,257.50
Fernando O Silva	86.70	645.00	55,921.50
Jon D Hecht	56.40	690.00	38,916.00
Michael Hartley	13.30	840.00	11,172.00
Mark F Rule	122.80	910.00	111,748.00
Jesse DelConte	0.30	950.00	285.00
Richard Collura	85.60	1,090.00	93,304.00
<b>Total Hours &amp; Fees</b>	<b>441.50</b>		<b>358,605.50</b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
03/01/20	SJC	Travel from ORD to HPN.	4.00
03/02/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
03/02/20	RDS	Travel from NYC to Stamford.	1.20
03/02/20	HK	Travel from NYC to Stamford	1.00
03/02/20	ADD	Travel from MCO to JFK	4.00
03/03/20	KM	Travel from Toronto to Stamford	4.50
03/03/20	JD	Travel from NYC to Stamford.	1.00
03/03/20	DS	Travel to Stamford, CT	1.00
03/04/20	DS	Travel from NYC to Stamford, CT	1.00
03/04/20	SKL	Travel from CT to DAL.	5.00
03/04/20	NAS	Travel from Stamford to Jersey City, NJ.	1.50
03/04/20	JD	Travel from Stamford to NYC.	1.00
03/04/20	HK	Travel from Stamford to NYC	1.00
03/04/20	IA	Travel from NYC to Stamford	1.00
03/05/20	ADD	Travel from LGA to MSP.	4.50
03/05/20	KM	Travel from Stamford to Toronto	4.50
03/05/20	SJC	Travel from HPN to ORD.	4.00
03/08/20	ADD	Travel from MSP to LGA.	4.50
03/09/20	MH	Travel from ATL to HPN.	4.00
03/09/20	SKL	Travel from DAL to CT.	5.00
03/09/20	NAS	Travel from Jersey City, NJ to Stamford, CT.	1.50
03/10/20	JD	Travel from NYC to Stamford.	1.00
03/11/20	JD	Travel from Stamford to NYC.	1.00
03/11/20	NAS	Travel from Stamford to Jersey City, NJ NYC	1.50
03/12/20	ADD	Travel from MSP to LGA.	4.50

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Consultant	Description of Services	Hours
03/12/20	MH	Travel From HPN to ATL.	4.00
03/12/20	SKL	Travel from CT to DAL.	5.00
<b>Total</b>			<b><u>73.70</u></b>



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

## Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	17.50	515.00	9,012.50
Sam K Lemack	15.00	515.00	7,725.00
Hart Ku	2.00	515.00	1,030.00
Nate A Simon	6.00	515.00	3,090.00
Sam J Canniff	8.00	645.00	5,160.00
David Samikkannu	2.00	690.00	1,380.00
Isabel Arana de Uriarte	1.00	690.00	690.00
Ryan D Sublett	1.20	735.00	882.00
Michael Hartley	8.00	840.00	6,720.00
Jesse DelConte	4.00	950.00	3,800.00
Kevin M McCafferty	9.00	950.00	8,550.00
<b>Total Hours &amp; Fees</b>	<b>73.70</b>		<b>48,039.50</b>
<b>Less: 50% Travel Adjustment</b>			<b>(24,019.75)</b>
<b>Total Fees</b>			<b>24,019.75</b>

## **Exhibit B**

**Alix Partners, LLP**

### **Summary and Detailed Description of AlixPartners' Expenses**

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
02/07/19	Airfare Service Charge Kevin McCafferty	19.00
01/08/20	Cab Fare/Ground Transportation Gabriel Koch Stamford to New York	75.36
02/02/20	Lodging David Samikkannu Residence Inn - Stamford 02/02/2020 - 02/03/2020	249.00
02/11/20	Airfare Andrew DePalma 2020-02-17 MSP - LGA	439.72
02/16/20	Cab Fare/Ground Transportation Kevin McCafferty Airport to Hotel	88.11
02/17/20	Airfare Service Charge Andrew DePalma	25.00
02/17/20	Cab Fare/Ground Transportation Andrew DePalma LGA to Hotel	156.00
02/17/20	Cab Fare/Ground Transportation Andrew DePalma Apartment to Airport	61.32
02/17/20	Cab Fare/Ground Transportation Andrew DePalma Stamford to NYC	158.58
02/17/20	Rental Car Kevin McCafferty 2 Days Toronto	164.05
02/17/20	Lodging Kevin McCafferty Pinehurst Resort - Pinehurst 02/17/2020 - 02/18/2020	326.53
02/17/20	Lodging Andrew DePalma Courtyard Stamford - Stamford 02/17/2020 - 02/20/2020	756.28
02/17/20	Lodging Samuel Lemack Springhill Suites New York - New York 02/17/2020 - 02/18/2020	212.79
02/17/20	Meals Samuel Lemack - Breakfast	20.71
02/17/20	Meals Andrew DePalma - Dinner	17.43
02/17/20	Meals Andrew DePalma - Breakfast	13.51
02/18/20	Airfare Samuel Lemack 2020-02-24 DAL - LGA	566.98
02/18/20	Airfare Samuel Lemack 2020-02-20 LGA - DAL	566.98

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
02/18/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	17.05
02/18/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	54.12
02/18/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	71.77
02/18/20	Lodging Kevin McCafferty Renaissance Raleigh North - Raleigh 02/18/2020 - 02/20/2020	776.90
02/18/20	Lodging Samuel Lemack Springhill Suites New York - New York 02/18/2020 - 02/20/2020	566.98
02/18/20	Meals Samuel Lemack - Breakfast	10.00
02/18/20	Meals Samuel Lemack - Dinner	45.57
02/19/20	Airfare Kevin McCafferty 2020-02-21 RDU - ATL	584.18
02/19/20	Airfare Service Charge Kevin McCafferty	9.00
02/19/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	1.03
02/19/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	13.92
02/19/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	12.50
02/19/20	Meals Andrew DePalma - Dinner	50.00
02/19/20	Meals Samuel Lemack - Breakfast	10.00
02/19/20	Meals Andrew DePalma - Breakfast	25.00
02/19/20	Meals Kevin McCafferty - Breakfast	25.00
02/19/20	Meals Kevin McCafferty - Dinner	50.00
02/20/20	Airfare Service Charge Kevin McCafferty	43.13
02/20/20	Airfare Service Charge Kevin McCafferty	27.75
02/20/20	Airfare Service Charge Kevin McCafferty	27.75
02/20/20	Airfare Change Fees Kevin McCafferty	(29.00)
02/20/20	Gas/Fuel Kevin McCafferty Rental Refill	45.45
02/20/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to	11.80

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
	Client	
02/20/20	Meals Andrew DePalma - Dinner	48.91
02/20/20	Meals Andrew DePalma - Breakfast	25.00
02/20/20	Meals Samuel Lemack - Breakfast	10.00
02/20/20	Meals Samuel Lemack - Dinner	41.64
02/20/20	Meals Kevin McCafferty - Breakfast	19.69
02/21/20	Airfare Change Fees Kevin McCafferty	30.00
02/21/20	Cab Fare/Ground Transportation Kevin McCafferty YYZ to Home	71.56
02/21/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	47.07
02/21/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	62.65
02/21/20	Meals Andrew DePalma - Breakfast	25.00
02/21/20	Meals Andrew DePalma - Dinner	50.00
02/22/20	Airfare Service Charge Kevin McCafferty	10.00
02/22/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	9.41
02/24/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	47.61
02/24/20	Lodging Samuel Lemack Marriott Vacation Club Pu - New York 02/24/2020 - 02/26/2020	544.04
02/24/20	Meals Samuel Lemack - Breakfast	2.22
02/25/20	Airfare Samuel Lemack 02.26.20 NYC - IAH	485.70
02/25/20	Airfare Samuel Lemack 2020-03-09 DAL - LGA	566.98
02/25/20	Airfare Samuel Lemack 2020-03-02 DAL - LGA	566.98
02/25/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	50.29
02/25/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	12.70
02/25/20	Meals Samuel Lemack - Breakfast	18.40
02/25/20	Meals Samuel Lemack - Dinner	49.90

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
02/26/20	Cab Fare/Ground Transportation Mark Rule Office to Home	13.33
02/26/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	14.88
02/26/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	1.03
02/26/20	Meals Samuel Lemack - Breakfast	20.52
02/26/20	Meals Samuel Lemack - Dinner	39.98
02/27/20	Airfare Service Charge Samuel Lemack	12.00
02/27/20	Cab Fare/Ground Transportation Samuel Lemack Houston to Houston	77.34
02/27/20	Cab Fare/Ground Transportation Samuel Lemack NYC to NYC	128.28
02/27/20	Cab Fare/Ground Transportation Mark Rule Office to Home	12.09
02/28/20	Airfare Samantha Canniff 03/01/2020 ORD - HPN	415.40
02/28/20	Airfare Kevin McCafferty 2020-03-03 YYZ - LGA	166.70
02/28/20	Cab Fare/Ground Transportation Mark Rule Office to Home	9.91
02/28/20	Computer Supplies / Support Vendor: Relativity ODA 6 Relativity users @ \$75	450.00
02/29/20	Airfare Samuel Lemack 2020-03-16 DAL - LGA	566.98
03/01/20	Airfare Service Charge Ryan Sublett	70.00
03/01/20	Cab Fare/Ground Transportation Samantha Canniff Home to ORD	77.47
03/01/20	Lodging Samantha Canniff Marriott Hotels - 02/23/2020 - 03/02/2020	1,167.30
03/01/20	Meals Samantha Canniff - Breakfast	13.48
03/02/20	Airfare Service Charge Andrew DePalma	25.00
03/02/20	Cab Fare/Ground Transportation Andrew DePalma Airport to Hotel	80.54
03/02/20	Cab Fare/Ground Transportation Samantha Canniff HPN to Hotel	61.12

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/02/20	Cab Fare/Ground Transportation Samantha Canniff Hotel to Purdue	16.43
03/02/20	Mileage Nathaniel Simon 48 Miles	27.60
03/02/20	Parking & Tolls Nathaniel Simon	12.00
03/02/20	Parking & Tolls Ryan Sublett	10.00
03/02/20	Mileage Hart Ku 39 Miles	22.43
03/02/20	Parking & Tolls Hart Ku	7.78
03/02/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	38.26
03/02/20	Cab Fare/Ground Transportation Isabel Arana De Uriarte Upper East to Avrio	17.16
03/02/20	Lodging Samuel Lemack Courtyard Stamford - Stamford 03/02/2020 - 03/05/2020	796.36
03/02/20	Lodging Ryan Sublett Courtyard Stamford - Stamford 03/02/2020 - 03/04/2020	572.72
03/02/20	Lodging Nathaniel Simon Residence Inns - Stamford 03/02/2020 - 03/04/2020	643.24
03/02/20	Lodging Hart Ku Sheraton Hotel Stamford - Stamford 03/02/2020 - 03/05/2020	695.35
03/02/20	Lodging Andrew DePalma Marriott Hotels - 03/02/2020 - 03/05/2020	741.78
03/02/20	Lodging Samantha Canniff Courtyard Stamford - Stamford 03/02/2020 - 03/05/2020	741.78
03/02/20	Meals Samuel Lemack - Breakfast	17.22
03/02/20	Meals Hart Ku - Breakfast	7.35
03/02/20	Meals Hart Ku - Dinner	30.00
03/02/20	Meals Nathaniel Simon - Breakfast	4.94
03/02/20	Meals Ryan Sublett - Dinner	50.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/02/20	Meals Samantha Canniff - Dinner	48.40
03/02/20	Meals Nathaniel Simon - Dinner	11.11
03/02/20	Meals Samuel Lemack - Dinner	35.11
03/03/20	Airfare Samuel Lemack 2020-03-05 LGA - DAL	566.98
03/03/20	Airfare Samantha Canniff 3/4/20 HPN - ORD	415.40
03/03/20	Airfare Service Charge Kevin McCafferty	9.00
03/03/20	Airfare Change Fees Kevin McCafferty	68.84
03/03/20	Airfare Service Charge Ryan Sublett	9.00
03/03/20	Airfare Ryan Sublett 2020-03-08 TPA - LGA	239.03
03/03/20	Airfare Service Charge Nathaniel Simon	9.00
03/03/20	Parking & Tolls Nathaniel Simon	12.00
03/03/20	Cab Fare/Ground Transportation Ryan Sublett NYC to Stamford	133.42
03/03/20	Cab Fare/Ground Transportation Jesse DelConte Home to Pp Office	159.62
03/03/20	Cab Fare/Ground Transportation Gabriel Koch to	5.00
03/03/20	Cab Fare/Ground Transportation Andrew DePalma Airport to Hotel	134.74
03/03/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	9.30
03/03/20	Cab Fare/Ground Transportation Mark Rule Office to Home	11.25
03/03/20	Cab Fare/Ground Transportation Isabel Arana De Uriarte Manhattan to Stamford	116.93
03/03/20	Cab Fare/Ground Transportation Kevin McCafferty LGA to Stamford	106.62
03/03/20	Cab Fare/Ground Transportation David Samikkannu New York to Stamford	114.82



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/03/20	Cab Fare/Ground Transportation David Samikkannu Stamford to Stamford	21.17
03/03/20	Lodging David Samikkannu Marriott Hotels & Resorts - Stamford 03/03/2020 - 03/04/2020	286.35
03/03/20	Lodging David Samikkannu Residence Inn - Stamford 03/03/2020 - 03/04/2020	(249.00)
03/03/20	Lodging Kevin McCafferty Residence Inn - Stamford 03/03/2020 - 03/05/2020	572.72
03/03/20	Lodging Isabel Arana De Uriarte Residence Inn - Stamford 03/03/2020 - 03/04/2020	297.86
03/03/20	Meals Isabel Arana De Uriarte - Breakfast	9.20
03/03/20	Meals Kevin McCafferty - Breakfast	8.87
03/03/20	Meals Samantha Canniff - Breakfast	5.00
03/03/20	Meals Samuel Lemack - Breakfast	17.63
03/03/20	Meals Samuel Lemack - Dinner	5.00
03/03/20	Meals Samantha Canniff - Dinner	35.60
03/03/20	Meals Andrew DePalma - Breakfast	25.00
03/03/20	Meals Andrew DePalma - Dinner	50.00
03/03/20	Meals Hart Ku - Dinner	24.36
03/03/20	Meals Jesse DelConte - Breakfast	5.61
03/03/20	Meals - Engagement Team Jesse DelConte - Dinner - Isabel Arana De Uriarte; Jesse DelConte; David Samikkannu; Kevin McCafferty; Ryan Sublett; David Fogel	233.97
03/03/20	Meals Nathaniel Simon - Breakfast	7.95
03/03/20	Meals Nathaniel Simon - Dinner	19.43
03/03/20	Meals Ryan Sublett - Breakfast	10.38
03/04/20	Airfare Samuel Lemack 2020-03-04 LGA - DSM	500.33

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/04/20	Airfare Samuel Lemack 03.05.20 LGA - DAL	(566.98)
03/04/20	Airfare Service Charge Samuel Lemack	9.00
03/04/20	Airfare Service Charge Kevin McCafferty	9.00
03/04/20	Airfare Service Charge Kevin McCafferty	9.00
03/04/20	Airfare Kevin McCafferty 2020-03-09 YYZ - BOS	268.97
03/04/20	Parking & Tolls Kevin McCafferty	15.40
03/04/20	Cab Fare/Ground Transportation David Samikkannu Stamford to Stamford	15.30
03/04/20	Rental Car Samuel Lemack 3 Days Elmhurst	250.23
03/04/20	Parking & Tolls Hart Ku	7.78
03/04/20	Mileage Nathaniel Simon 48 Miles	27.60
03/04/20	Parking & Tolls Nathaniel Simon Commute Home	5.55
03/04/20	Cab Fare/Ground Transportation Samantha Canniff Purdue to HPN	49.51
03/04/20	Cab Fare/Ground Transportation Samantha Canniff Hotel to Purdue	13.30
03/04/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	12.06
03/04/20	Cab Fare/Ground Transportation Mark Rule Office to Home	10.50
03/04/20	Lodging Jesse DelConte Sheraton Hotel Stamford - Stamford 03/04/2020 - 03/05/2020	291.89
03/04/20	Meals Nathaniel Simon - Breakfast	9.11
03/04/20	Meals Ryan Sublett - Breakfast	12.35
03/04/20	Meals Hart Ku - Dinner	33.58
03/04/20	Meals Hart Ku - Breakfast	12.15
03/04/20	Meals Andrew DePalma - Breakfast	19.68

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/04/20	Meals Samantha Canniff - Dinner	10.35
03/04/20	Meals Samuel Lemack - Dinner	50.00
03/04/20	Meals Samuel Lemack - Breakfast	10.00
03/04/20	Meals Kevin McCafferty - Dinner	45.37
03/04/20	Meals Kevin McCafferty - Breakfast	7.55
03/04/20	Meals Isabel Arana De Uriarte - Breakfast	20.58
03/05/20	Airfare Service Charge Kevin McCafferty	9.00
03/05/20	Airfare Change Fees Kevin McCafferty	20.00
03/05/20	Airfare Service Charge Andrew DePalma	25.00
03/05/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	9.44
03/05/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Airport	118.51
03/05/20	Cab Fare/Ground Transportation Andrew DePalma Airport to Apartment	43.14
03/05/20	Cab Fare/Ground Transportation Ryan Sublett Stamford to NYC	77.81
03/05/20	Mileage Hart Ku 40 Miles	23.00
03/05/20	Cab Fare/Ground Transportation Samantha Canniff ORD to Home	78.12
03/05/20	Cab Fare/Ground Transportation Andrew DePalma to	2.00
03/05/20	Cab Fare/Ground Transportation Kevin McCafferty Stamford to LGA	80.88
03/05/20	Cab Fare/Ground Transportation Kevin McCafferty to	16.17
03/05/20	Cab Fare/Ground Transportation Isabel Arana De Uriarte Stamford to Manhattan	68.93
03/05/20	Meals Jesse DelConte - Breakfast	5.03

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/05/20	Meals Kevin McCafferty - Dinner	11.69
03/05/20	Meals Samantha Canniff - Dinner	6.50
03/05/20	Meals Ryan Sublett - Dinner	50.00
03/05/20	Meals Andrew DePalma - Dinner	50.00
03/05/20	Phone - Internet Access Gabriel Koch	62.83
03/06/20	Airfare Service Charge Samantha Canniff	6.99
03/07/20	Airfare Samuel Lemack 03.09.20 DAL - LGA	(566.98)
03/07/20	Parking & Tolls Michael Hartley	9.45
03/08/20	Airfare Service Charge Michael Hartley	9.00
03/08/20	Airfare Michael Hartley 2020-03-09 ATL - HPN	59.09
03/08/20	Airfare Service Charge Samuel Lemack	9.00
03/08/20	Airfare Samuel Lemack 2020-03-09 DSM - ORD	221.92
03/08/20	Airfare Service Charge Andrew DePalma	25.00
03/08/20	Cab Fare/Ground Transportation Andrew DePalma Apartment to Airport	41.41
03/08/20	Cab Fare/Ground Transportation Andrew DePalma LGA to Stamford	161.82
03/08/20	Lodging Andrew DePalma Marriott Hotels - 03/08/2020 - 03/12/2020	926.94
03/08/20	Meals Andrew DePalma - Dinner	17.05
03/09/20	Airfare Andrew DePalma 2020-03-20 LGA - DCA	264.33
03/09/20	Airfare Service Charge Andrew DePalma	9.00
03/09/20	Cab Fare/Ground Transportation Isabel Arana De Uriarte Avrio to AlixPartners	17.21
03/09/20	Cab Fare/Ground Transportation Jesse DelConte Alix NYC Office to Home	44.29

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/09/20	Cab Fare/Ground Transportation Michael Hartley Home to Airport	81.00
03/09/20	Cab Fare/Ground Transportation Kevin McCafferty YYZ to Home	69.96
03/09/20	Cab Fare/Ground Transportation Ryan Sublett Office to Home	15.15
03/09/20	Cab Fare/Ground Transportation Ryan Sublett JFK to Home	79.87
03/09/20	Mileage Nathaniel Simon 48 Miles	27.60
03/09/20	Parking & Tolls Nathaniel Simon Commute To Stamford	13.75
03/09/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client Site	11.30
03/09/20	Parking & Tolls Nathaniel Simon	12.00
03/09/20	Lodging Nathaniel Simon Residence Inns - Stamford 03/09/2020 - 03/11/2020	549.72
03/09/20	Lodging Samuel Lemack Courtyard Stamford - Stamford 03/09/2020 - 03/12/2020	781.10
03/09/20	Lodging Michael Hartley Courtyard Stamford - Stamford 03/09/2020 - 03/12/2020	755.58
03/09/20	Meals Samuel Lemack - Breakfast	15.00
03/09/20	Meals Samuel Lemack - Dinner	37.61
03/09/20	Meals Andrew DePalma - Breakfast	22.90
03/09/20	Meals Andrew DePalma - Dinner	50.00
03/09/20	Meals Nathaniel Simon - Dinner	14.05
03/09/20	Meals Nathaniel Simon - Breakfast	3.02
03/09/20	Conference Calls Vendor: Vodafone Kevin McCafferty	0.23
03/09/20	Conference Calls Vendor: Vodafone Kevin McCafferty	2.77
03/09/20	Conference Calls Vendor: Vodafone Kevin McCafferty	30.14
03/10/20	Airfare Service Charge Michael Hartley	10.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/10/20	Airfare Service Charge Andrew DePalma	9.00
03/10/20	Airfare Service Charge Andrew DePalma	9.00
03/10/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	13.30
03/10/20	Parking & Tolls Nathaniel Simon	12.00
03/10/20	Cab Fare/Ground Transportation Jesse DelConte Home to Pp Office	126.91
03/10/20	Lodging Jesse DelConte Residence Inn - Stamford 03/10/2020 - 03/11/2020	269.10
03/10/20	Meals - Engagement Team Jesse DelConte - Dinner - Nathaniel Simon; Jesse DelConte; Andrew DePalma	150.00
03/10/20	Meals Michael Hartley - Dinner	50.00
03/10/20	Meals Samuel Lemack - Breakfast	16.36
03/10/20	Meals Samuel Lemack - Dinner	45.01
03/10/20	Meals Ryan Sublett - Breakfast	11.16
03/10/20	Meals Andrew DePalma - Breakfast	25.00
03/10/20	Meals Nathaniel Simon - Breakfast	7.95
03/10/20	Meals Michael Hartley - Breakfast	9.53
03/10/20	Conference Calls Vendor: Vodafone Kevin McCafferty	22.65
03/11/20	Parking & Tolls Nathaniel Simon Commute From Stamford	2.75
03/11/20	Mileage Nathaniel Simon 48 Miles	27.60
03/11/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	9.25
03/11/20	Parking & Tolls Samuel Lemack	12.76
03/11/20	Rental Car Samuel Lemack 3 Days Elmhurst	203.29
03/11/20	Meals Samuel Lemack - Breakfast	20.00

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/11/20	Meals Samuel Lemack - Dinner	20.16
03/11/20	Meals Ryan Sublett - Breakfast	21.88
03/11/20	Meals Ryan Sublett - Dinner	50.00
03/11/20	Meals Michael Hartley - Dinner	40.74
03/11/20	Meals Michael Hartley - Breakfast	13.01
03/11/20	Meals Jesse DelConte - Breakfast	3.00
03/11/20	Meals Andrew DePalma - Dinner	50.00
03/11/20	Meals Andrew DePalma - Breakfast	25.00
03/11/20	Meals Nathaniel Simon - Breakfast	7.48
03/11/20	Conference Calls Vendor: Vodafone Kevin McCafferty	14.46
03/12/20	Airfare Andrew DePalma 2020-03-12 LGA - MSP	352.32
03/12/20	Airfare Service Charge Andrew DePalma	10.00
03/12/20	Airfare Service Charge Andrew DePalma	9.00
03/12/20	Airfare Service Charge Andrew DePalma	25.00
03/12/20	Cab Fare/Ground Transportation Andrew DePalma Hotel to Client	12.46
03/12/20	Cab Fare/Ground Transportation Andrew DePalma Airport to Hotel	45.56
03/12/20	Cab Fare/Ground Transportation Andrew DePalma Stamford to LGA	130.85
03/12/20	Cab Fare/Ground Transportation Michael Hartley Airport to Home	81.00
03/12/20	Cab Fare/Ground Transportation Michael Hartley Client to Airport	34.43
03/12/20	Cab Fare/Ground Transportation Jesse DelConte Stamford to NYC	74.79
03/12/20	Cab Fare/Ground Transportation Isabel Arana De Uriarte	20.54

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
	Upper East Side to Avrio	
03/12/20	Cab Fare/Ground Transportation Samuel Lemack to	10.00
03/12/20	Parking & Tolls Samuel Lemack	15.20
03/12/20	Cab Fare/Ground Transportation Samuel Lemack DAL to DAL	80.38
03/12/20	Meals Ryan Sublett - Breakfast	14.97
03/12/20	Meals Michael Hartley - Dinner	33.23
03/12/20	Meals Andrew DePalma - Breakfast	25.00
03/12/20	Meals Andrew DePalma - Dinner	50.00
03/12/20	Conference Calls Vendor: Vodafone Kevin McCafferty	21.76
03/13/20	Airfare Service Charge Andrew DePalma	9.00
03/13/20	Airfare Service Charge Andrew DePalma	9.00
03/13/20	Meals Ryan Sublett - Dinner	50.00
03/13/20	Meals Ryan Sublett - Breakfast	25.00
03/14/20	Airfare Service Charge Samantha Canniff	5.99
03/15/20	Airfare Service Charge Samantha Canniff	5.99
03/16/20	Lodging Ryan Sublett Pinehurst - 03/16/2020 - 03/17/2020	326.53
03/16/20	Conference Calls Vendor: Vodafone Kevin McCafferty	22.60
03/16/20	Conference Calls Vendor: Vodafone Kevin McCafferty	17.96
03/16/20	Conference Calls Vendor: Vodafone Kevin McCafferty	14.32
03/17/20	Parking & Tolls Samuel Lemack	13.45
03/18/20	Cab Fare/Ground Transportation Samuel Lemack to	10.00
03/18/20	Parking & Tolls Samuel Lemack	15.20
03/19/20	Conference Calls Vendor: Vodafone Kevin McCafferty	1.63
03/20/20	Conference Calls Vendor: Vodafone Kevin McCafferty	18.99
03/23/20	Parking & Tolls Samuel Lemack	13.45



# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

<b>Date</b>	<b>Disbursement Description</b>	<b>Amount</b>
03/23/20	Conference Calls Vendor: Vodafone Kevin McCafferty	1.78
03/25/20	Conference Calls Vendor: Vodafone Kevin McCafferty	23.14
03/25/20	Conference Calls Vendor: Vodafone Kevin McCafferty	26.21
03/31/20	Client Research - - VENDOR: Euromonitor International Euromonitor International - Euromonitor passport 13/09/19 - 12/09-20	619.66
<b>Total Disbursements</b>		<b><u>29,971.64</u></b>

# AlixPartners

Mr. Jon Lowne  
Chief Financial Officer  
Purdue Pharma L.P.  
One Stamford Forum  
201 Tresser Boulevard  
Stamford, CT 06901-3431

Mr. James P. Doyle  
Vice President & General Counsel  
Rhodes Technologies  
Rhodes Pharmaceuticals L.P.  
498 Washington Street  
Coventry, RI 02816

Invoice # 2123373-2

Re: Travel and Expense  
Client/Matter # 012589.00150

## Disbursement Recap:

Description	Amount
Airfare	7,288.45
Ground Transportation	5,160.08
Lodging	13,599.84
Meals	2,572.14
Other	1,351.13
<b>Total Disbursements</b>	<b><u>29,971.64</u></b>